



Project No. TREN-05-FP6TR-S07.61320-518404-DRUID

DRUID
Driving under the Influence of Drugs, Alcohol and Medicines

Integrated Project
1.6. Sustainable Development, Global Change and Ecosystem
1.6.2: Sustainable Surface Transport

6th Framework Programme
Deliverable 4.1.1

Review of existing classification efforts

Due date of deliverable: (15.01.2008)
Actual submission date: (07.02.2008)

Start date of project: 15.10.2006
Duration: 48 months
Organisation name of lead contractor for this deliverable: UGent
Revision 1.0

| Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) | | |
|---|---|---|
| Dissemination Level | | |
| PU | Public | X |
| PP | Restricted to other programme participants (including the Commission Services) | |
| RE | Restricted to a group specified by the consortium (including the Commission Services) | |
| CO | Confidential, only for members of the consortium (including the Commission Services) | |

Task 4.1 : Review of existing classification efforts

Authors:

Kristof Pil, Elke Raes, Thomas Van den Neste, An-Sofie Goessaert, Jolien Veramme, Alain Verstraete (Ghent University, Belgium)

Partners:

- F. Javier Alvarez (work package leader), M. Trinidad Gómez-Talegón, Inmaculada Fierro (University of Valladolid, Spain)
- Monica Colas, Juan Carlos Gonzalez-Luque (DGT, Spain)
- Han de Gier, Sylvia Hummel, Sholeh Mobaser (University of Groningen, the Netherlands)
- Martina Albrecht, Michael Heißing (Bundesanstalt für Straßenwesen, Germany)
- Michel Mallaret, Charles Mercier-Guyon (University of Grenoble, Centre Regional de Pharmacovigilance, France)
- Vassilis Papakostopoulos, Villy Portouli, Andriani Mousadakou (Centre for Research and Technology Hellas, Greece)

Introduction

DRUID work package 4 focusses on the classification and labeling of medicinal drugs according to their influence on driving performance. The final goal of this work package is to propose a new classification/categorisation system for the relevant therapeutic groups of medicines available on the European market. The first task (DRUID task 4.1) to reach this goal was making a review of the existing systems.

Deliverable 1 of the ROSITA project described the existing systems in 1999.¹ An update was necessary because since then new lists have been introduced and some older lists have been updated.

In this report, the past and current systems across Europe are described and compared.

This document will serve as input for DRUID tasks 4.2 and 4.3 (the establishment of a framework and criteria for a European classification). Therefore it is important that this report allows an easy comparison of the existing systems on two levels:

- comparison of ratings/labels per molecule
- comparison of ratings/labels within one therapeutic class

To achieve this goal, two overview tables were made that include the ratings from the different available systems.

In the first overview table (Annex I), the substances are arranged according to the Anatomical Therapeutic Chemical (ATC) classification system. This system divides drugs into different groups according to the organ or system on which they act and/or their therapeutic and chemical characteristics. Small adaptations were made to the ATC system to further increase readability.

In the second overview table (Annex II), the substances are arranged in alphabetic order.

Based on these tables, substances and groups of substances were identified for which there is a general agreement or a significant disagreement among the existing classification systems. This list will be serve as input during the first steps of the establishment of new system.

¹ Maes V, Charlier C, Grenez E, Verstraete A. Drugs and medicines that are suspected to have a detrimental impact on road user performance. In: Verstraete A, editor. Rosita. Roadside Testing Assessment. Gent: Rosita Consortium; 2001. p. 5-44

Materials & Methods

To gather the necessary information, questionnaires were distributed to all institutes involved in DRUID and to some contacts outside the DRUID consortium. Additionally internet searches were performed.

The official ATC system is maintained by the WHO Collaborating Centre for Drug Statistics Methodology and can be accessed online.² Some adaptations were made to the official ATC codes to enhance the comparability:

- Some substances have multiple ATC codes (e.g. if the substance can be used for different indications). Therefore these can be mentioned more than once in the overview table. A list of substances with multiple codes is added in Annex III.
When multiple ATC codes exist, the choice is based on these rules:
 - o If the classification system specifically mentions a specific ATC code or indication, then this code is used.
 - o ATC class 'V: Various' is not used if another ATC code is available.
 - o ATC classes that are not relevant to driving impairment (e.g. topical use) are not included, unless there is no other ATC code or the classification specifically mentions this indication.
 - o ATC codes starting with S02 (otologicals) or S03 (ophthalmological and otological preparations) are not included because these substances also have a S01 ATC code (ophthalmologicals), which is more relevant.
 - o Groups with specific chemical characteristics are grouped together (e.g. all barbiturates in N05, and none in N01).
- Six substances have an official ATC code but are mentioned in the overview table in another ATC class (as ATC 'not yet determined'). A list of these substances and the reasons why they have been placed in different categories is added in Annex IV.
- The CERMT-list (later referred to as 'France I') mentions a lot of indications, time frames since administration and durations of treatment. These often can not be matched to a ATC code. To keep the list readable, there is not always a separate row for each indication. Instead, the different ratings have been added in one ATC code, and the more detailed information is added in Annex V. For some substances there are double ATC codes because both ATC codes (e.g. buprenorphine: Temgesic[®] N02AE01 and Subutex[®] N07BC01) are dealt with separately in other systems as well.

² <http://www.whocc.no/atcddd>

Results

1. Wolschrijn classification ³

This categorisation system was established in 1991 and was based on expert ratings (thirty experts responded to a questionnaire). The responses provided a categorisation of 572 drug doses/formulations or effects for a certain time-interval after intake. The system contains 7 categories, each category also received a numerical scale value (table 1). The mean value of all expert ratings gives an estimation of the impairment intensity.

For some drugs, alternative formulations are mentioned: slow release (SR), soft gel capsule (SGC) and transdermal therapeutic system (TTS). These have not been added in the overview table (Annex I) but are mentioned separately in Annex VI.

For benzodiazepines, barbiturates and other tranquilizers/hypnotics, both acute and residual effects (categories 8-12h, 12-16h, 16-22h for every dose considered in the 'acute effects') were assessed. Only the acute effects are added in the overview table. The residual effects are added separately in Annex VII.

Categorisation using expert ratings is possible for extensively investigated drugs. Although for many drugs experts do not agree in their ratings, it was possible to achieve consensus concerning an important number of drugs in about every pharmacological group. Their rank-ordering of drugs/doses is clinically relevant and is important for prescribing physicians.

Table 1: Description of the categories of the Wolschrijn system.

| Category | Scale Value | Description |
|----------|-------------|--|
| I | 1 | No impairment |
| I* | 1 | No impairment presumed |
| II.1 | 2 | Minor impairment |
| II.2 | 3 | Moderate impairment |
| II* | 3 | No severe impairment presumed |
| III | 4 | Severe impairment |
| III* | U | Unknown effects, but suspected to cause impairment |

Overview table: - mean value for acute effects per molecule and per dose
- number of experts with ratings I,II.1,II.2 and III / number of experts with ratings I*,II*and III*

³ Wolschrijn H, De Gier J, de Smet P. Drugs and driving: a new categorization system for drugs affecting psychomotor performance. Maastricht: Institute for drugs, safety and behaviour, University of Limburg, IVGV 91-24, 1991

2. Germany ⁴

A brochure for health care professionals (with a classification of medicines) was published by the ABDA (Bundesvereinigung Deutscher Apothekerverbände - Federal Union of German Associations of Pharmacists) and is based on the mean values from the Wolschrijn classification. These values are given for 406 substances.

Overview table: same mean values as Wolschrijn

The 'Rote Liste' (the most important German catalogue of medicines), published by the BPI (Bundesverband der Pharmazeutischen Industrie - Pharmaceutical Industry Association) in cooperation with the Ministry of Health, also includes seven categories related to impaired driving. (Table 2) A standard warning (V) will always be given, as long as there does not exist any proof that the respective medicinal drug has no impact on driving at all.

Table 2: Descriptions of categories in the 'Rote Liste'

| Category | Description |
|----------|---|
| V | Standard warning |
| A | Medicines containing alcohol |
| RR | Medicines lowering blood pressure |
| D | Medicines lowering the level of blood sugar |
| L | Local anaesthetics |
| N | Anaesthetics |
| S | Medicines influencing visual functions |

Overview table: not mentioned

The German lists have no legal consequences. According to the German Road Traffic Act, everyone has a responsibility of his own. Everyone is obliged to check his driving ability before driving a vehicle, this includes not to drive under the influence of certain medicines (as informed by the physician or the patient information leaflet). Physicians are obliged to inform their patients on possible side effects of the medicinal drugs they prescribed and to document this accordingly. This includes effects on the driving ability. In case of inadequate information and documentation the physician may be held responsible.

⁴ Gräfe-Bub A-K. Brochure: Ihr Leitfaden rund ums Thema "Arzneimittel im Straßenverkehr". ABDA, Eschborn Germany, 1997.

3. Belgium ⁵

In 1999, the BLT (Toxicological Society of Belgium and Luxemburg) and the BIVV (Belgian Road Safety Institute) made a categorization of all medication that was available on the market at that time and that belonged to therapeutic classes susceptible of impairing driving performance.

The categories were the same as in the Wolschrijn classification (table 1), but now the assignment of each substance to a category was based on the results of a literature search (with about 500 references) on the impairing effects. In this way, 182 substances were categorized. For each substance, a monograph was written with information about brand names that were available at that moment, some pharmacokinetic properties and the results of the literature search for this compound.

The classification of the substances proved to be problematic due to the lack of study data (42% of the substances in 'presumed' categories) and the diversity of the study protocols. As the effect of the drug is dose-dependent and time-related, the assignment of one category per drug is often inadequate.

The classification was also published in a brochure, distributed among the Belgian physicians, pharmacists and the public.

Overview table: mentions the assigned category per molecule

+ : mentioned as driving impairing, no category assigned

⁵ Report of the Toxicological society of Belgium and Luxembourg (BLT): Invloed van geneesmiddelen op de rijvaardigheid / Influence des médicaments sur les capacités de conduite. Belgian Road Safety Institute, 1999.

4. Spain

The DGT (Dirección General De Tráfico - Traffic General Directorate) and the University of Valladolid (UVa) issued a guide on the prescription of medicines affecting driving performance in 2001, an updated version was published in 2002.⁶ The 3 categories used were originally published in the European Note for Guidance for the Summary of Product Characteristics III/9163/90-EN and can be considered a summary of the Wolschrijn categories (table 3).

Categories were assigned to 171 substances. Another 192 medicinal drugs were mentioned as driving impairing, but no category was assigned to these drugs.

Table 3: Description of the categories in the DGT/UVa

| Category | Description |
|----------|--|
| I | Presumed to be safe or unlikely to produce an effect |
| II | Likely to produce minor or moderate adverse effects |
| III | Likely to produce severe effects or presumed to be potentially dangerous |

*Overview table: Referred to as 'Spain I', mentions the assigned category per molecule
+ = mentioned as driving impairing, but not assigned to a category*

⁶ Del Rio MC, Alvarez FJ, Gonzalez-Luque JC. Guía de prescripción farmacológica y Seguridad Vial. Madrid: Dirección Gral. de Tráfico, 2001. Second Updated Edition, 2002.

A second Spanish list was made by semFYC (Sociedad Española de Medicina de Familia y Comunitaria - Spanish Society of Family and Community Medicine) in 2002. In 2005, an update was released in cooperation with the university of Valladolid.⁷ It divides 130 substances into 4 categories (table 4). The category 0 was used to rate medication not affecting driving performance. It should be noted that this guide for health professionals focussed on medicinal drugs considered to be of special relevance for general practitioners, and therefore it included several drugs not affecting driving performance. Of the 395 substances, only 178 are mentioned in the overview table. (substances with category 0 and that are not mentioned in any other system are not included)

Table 4: Description of the categories in the semFYC/UVa classification

| Category | Description |
|----------|--|
| 0 | Medication not affecting driving performance |
| I | Presumed to be safe or unlikely to produce an effect |
| II | Likely to produce minor or moderate adverse effects |
| III | Likely to produce severe effects or presumed to be potentially dangerous |

Overview table: Referred to as 'Spain II', mentions the assigned category per molecule

New legislation concerning driver impairing medicines has recently been approved in Spain.⁸ It includes the introduction of a warning label on medicines that can impair driving. The label consists of a black car inside a red triangle, so it is very similar to the first French warning label. At this moment no list of substances with the label exists. Hence it can not yet be compared to other systems in the overview table.

⁷ Guía terapéutica en Atención primaria basada en la evidencia. 2nd Ed. Barcelona: SemFYC, 2004.

⁸ REAL DECRETO 1345/2007, de 11 de octubre, por el que se regula el procedimiento de autorización, registro y condiciones de dispensación de los medicamentos de uso humano fabricados industrialmente. BOE de 7 de Noviembre de 2007, pp: 45652-45698

5. France

The classification by the CERMT (Centre d'Etudes et de Recherches en Medecine du Trafic - Centre for Research in Traffic Medicine) was published in 2000 and is the most extensive list found (508 substances) besides the Wolschrijn classification. It is based on 4 categories (table 5). This list differs from the others because of the subdivision into light and heavy driving groups on type of driver's license (heavy: C, D , E 'heavy': trucks, public transportation, taxis and ambulances; light: A, B, E 'light': motorcycles, cars, light trailers). and because the description of the categories includes advice to patient and doctor.⁹

Overview table: Referred to as 'France I', mentions the assigned category per molecule

Table 5: Description of the categories in the CERMT classification

| Category | Description |
|----------|--|
| 0 | Currently no effects on driving performance are known |
| I | Authorized to drive with heavy and light driver's licenses, but necessity to inform patient about precautionary measures |
| II | Authorized to drive with light license, but not with heavy (except when the medical commission for driver's licenses grants an exception). |
| III | Incompatible with any driver's license. (except when the medical commission for driver's licenses grants an exception). |

In 1999, a warning label (figure 1) was introduced to indicate potential effects on driving performance. This system did not last long, because it was believed that the system has several significant downsides:

- There was no subdivision between less and more impairing medication.
- Patients and doctors did not get an explanation about the practical implications of the label.
- The sticker appeared on over 4000 medications (one out of three available on the market) and therefore largely lost its meaning.

⁹ Médicaments et aptitude à la conduite automobile. Rapport du CERMT sur la classification des médicaments. Centre d'Etudes et de Recherches en Medecine du Trafic, november 2000






Figure 1: Old warning label for driving impairing medication in France

Because of these downsides, a new classification (311 substances) with 3 categories and stickers (table 6) was introduced.¹⁰ It was published in the ‘Journal Officiel de la République Française’ and is therefore legally binding. In the new system, the information given to both patients using and doctors prescribing impairing medication is more practical, more detailed. Because the sticker is legally binding, it is only present on relevant medication. The description of the categories is also printed on the boxes. The list sometimes mentions more than one category per ATC code, based on formulation (e.g. oral vs. parenteral forms) and dose. The different categories are all mentioned in the overview tables, more detailed information can be found in Annex VIII.

Overview table: Referred to as ‘France II’, mentions the assigned warning sign per molecule

Table 6: Description of the categories and new warning stickers in France as published in the ‘Journal Officiel de la République Française’

| Warning sign | Description |
|---|---|
|  | Be careful. Do not drive without having read the leaflet. |
|  | Be very careful. Do not drive without advice of a medical professional. |
|  | Attention: danger: Do not drive. |

¹⁰ Arrêté du juillet 2005 pris pur l’application de l’article R. 5121-139 du code de la santé publique et relatif à l’apposition d’un pictogramme sur le conditionnement extérieur de certains médicaments et produits. Journal Officiel de la République Française, texte 16 sur 94. 2 août 2005.

6. ICADTS ¹¹

This list, published in 2006 by ICADTS (International Council on Alcohol, Drugs and Traffic Safety), is a combination of 3 existing classifications: Belgium, the Uva/DGT list (referred to as Spain I) and the CERMT list (referred to as France II) and includes 389 substances in total. It contains 3 categories with easy descriptions. Each category has additional information on correct interpretation and practical use.

This is the first system that includes calibrations to blood alcohol concentrations in the clarification of the terminology (table 7).

Table 7: Description of the categories in the ICADTS list

| Description of category | Interpretation and practical use |
|--|--|
| <p>Category I:</p> <p>Presumed to be safe or unlikely to produce an effect</p> | <p>In various experimental circumstances negligible or no impairment of driving performance, or performance related to driving, is repeatedly demonstrated. Also for medicinal drugs that are presumed not to be dangerous based on their pharmacological profile, even though there are no experimental studies that support this presumption.</p> <p>For the most frequently used drugs in this category the effect has been assessed in on-the-road driving tests as equivalent to blood alcohol concentrations < 0,5 g/l (<0,05 %)</p> <p><u>Advice to the patient:</u> Be careful not to drive before having read the warnings in the package insert.</p> |
| <p>Category II:</p> <p>Likely to produce minor or moderate adverse effects</p> | <p>Some impairment of driving performance, or performance related to driving, is seen in various experimental laboratory circumstances.</p> <p>Also for drugs that will not produce severe adverse effects, but because of a lack of sufficient experimental studies it can not be established if the effect is moderate, light or absent.</p> <p>For the most frequently used drugs in this category the effect has been assessed in over-the-road driving tests as equivalent to blood alcohol concentrations 0,5-0,8 g/l (0,05 – 0,08 %)</p> <p><u>Advice for the patient:</u> Do not drive without consulting a healthcare professional about the possible impairing effects</p> |
| <p>Category III:</p> <p>Likely to produce severe effects or presumed to be potentially dangerous</p> | <p>In various experimental circumstances gross impairment of driving performance, or performance related to driving, is repeatedly seen.</p> <p>Also for drugs presumed to be potentially dangerous based upon their pharmacological profile, but there are not sufficient experimental studies to support this presumption. For the most</p> |

¹¹ <http://www.icadts.nl/medicinal.html>

| | |
|--|--|
| | <p>frequently used drugs in this category the effect has been assessed in on-the-road driving tests as equivalent to blood alcohol concentrations > 0,8 g/l (> 0,08 %)</p> <p><u>Advice to the patient:</u> Do not drive when this drug is taken and consult a healthcare professional when to start driving again after evaluation of the treatment outcomes.</p> |
|--|--|

7. Portugal ¹²

INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde – The National Authority of Medicines and Health Products) developed the « Prontuário Terapêutico » in 2004 and revises it annually. It includes monographs for medicines commercially available in Portugal and intends to be a basic instrument for the rational use of medicines. A list of 241 substances that impair driving is included. There are five descriptions of categories ranging from no impairment to severe impairment. Some medicines are mentioned as impairing. For clarity, similar categories as those of Wolschrijn (I-III, with * categories for presumed impairment) have been assigned to these descriptions in this report (table 8).

Table 8: Description of the categories in the Portuguese classification

| Category | Description |
|----------|---|
| I | No impairment |
| I* | No impairment presumed |
| II | Impairment |
| II* | Impairment presumed |
| III | Severe impairment |
| + | Risk of hypoglycemia (but no category assigned) |

Overview table: mentions the assigned category per molecule.

+ =no category assigned, but mentioned as dangerous because of risk of hypoglycemia

¹² <http://www.infarmed.pt/prontuario/index.php>

8. Greece ¹³

In 1987, a law about drug spreading prevention was introduced in Greece. Drugs are subdivided into four categories, according to the organization responsible for their distribution. All of these substances are illegal to be used while driving. It contains 172 medicinal drugs, illegal drugs, metabolites and designer drugs. Only the medicinal drugs (89) are mentioned in the overview table

Overview table: *Referred to as 'Greece I'*
+ = *illegal to use while driving*

Apart from this law, the National Organisation of Medicines of Greece maintains a list of monographs for substances available in Greece. This is to be used as a guide for prescribing these medicines. In these monographs there are indications about impact of substances on driving ability. There is no explicit categorisation system regarding driving ability, but reading the indications, a rough categorisation of indications can be:

- 1) Driving ability may be affected significantly
- 2) Driving ability is affected
- 3) Driving ability may be affected
- 4) Avoid driving during use of medicine
- 5) Attention during driving / Drivers should be informed about possible risks

In this list there are indications for another 188 substances, additional to those mentioned in the Drugs law.

Overview table: *Referred to as 'Greece II'*
+ = *affecting driving ability according to list of the National Organisation of Medicines*

¹³ 1729/1987/A 144 19870807: drug spreading prevention law, 1987. Hellenic Ministry of Health; Hellenic Ministry of Justice.

9. The Netherlands


The Royal Dutch Society for the Advancement of Pharmacy has composed a list (of 156 substances) of drugs that can affect driving based on the pharmacodynamic profile or therapeutic class. Originally, two warning labels existed: a yellow and a red one.

The list has been in effect since 1973. It was introduced by the professional organizations of physicians and pharmacists. According to a national agreement (which is not legally binding or mandatory) between these organizations, any pharmacist receiving a prescription for a drug on the list dispenses the drug with a label. If the prescribing physician does not consider driving to be safe, (s)he should mention 'd.c.p = da cum prohibitione' on the prescription. In this case, the red label ("Do not drive after using this medication") is stuck on the box by the pharmacist. If the physician is of the opinion that driving while using a specific medicine was safe, (s)he would mention "d.s.m. = da sine monitione'. The pharmacist would not stick a warning label. If the doctor does not mention anything on the prescription, the yellow label ("This drug can influence your reactions. Beware when using alcohol") is used. (figure 2)

In practice, the physician does not present any information on the prescription regarding the warning for impaired driving and therefore the red label disappeared. The yellow label is still used to date.

In addition to label warnings issued by pharmacists, the Dutch Registration authorities required special warnings for drivers in the package insert for all drugs possessing known side effects that are potentially hazardous. In general, pharmacological class warnings were the rule.

Overview table: + = drug with a yellow warning label



**Dit geneesmiddel kan het reactievermogen beïnvloeden.
Pas op met alcohol.**

Figure 2: Warning label on (potentially) impairing medicines in the Netherlands

10. Nordic Countries

In 1981 a warning label (maintained by the Nordic committee on Medicines) was introduced in Norway and adopted by Denmark, Finland, Iceland and Sweden. It consists of a red triangle printed by the manufacturer on packages of drugs (87 substances) considered especially dangerous. The red triangle is combined with a warning concerning driving in the specific description in the Norwegian Catalogue for medicinal drugs. For other medicines there is only a warning in the catalogue (no triangle). At first, pharmacists that dispensed labeled medication were required to give the patient a leaflet containing additional information. In 1984, the extra leaflet was eliminated because the information was judged to be redundant.

Overview table: + = drug with a red triangle warning label
w = drug with warning in Norwegian Catalogue

On July 1st 2005, Sweden started removing the warning triangles, mainly because it was believed that the list did not take enough factors into consideration (e.g. individual variations, fatigue and the illness for which the medicine is used). The removal became official on July 1st 2007. The list has not been replaced by another. As a reaction to this, Norway has officially declared that they will keep using the warning label.

Both in Finland¹⁴ and Denmark¹⁵, a list of medicines that currently have the triangle on the package is published online. The Finnish list contains 83 active substances, while the Danish list includes 68 active substances.

Overview table: + = mentioned as driver impairing

¹⁴ <http://namweb.nam.fi/namweb/do/haku/process?tapa=lv>

¹⁵ <http://www.laegemiddelstyrelsen.dk/1024/visLSArtikel.asp?artikelID=9058>

Summary

In total, 16 systems were found (table 9). Some of these systems are no true categorization systems: Germany directly reproduced ratings from Wolschrijn, and 5 systems have not defined categories (Greece, the Netherlands, Norway, Denmark and Finland). Only one true categorization system also included warning labels (France II).

Clear relations can be seen between the different systems (figure 3). In this way, all categorizations (except Portugal) are linked to Wolschrijn. When looking at the structure of the systems, the largest evolution has been the number (and descriptions) of categories. The list by Wolschrijn included 7 categories. At first, the categories were copied (Belgium), but later on the categories were summarized and only three categories remained (Spain I). The most recent and extensive lists (France II and ICADTS) have maintained these three categories, but have added practical guidelines for patient and doctor. One list (ICADTS) introduced a calibration to BAC levels.

Table 9: Comparison of classification and labeling systems

| | # medicinal drugs | Classification | # categories | Warning label | Legal |
|------------------------|-------------------|----------------|--------------|---------------|-------|
| Wolschrijn | 572 | X | 7 | | |
| Germany | 406 | | Scale values | | |
| Belgium | 182 | X | 7 | | |
| Spain I (DGT/UVa) | 363 | X | 3 | | |
| Spain II (semFYC/UVa) | 395 | X | 4 | | |
| Spain | | | | X | |
| France I (CERMT) | 508 | X | 4 | | |
| France II (official) | 311 | X | 3 | X | X |
| ICADTS | 389 | X | 3 | | |
| Portugal | 241 | X | 5 | | |
| Greece I (legal) | 89 | | NA | | X |
| Greece II (monographs) | 92 | | NA | | |
| The Netherlands | 156 | | NA | X | |
| Norway | 87 | | NA | X | |
| Denmark | 83 | | NA | X | |
| Finland | 68 | | NA | X | |




Figure 3: Relations between the different classification and labeling systems

Discussion

Although categorizations are present for a large amount of substances, none of the existing classifications have defined clear criteria on which the categorization is based. This is however necessary for a fast and comparable categorizing of newly approved drugs.

Impairment is not only dependent on the active substance, but also on dose, time interval and indication. Ideally, these factors should be taken into consideration when developing a new classification. As shown in Sweden, a lack of nuance in the gradings can lead to the discontinuation of the system.

Impairment is also dependent on individual variations. Both patients and medical practitioners have a vital role in judging the individual situation. Therefore it is advisable that both these groups (as well as the pharmacists) receive guidelines on how to apply the new categorization (as already done in the newest French list and the ICADTS list). This also implies that the new system should be easy to understand and use, both for patients and in the prescribing and dispensing practice.

As the French situation shows, a legally binding list has major advantages, this stresses the necessity of contact with the official authorities when making a new classification.

An exact comparison of systems per substance is not possible because of differences in the descriptions of the categories and the use of multiple ratings per substance (based on dosing and time interval). However for some substances or groups of substances, there is clear agreement or disagreement among the existing classification systems. These are pointed out in the list below. This list can be a starting point for tasks 4.2 and 4.3 since the focus of the first steps of these tasks will be on those substances for which the largest discussion among existing classification exists.

- A02BA : H2-receptor antagonists
In general, H2-receptor antagonists get rating I. However famotidine (A02BA03) and nizatidine (A02BA04) receive a higher rating both in Belgium, ICADTS and Portugal. Surprisingly these two substances and ranitidine (A02BA02) receive rating 0 in France I.

- A10 : Drugs used in diabetes
There is disagreement for the categorization of these drugs, especially insulin. Belgium, Spain I and Portugal mention these substances as impairing, but do not categorize them. In Spain II and France I, the A10-drugs are rated I with the exception of metformin (A10BA02, rated 0 in Spain II) and insulin (A10A, rated II for insulin-requiring patients and III for insulin-dependent patients in France I). France II and ICADTS give all these drugs rating II.
It is also noteworthy to mention that glucagon (H04AA01) does not receive a

rating in France I and France II and gets a lower rating (0) in Spain II compared to insulin.

- G04BD02 : Oxybutynin
All G04 drugs are rated either 0 or I in Spain II and France I. Oxybutynin is the only G04-drug with rating II in Spain II.
- H02AB : Glucocorticoids
All the glucocorticoids get rating 0 in Spain II while France I gives them rating I.
- J01M : Quinolone antibacterials
France I gives quinolones rating I (without exceptions) while Spain II gives more nuanced ratings: 0 for ofloxacin (J01MA01) and norfloxacin (J01MA06), I for ciprofloxacin (J01MA02) and piperidic acid (J01MB05).
- L01 : Antineoplastic substances
In general, antineoplastic substances receive a rating II in France I. Exceptions are rating 0 for estramustine (L01XX11), rating I for busulfan (L01AB01), temozolomide (L01AX03), dacarbazine (L01AX04), raltitrexed (L01BA04) and rating III for carmustine (L01AD01).
Two antineoplastic receive a rating 0 in Spain II: fluorouracil (L01BC05) and tretinoin (L01XX14). This is in contradiction with France I in which these substances received the standard rating II.
- N01A : Anesthetics, general
General anesthetics receive rating III in both France I (< 24 hours after administration), France II and ICADTS. Fentanyl (N01AH01) is the only general anesthetic that is mentioned in almost every system. It always receives the highest rating.
Only one general anesthetic receives a rating lower than III: nitrous oxide (N01AX13) is rated II in both France II and ICADTS.
- N01B : Anesthetics, local
Variations occur for every local anesthetic because these drugs all received rating I in France I and rating II in France II and ICADTS. The variation for bupivacaine (N01BB02) is even higher, since France II and ICADTS both give this drug rating III. The ratings for mepivacaine (N01BB03) are also very variable since it is rated 0 in Spain II.
- N02AA01 : Morphine, N02AB02 : Pethidine, N02AA08 : Dihydrocodeine, N02AC01 : Dextromoramide, N02AC04 : Dextropropoxyphene, N02AD01: Pentazocine, N02AE01: Buprenorphine, N02AF02: Nalbuphine, N02AX02: Tramadol and N02AX52: Tramadol combinations

For all of these opioids, France I and France II deviate from the consensus amongst the other classification systems. In most cases, the rating is one grade lower in the French systems.

For tramadol, the ratings differ widely, ranging from I (France I) to II (Belgium and Portugal) and III (Spain I, Spain II, ICADTS).

For buprenorphine there is an extra variation: Temgesic[®] (N02AE01) gets rating II in France I and rating III in ICADTS while the the situation for Subutex[®] (N07BC01) is the other way around (rating III in Spain II and rating II in ICADTS).

- N02AB : Lysine acetylsalicylate – metoclopramide
Only two systems have rated this combination, but gave different ratings: rating I in France I and rating II in France II.

- N02C : Antimigraine preparations
Small variations occur for every N02C-drug since rating I is given by Spain I and France I and rating II is given by ICADTS and Portugal. Spain I mentions these substances as impairing but does not give a rating.
More significant variations is found with dihydroergotamine (N02CA01) because France I gives rating 0, Portugal gives rating II*.

- N03A : Antiepileptics
There is a consensus amongst the different system that all antiepileptics should receive a high rating. All systems give both ratings II and III but rating II is most often in Belgium, Spain I, Spain II and France II and rating III is most often used in France II.
The largest consensus to use rating III is found with phenobarbital (N03AA02), primidone (N03AA03) and phenytoin (N03AB02) since only the rating from France II deviates for these drugs.

- N04A : Anti-Parkinson drugs
Anti-parkinson drugs are most often given rating II (and mentioned without category in Spain I), but for several substances deviations occur:
 - o N04AA01 : Trihexyphenidyl and N04AA02 : Biperiden
France I, France II and ICADTS use rating II but Spain II uses rating III. Portugal also uses rating III for biperiden but does not rate trihexyphenidyl.
 - o N04BA02 : Levodopa and decarboxylase inhibitor
The most significant differences are found here since ratings vary between I (Spain II), II (France I, France II and ICADTS) and III (Portugal).
 - o N04BB01 : Amantadine and N04BD01 : Selegiline
France II and ICADTS give rating I, France I and Portugal give rating II.
 - o N04BC01 : Bromocriptine

- Spain II is the only system that uses rating I (all other systems use rating II)
 - N04BC04 : Ropinirole and N04BC07 : Apomorphine
 - France I is the only system that uses rating III (the other systems use rating II)

- N05A : Antipsychotics
 - There is a consensus that high ratings should be given to antipsychotics. Rating III is mostly used, but sometimes rating II is used as well. The most significant observations are:
 - N05AN01 : Lithium
 - Lithium gets the lowest ratings amongst antipsychotics (I in Portugal and II in all other systems)
 - Within the different ATC-subclasses there is a consensus to use either rating II (N05AB, N05AD, N05AE, N05AF, N05AG, N05AH, N05AL) or rating III (N05AA, N05AC). Only the French systems often deviate. Smaller deviations from this consensus are
 - Rating III for trifluoperazine (N05AB06) and thioproperazine (N05AB08) in Spain I and ICADTS.
 - Rating III for penfluridol (N05AG03) in Spain I.
 - Rating III* for loxapine (N05AH01) in Belgium and ICADTS.

- N05B : Anxiolytics
 - Anxiolytics get high ratings in all classifications. Differences occur because of the use of multiple categories in France I and France II. The clearest difference is found for chlordiazepoxide (N05BA02): ratings I and II are used in France I while Belgium, Spain I, ICADTS and Portugal give this substance rating III.

- N05C : Hypnotics and sedatives
 - N05CA : Barbiturates, plain
 - Plain barbiturates always get rating III in every system.
 - N05CD : Benzodiazepine derivatives
 - All systems acknowledge that N05CD-drugs are impairing, but comparison is difficult. The most significant observations are:
 - Flurazepam (N05CD01) and midazolam (N05CD08) get the highest rating of all N05CD-drugs: rating III in all systems.
 - All other N05CD-drugs get similar ratings: II (or a related rating) in Belgium and Portugal and rating III in Spain I. France II and ICADTS. France I gives ratings I, II and III depending on time interval since administration and duration of the treatment.
 - N05CF : Benzodiazepine related drugs
 - Most systems give zopiclone (N05CF01) and zolpidem (N05CF02) get rating II (so these drugs get a lower rating than most benzodiazepines).

Only France II gives both drugs rating III. ICADTS only gives rating III to zopiclone.

Zaleplone (N05CF03) is not included in any categorization system. It is only mentioned on the Danish and Finnish lists.

- N06A : Antidepressants

The standard rating for antidepressants is I in France I and II in Belgium, France II, ICADTS and Portugal.

Spain I and Spain II give high ratings (II, III or +) to most antidepressants, with the exception of the selective serotonin reuptake inhibitors (N06AB) and moclobemide (N06AG02); these drugs get rating I.

For some substances the systems divert from their standard ratings. This can lead to variations in ratings between I and III for some substances.

o N06AX05 : Trazodone

Trazodone gets rating III in all systems (but is not rated in France I and France II).

o N06AA09 : Amitriptyline and N06AX03: Mianserin

Most systems give amitriptyline and mianserin rating III. Only France I and France II give rating II (which is also higher than their standard rating for antidepressants).

o N06AA12 : Doxepin, N06AA16 : Dosulepin, N06AA17 : Amoxapine and N06AX11 : Mirtazapine

ICADTS gives these four drugs rating III while the other systems still use the standard ratings. The adjustments are in concordance with the ratings in Spain I. As a result, ratings for these drugs vary between I and III.

o ICADTS gives fluoxetine (N06AB03) and paroxetine (N06AB05) rating I while the other SSRI's get the standard rating II.

- N06BA04 : Methylphenidate

All systems give rating I, except France I and France II which give rating II.

- N06D : Anti-dementia drugs

France II and ICADTS always give these drugs rating II. In Portugal, ratings vary between I* to III. Spain II only mentions donepezil (N06DA02) and gives it rating 0.

- N07B : Drugs used in addictive disorders

France I gives all drugs used in alcohol and opioid dependence rating III. Drugs used in nicotine dependence get rating 0 or I. France II and ICADTS give a standard rating II to all these categories. Spain II gives ratings 0 or I both to drugs used in nicotine and alcohol dependence.

In this way, the largest variation (from I to III) is present for disulfiram (N07BB01).

- N07CA03 : Flunarizine
Spain I, Spain II, France II and ICADTS all give rating II to flunarizine. Only France I gives rating I.

- R05DA01 : Ethylmorphine
Ratings for ethylmorphine vary from I (France I and France II) over II* (Belgium) to III (Spain I and ICADTS).
A similar variation (although smaller) exists for pholcodine (rated I in France I and France II, rated II in Spain I and ICADTS).

- R06A : Antihistamines for systemic use
Variations exists almost for every R06A-drug, mainly because France I often rates R06A-drugs one level lower than the other systems.
Overall, the highest ratings are given to diphenhydramine (R06AA02), doxylamine (R06AA09), promethazine (R06AD02) and hydroxyzine (R06AE).
The highest variations occur for doxylamine (R06AA09), alimemazine (R06AD01) and hydroxyzine (R06AE).

- S01FA : Anticholinergics
In general, anticholinergic ophthalmologicals receive a high rating (II* in Portugal, III in France II and ICADTS). Only one large variation occurs: cyclopentolate (S01FA04) gets rating I in Spain I.

Annex I – Overview Table, per ATC code

Descriptions of categories and values can be found in the specific section for each system in 'Results'

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|-------------------------------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| A ALIMENTARY TRACT AND METABOLISM | | | | | | | | | | | | | | | | |
| A02 DRUGS FOR ACID RELATED DISORDERS | | | | | | | | | | | | | | | | |
| A02B Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) | | | | | | | | | | | | | | | | |
| <i>A02BA H2-receptor antagonists</i> | | | | | | | | | | | | | | | | |
| A02BA01 | Cimetidine | 200 | 1.4 | 4/1 | I | I | I | | I | I | | | | | | |
| | | 400 | 1.4 | 4/1 | | | | | | | | | | | | |
| | | 800 | 1 | 1/0 | | | | | | | | | | | | |
| A02BA02 | Ranitidine | 150 | 1.6 | 2/1 | I | I | I | 0 | I | I | | | | | | |
| | | 300 | 1.6 | 2/1 | | | | | | | | | | | | |
| A02BA03 | Famotidine | 20-40 | 1 | 1/0 | II.1 | I | I | 0 | II | II* | | | | | | |
| A02BA04 | Nizatidine | 150-300 | 1.6 | 2/1 | II.1 | I | | 0 | II | II* | | | | | | |
| | | 600 | 1 | 1/0 | | | | | | | | | | | | |
| A02BA06 | Roxatidine | | | | | I | | | I | | | | | | | |
| <i>A02BC Proton pump inhibitors</i> | | | | | | | | | | | | | | | | |
| A02BC01 | Omeprazole | | | | | | 0 | I | | | | | | | | |
| A02BC02 | Pantoprazole | | | | | | | I | | | | | | | | |
| A02BC03 | Lansoprazole | | | | | | | I | | | | | | | | |
| <i>A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)</i> | | | | | | | | | | | | | | | | |
| A02BX03 | Pirenzepine | | | | | + | | | | | | | | | | |
| A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS | | | | | | | | | | | | | | | | |
| A03A Drugs for functional gut disorders | | | | | | | | | | | | | | | | |
| <i>A03AA Synthetic anticholinergics, esters with tertiary amino group</i> | | | | | | | | | | | | | | | | |
| A03AA08 | Dihexyverine | | | | | | | I,II | | | | | | | | |
| <i>A03AB Synthetic anticholinergics, quaternary ammonium compounds</i> | | | | | | | | | | | | | | | | |
| A03AB02 | Glycopyrronium | | | | | | | | | | | | | | | + |
| A03AB17 | Tiemonium iodide | | | | | | | 0 | | | | | | | | |
| <i>A03AX Other preparations</i> | | | | | | | | | | | | | | | | |
| A03AX58 | Alverine, combinations | | | | | | | | | | | | | | | |
| | Alverini citras - benzocainum | | | | | | | 0 | | | | | | | | |

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| A03AX12 Phloroglucinol | | | | | | | 0 | | | | | | | | | |
| A03B Belladonna and derivatives | | | | | | | | | | | | | | | | |
| A03BA Belladonna alkaloids, tertiary amines | | | | | | | | | | | | | | | | |
| A03BA01 Atropine | | | | | | | II | | | | | + | | | | |
| A03BA03 Hyoscyamine | | | | | | | | | | | | + | | | | |
| A03BA04 Belladonna, total alkaloids | | | | | | | | | | | | + | | | | |
| Atropine sulfate | | | | | | | I | | | | | | | | | |
| A03BB Belladonna alkaloids, semisynthetic, quaternary ammonium compounds | | | | | | | | | | | | | | | | |
| A03BB01 Butylscopolamine | | | | | | | I | | | | | + | | | | |
| A03C Antispasmodics in combination with psycholeptics | | | | | | | | | | | | | | | | |
| A03CA Synthetic anticholinergic agents in combination with psycholeptics | | | | | | | | | | | | | | | | |
| A03CA02 Clidinium and psycholeptics | | | | | | | | | | | | | | | | |
| Clidinium - chlordiazepoxide | | | | | | | II | | | | | | | | | |
| Buzepide metiodide - haloperidol | | | | | | | II | | | | | | | | | |
| A03D Antispasmodics in combination with analgesics | | | | | | | | | | | | | | | | |
| A03DA Synthetic anticholinergic agents in combination with analgesics | | | | | | | | | | | | | | | | |
| A03DA05 Camylofine and analgesics | | | | | | | | | | | | | | | | |
| Camylofine - metamizol sodium | | | | | | | 0 | | | | | | | | | |
| A03F Propulsives | | | | | | | | | | | | | | | | |
| A03FA Propulsives | | | | | | | | | | | | | | | | |
| A03FA01 Metoclopramide | 5-10 | U | 0/1 | | + | I | I | | II | | | + | + | | | |
| A03FA02 Cisapride | | | | | | | I | | | | | | | | | |
| A03FA03 Domperidone | 10-20 | U | 0/1 | | | | 0 | 0 | | | | | | | | |
| A03FA05 Alizapride | | | | | + | | I | | | | | | | | | |
| A03FA06 Clebopride | | | | | + | | | | | | | | | | | |
| not yet determined Cinitapride | | | | | + | | | | | | | | | | | |
| A04 ANTIEMETICS AND ANTINAUSEANTS | | | | | | | | | | | | | | | | |
| A04A Antiemetics and antinauseants | | | | | | | | | | | | | | | | |
| A04AA Serotonin (5HT3) antagonists | | | | | | | | | | | | | | | | |
| A04AA01 Ondansetron | | | | I | + | | I | | I | I | | | | | | |
| A04AA02 Granisetron | | | | I | + | | I | I | I | | | | | | | |
| A04AA03 Tropisetron | | | | | + | | I | I | I | | | | | | | |

| ATC + SUBSTANCE NAME | | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|---------------------------|---------|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| A04AA04 | Dolasetron | | | | | | | | I | I | I | | | | | | | |
| <i>A04AD Other antiemetics</i> | | | | | | | | | | | | | | | | | | |
| A04AD01 | Scopolamine | 0.4-0.8 | 4 | 1/2 | | + | | | II | II | II | | | | + | + | + | + |
| A04AD05 | Metopimazine | | | | | + | | | I | II | II | | | | | | | |
| A04AD10 | Dronabinol | | | | | | | | | | | | | | + | | | |
| not yet determined | Dimenhydrinate | | 3 | 1/1 | III | III | III | | II | II | III | III | | + | + | | | |
| not yet determined | Dimenhydrinate - caffeine | | | | | | | | II | | | | | | | | | |
| A07 ANTI-DIARRHEALS, INTESTINAL ANTI-INFLAMMATORY/ANTI-INFECTION AGENTS | | | | | | | | | | | | | | | | | | |
| <i>A07D Antipropulsives</i> | | | | | | | | | | | | | | | | | | |
| <i>A07DA Antipropulsives</i> | | | | | | | | | | | | | | | | | | |
| A07DA01 | Diphenoxylate | | | | | | | | | | | | + | | | | | |
| A07DA02 | Opium | | | | | | | | | | | | + | | | | + | |
| A07DA03 | Loperamide | | | | | | | 0 | | | | | | | | | | |
| A07DA04 | Difenoxin | | | | | | | | | | | | + | | | | | |
| A07DA05 | Loperamide oxide | | | | | | | | | | | | | | | | | |
| <i>A07E Intestinal anti-inflammatory agents</i> | | | | | | | | | | | | | | | | | | |
| <i>A07EC Aminosalicic acid and similar agents</i> | | | | | | | | | | | | | | | | | | |
| A07EC02 | Mesalazine | | | | | | | 0 | | | | | | | | | | + |
| A08 ANTI-OBESITY PREPARATIONS, EXCL. DIET PRODUCTS | | | | | | | | | | | | | | | | | | |
| <i>A08A Antiobesity preparations, excl diet products</i> | | | | | | | | | | | | | | | | | | |
| <i>A08AA Centrally acting antiobesity products</i> | | | | | | | | | | | | | | | | | | |
| A08AA01 | Phentermine | | | | I* | | | | | | I | | + | | | | | |
| A08AA02 | Fenfluramine | 20 | U | 0/1 | | + | | | | | | | | | + | + | | |
| | | 40 | 2 | 1/0 | | | | | | | | | | | | | | |
| A08AA03 | Amfepramone | 50 | U | 0/1 | I* | I | | | | | I | | + | | | | + | |
| A08AA04 | Dexfenfluramine | | | | | + | | | | | | | | | | | | |
| A08AA05 | Mazindol | 1 | 3 | 0/1 | | | | | | | | | + | | + | | | |
| A08AA06 | Etilamfetamine | | | | I* | | | | | | | | | | | | | |
| A08AA08 | Clobenzorex | | | | | | I | | | | | | | | | | | |
| A08AA10 | Sibutramine | | | | | | | | | | | II | | | | | | |
| not yet determined | Phendimetrazine | | | | I* | | | | | | | | + | | | | | |
| not yet determined | Benzphetamine | | | | | | | | | | | | + | | | | | |

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|-----------|------------|--|-----|------|-------|--------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| not yet determined Phenmetrazine | | | | | | | | | | | + | | | | | |
| A10 DRUGS USED IN DIABETES | | | | | | | | | | | | | | | | |
| A10A <i>Insulins and analogues</i> | | | | | | | | | | | | | | | | |
| Insulin | | | | + | + | I | II,III | II | II | + | | + | | | | |
| A10B <i>Blood glucose lowering drugs, excl. Insulins</i> | | | | | | | | | | | | | | | | |
| A10BA <i>Biguanides</i> | | | | | | | | | | | | | | | | |
| A10BA01 Phenformin | | | | | + | | | | II | | | | | | | |
| A10BA02 Metformin | | | | + | + | 0 | I | | II | + | | | | | | |
| A10BA03 Buformin | | | | | + | | | | II | | | | | | | |
| A10BB <i>Sulfonamides, urea derivatives</i> | | | | | | | | | | | | | | | | |
| A10BB01 Glibenclamide | | | | + | + | I | I | II | II | + | | | | | | |
| A10BB02 Chlorpropamide | | | | + | + | | | II | II | | | | | | | |
| A10BB03 Tolbutamide | | | | + | + | | | | II | | | | | | | |
| A10BB04 Glibornuride | | | | | | | I | II | II | | | | | | | |
| A10BB06 Carbutamide | | | | | | | I | II | II | | | | | | | |
| A10BB07 Glipizide | | | | + | + | I | I | II | II | + | | | | | | |
| A10BB08 Gliquidone | | | | + | + | I | | | II | | | | | | | |
| A10BB09 Gliclazide | | | | + | + | I | I | II | II | + | | | | | | |
| A10BB12 Glimepiride | | | | | | | I | II | II | | | | | | | |
| not yet determined Glisentide | | | | | + | | | | II | | | | | | | |
| A10BD <i>Combinations of oral blood glucose lowering drugs</i> | | | | | | | | | | | | | | | | |
| A10BD01 Phenformin - sulfonamides | | | | | | | | | II | | | | | | | |
| A10BD02 Metformin - sulfonamides | | | | | | | | II | II | | | | | | | |
| A10BD03 Metformin - rosiglitazone | | | | | | | | | II | | | | | | | |
| A10BF <i>Alpha glucosidase inhibitors</i> | | | | | | | | | | | | | | | | |
| A10BF01 Acarbose | | | | + | + | I | I | | II | + | | | | | | |
| A10BF02 Miglitol | | | | | | I | I | | | | | | | | | |
| A10BX <i>Other blood glucose lowering drugs, excl. Insulins</i> | | | | | | | | | | | | | | | | |
| A10BX02 Repaglinide | | | | | | I | I | II | II | | | | | | | |
| A10BX03 Nateglinide | | | | | | I | | II | II | | | | | | | |
| A11 VITAMINES | | | | | | | | | | | | | | | | |
| A11D <i>Vitamin B1, plain and in combination with vitamin B6 and B12</i> | | | | | | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| A11DA Vitamin B1, plain | | | | | | | | | | | | | | | | |
| A11DA02 Sulbutiamine | | | | | | | | | | II* | | | | | | |
| A11H Other plain vitamin preparations | | | | | | | | | | | | | | | | |
| A11HA Other plain vitamin preparations | | | | | | | | | | | | | | | | |
| A11HA03 Tocopherol (vit E) | | | | | | | 0 | | | | | | | | | |
| A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS | | | | | | | | | | | | | | | | |
| A16A Other alimentary tract and metabolism products | | | | | | | | | | | | | | | | |
| A16AA Aminoacids and derivatives | | | | | | | | | | | | | | | | |
| A16AA01 Levocarnitine | | | | | | | | | | I | | | | | | |
| B BLOOD AND BLOOD FORMING ORGANS | | | | | | | | | | | | | | | | |
| B01 ANTITROMBOTIC AGENTS | | | | | | | | | | | | | | | | |
| B01A Antitrombotic agents | | | | | | | | | | | | | | | | |
| B01AC Platelet aggregation inhibitors, excl. Heparin | | | | | | | | | | | | | | | | |
| B01AC07 Dipyridamole | | | | | + | | | | | | | | | | | |
| B03 ANTIANEMICS | | | | | | | | | | | | | | | | |
| B03A Ironpreparations | | | | | | | | | | | | | | | | |
| B03AA Iron bivalent, oral preparations | | | | | | | | | | | | | | | | |
| B03AA07 Ferrous sulfate | | | | | | I | | | | | | | | | | |
| B03X Other antianemic preparations | | | | | | | | | | | | | | | | |
| B03XA Other antianemic preparations | | | | | | | | | | | | | | | | |
| B03XA01 Erythropoietin alpha | | | | | + | | I | | | | | | | | | |
| B03XA01 Erythropoietin beta | | | | | + | | I | | | | | | | | | |
| C CARDIOVASCULAR SYSTEM | | | | | | | | | | | | | | | | |
| C01 CARDIAC THERAPY | | | | | | | | | | | | | | | | |
| C01A Cardiac glycosides | | | | | | | | | | | | | | | | |
| C01AA04 Digitoxin | | | | | | | II | | | | | | | | | |
| C01AA05 Digoxin | | | | | | 0 | II | | | II* | | | | | | |
| C01AA08 Methylidigoxin | | | | | | | | | | II* | | | | | | |
| C01B Antiarrhythmics, class I and III | | | | | | | | | | | | | | | | |
| C01BA Antiarrhythmics class Ia | | | | | | | | | | | | | | | | |
| C01BA01 Quinidine | | | | | | | I | | | | | | | | | |
| C01BA03 Disopyramide | | | | | | | I | | | | | | | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|----------------------|--|----------------------------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| | not yet determined | Hydroquinidine | | | | | | I | | | | | | | | | |
| <i>C01BB</i> | <i>Antiarrhythmics class Ib</i> | | | | | | | | | | | | | | | | |
| | C01BB01 | Lidocaine | | | | | | III | | | | | | | | | |
| | C01BB02 | Mexiletine | | | | | | I | | | | | | | | | |
| | C01BB04 | Aprindine | | | | | | I | | | | | | | | | |
| <i>C01B</i> | <i>Antiarrhythmics class Ic</i> | | | | | | | | | | | | | | | | |
| | C01BC03 | Propafenone | | | | | | | + | | | | | | | | |
| | C01BC04 | Flecainide | | | | | | | + | | | | | | | | |
| <i>C01BD</i> | <i>Antiarrhythmics class III</i> | | | | | | | | | | | | | | | | |
| | C01BD01 | Amiodarone | | | | | | | | 0 | | | | | | | |
| | C01BD05 | Ibutilide | | | | | | | | | | | | | | | |
| <i>C01BG</i> | <i>Other class I antiarrhythmics</i> | | | | | | | | | | | | | | | | |
| | C01BG07 | Cibenzoline | | | | | | | | | | | | | | | |
| <i>C01D</i> | <i>Vasodilators used in cardiac diseases</i> | | | | | | | | | | | | | | | | |
| <i>C01DA</i> | <i>Organic nitrates</i> | | | | | | | | | | | | | | | | |
| | C01DA02 | Glyceryl trinitrate | | | | | | | + | I | | | | | | | II* |
| | C01DA05 | Pentaerythryl tetranitrate | | | | | | | + | | | | | | | | |
| | C01DA08 | Isosorbide dinitrate | 20 | 1 | 1/0 | | | | + | | | | | | | | II* |
| | C01DA14 | Isosorbide mononitrate | | | | | | | + | I | | | | | | | |
| <i>C01DX</i> | <i>Other vasodilators used in cardiac diseases</i> | | | | | | | | | | | | | | | | |
| | C01DX03 | Oxyfedrine | | | | | | | | | | | | | | | I* |
| | C01DX06 | Hexobendine | | | | | | | + | | | | | | | | |
| | C01DX12 | Molsidomine | | | | | | | + | | | | | | | | |
| | C01DX15 | Cloridarol | | | | | | | + | | | | | | | | |
| | C01DX16 | Nicorandil | | | | | | | | | | | | | | | II* |
| <i>C01E</i> | <i>Other cardiac preparations</i> | | | | | | | | | | | | | | | | |
| <i>C01EB</i> | <i>Other cardiac preparations</i> | | | | | | | | | | | | | | | | |
| | C01EB09 | Ubidecarenone | | | | | | | | | | | | | | | I |
| | C01EB10 | Adenosine | | | | | | | | I | | | | | | | II |
| | C01EB15 | Trimetazidine | | | | | | | + | | | | | | | | 0 |
| | <i>Cardiac sedatives</i> | | | | | | | | | | | | | | | | |
| | not yet determined | Meprobamate | | | | | | | | | | | | | | | I |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCHRIJN | | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|---|-----------|------------|--|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| not yet determined | Phenobarbital | | | | | | | I | | | | | | | | | | |
| not yet determined | Phenobarbital - calcium gluconate and bromate | | | | | | | I | | | | | | | | | | |
| not yet determined | Passiflora aubepine | | | | | | | I | | | | | | | | | | |
| C02 ANTIHYPERTENSIVES | | | | | | | | | | | | | | | | | | |
| C02A Antiadrenergic agents, centrally acting | | | | | | | | | | | | | | | | | | |
| C02AA Rauwolfia alkaloids | | | | | | | | | | | | | | | | | | |
| C02AA02 | Reserpine | 0.1 | 3.6 | 3/0 | | | | | | | | | | | | | | + |
| | | 0.25 | 3.5 | 2/0 | | | | | | | | | | | | | | |
| C02AB Methyldopa | | | | | | | | | | | | | | | | | | |
| C02AB02 | Methyldopa (racemic) | 250 | 3.5 | 2/1 | | + | III | I | | | II* | | + | + | | | | |
| C02AB01 | Methyldopa (levorotatory) | 250 | 3 | 1/0 | | | | | | | | | + | + | | | | |
| C02AC Imidazolin receptor agonists | | | | | | | | | | | | | | | | | | |
| C02AC01 | Clonidine | 0.025 | 4 | 2/1 | | + | | I | | | II* | | + | + | | | | |
| | | 0.075 | 4 | 2/2 | | | | | | | | | | | | | | |
| | | 0.1 | 4 | 1/1 | | | | | | | | | | | | | | |
| C02AC02 | Guanfacine | | | | | + | | I | | | | | | | | | | + |
| C02AC05 | Moxonidine | | | | | | | I | | | | | | | | | | |
| C02AC06 | Rilmenidine | | | | | | | I | | | | | | | | | | |
| C02C Antiadrenergic agents, peripherally acting | | | | | | | | | | | | | | | | | | |
| C02CA Alpha-adrenoreceptor antagonists | | | | | | | | | | | | | | | | | | |
| C02CA01 | Prazosin | | | | | + | | I | | | | | | | | | | |
| C02CA02 | Indoramin | 25 | 3 | 1/0 | | + | | I | | | | | | | | | | |
| C02CA04 | Doxazosin | | | | | + | I | | | | | | | | | | | |
| C02CA06 | Urapidil | | | | | + | | I | | | | | | | | | | |
| C02CC Guanidine derivatives | | | | | | | | | | | | | | | | | | |
| C02CC02 | Guanethidine | 10 | 3 | 2/1 | | | | | | | | | | | | | | + |
| C02D Arteriolar smooth muscle, agents acting on | | | | | | | | | | | | | | | | | | |
| C02DA Thiazide derivatives | | | | | | | | | | | | | | | | | | |
| C02DA01 | Diazoxide | | | | | + | | | | | | | | | | | | |
| C02DB Hydrazinophthalazine derivatives | | | | | | | | | | | | | | | | | | |
| C02DB02 | Hydralazine | | | | | + | | | | | | | | | | | | |
| C02DC Pyrimidine derivatives | | | | | | | | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|------------------------------------|---|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| C02DC01 | Minoxidil | | | | | + | 0 | | | | II* | | | | | | |
| C03 DIURETICS | | | | | | | | | | | | | | | | | |
| C03A | Low ceiling diuretics, thiazides | | | | | | | | | | | | | | | | |
| C03AA | Thiazides, plain | | | | | | | | | | | | | | | | |
| C03AA | Thiazide diuretics | | | | | | | | | | | | | | | | |
| C03AA03 | Hydrochlorothiazide | | | | | + | I | | | | II* | | | | | | |
| C03AX | Thiazides, combinations with other drugs | | | | | | | | | | | | | | | | |
| | not yet determined Benflumethiazide - reserpine | | | | | | | | I | | | | | | | | |
| C03B | Low ceiling diuretics, excl. thiazides | | | | | | | | | | | | | | | | |
| C03BA | Sulfonamides, plain | | | | | | | | | | | | | | | | |
| C03BA04 | Chlortalidone | | | | | + | I | | | | II* | | | | | | |
| C03BA08 | Metolazone | | | | | | | | | | II* | | | | | | |
| C03BA10 | Xipamide | | | | | + | | | | | II* | | | | | | |
| C03BA11 | Indapamide | | | | | + | | | | | II* | | | | | | |
| C03C | High ceiling diuretics | | | | | | | | | | | | | | | | |
| C03CA | Sulfonamides, plain | | | | | | | | | | | | | | | | |
| C03CA01 | Furosemide | | | | | + | I | | | | II* | | | | | | |
| C03CA02 | Bumetanide | | | | | + | | | | | | | | | | | |
| C03CA03 | Piretanide | | | | | + | | | | | | | | | | | |
| C03CA04 | Torasemide | | | | | + | | | | | | | | | | | |
| C03CX | Other high ceiling diuretics | | | | | | | | | | | | | | | | |
| C03CX01 | Etozolin | | | | | + | | | | | | | | | | | |
| C03D | Potassium-sparing agents | | | | | | | | | | | | | | | | |
| C03DA | Aldosterone antagonists | | | | | | | | | | | | | | | | |
| C03DA01 | Spirolactone | | | | | + | I | | | | II | | | | | | |
| C03DB | Other Potassium-sparing agents | | | | | | | | | | | | | | | | |
| C03DB02 | Triamterene | | | | | + | | | | | | | | | | | |
| C04 PERIPHERAL VASODILATORS | | | | | | | | | | | | | | | | | |
| C04A | Peripheral vasodilators | | | | | | | | | | | | | | | | |
| C04AA | 2-amino-1-phenylethanol-derivatives | | | | | | | | | | | | | | | | |
| C04AA01 | Isoxsuprine | | | | | + | | | | | II* | | | | | | |
| C04AA02 | Buphenine | | | | | + | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN | |
|---------------------------------|---|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|---|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| C04AA31 | Bamethan | | | | | + | | | | | | | | | | | | |
| <i>C04AD</i> | <i>Purine derivatives</i> | | | | | | | | | | | | | | | | | |
| C04AD03 | Pentoxifylline | | | | | + | | | | | I | | | | | | | |
| <i>C04AE</i> | <i>Ergot alkaloides</i> | | | | | | | | | | | | | | | | | |
| C04AE02 | Nicergoline | | | | | + | | | | | II* | | | | | | | |
| C04AE04 | Dihydroergocristine | | | | | + | | | | | | | | | | | | |
| C04AE01 | Ergoloid mesylates (dihydroergotoxine) | | | | | + | | | | | | | | | | | | |
| <i>C04AX</i> | <i>Other peripheral vasodilators</i> | | | | | | | | | | | | | | | | | |
| C04AX01 | Cyclandelate | | | | | | | | | | II* | | | | | | | |
| C04AX07 | Vincamine | | | | | + | | | | | | | | | | | | |
| C04AX10 | Moxisylyte | | | | | + | | | | | | | | | | | | |
| C04AX17 | Vinburnine | | | | | + | | | | | | | | | | | | |
| C04AX20 | Buflomedil | | | | | + | | | | | II* | | | | | | | |
| C04AX21 | Naftidrofuryl | | | | | + | | | | | I | | | | | | | |
| C04AX23 | Butalamine | | | | | + | | | | | | | | | | | | |
| C04AX26 | Cetiedil | | | | | + | | | | | | | | | | | | |
| not yet determined | Oxovinca | | | | | + | | | | | | | | | | | | |
| C05 VASOPROTECTIVES | | | | | | | | | | | | | | | | | | |
| <i>C05A</i> | <i>Antihemorrhoidals for topical use</i> | | | | | | | | | | | | | | | | | |
| <i>C05AD</i> | <i>Products containing local anaesthetics</i> | | | | | | | | | | | | | | | | | |
| C05AD06 | Oxetacaine | | | | | | | | | | | | | | | | | + |
| C07 BETA BLOCKING AGENTS | | | | | | | | | | | | | | | | | | |
| <i>C07A</i> | <i>Beta blocking agents</i> | | | | | | | | | | | | | | | | | |
| <i>C07AA</i> | <i>Beta blocking agents, non-selective</i> | | | | | | | | | | | | | | | | | |
| C07AA01 | Alprenolol | | | | | I* | | | | | I | | | | | | | |
| C07AA02 | Oxprenolol | | | | | II* | II | | I | | II | | | | | | | |
| C07AA03 | Pindolol | | | | | II.2 | | | I | | II | | | | | | w | |
| C07AA05 | Propranolol | 40 | 1.4 | 7/0 | | II.2 | II | II | I | | II | II | | | | | | |
| | | 80 | 2.2 | 3/1 | | | | | | | | | | | | | | |
| C07AA06 | Timolol | | | | | II* | II | II | I | | II | | | | | | | |
| C07AA07 | Sotalol | | | | | I* | + | | 0 | | I | I* | | | | | | |
| C07AA12 | Nadolol | 40-80 | 1 | 1/1 | | II* | II | | I | | II | II | | | | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN | |
|----------------------|--|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|--|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| | | 80-320 | 1 | 1/1 | | | | | | | | | | | | | | |
| | C07AA15 Carteolol | 10 | 1 | 1/0 | I* | I | | 0 | | | II* | | | | | | | |
| | C07AA16 Tertatolol | | | | II* | | | I | | II | II | | | | | | | |
| | C07AA19 Bupranolol | 50-200 | 1 | 1/0 | | | | | | | | | | | | | | |
| | C07AA23 Penbutolol | | | | | | | | | | | | | | | | | |
| | not yet determined Levopenbutolol | | | | | | | 0 | | | | | | | | | | |
| | C07AB Beta blocking agents, selective | | | | | | | | | | | | | | | | | |
| | C07AB02 Metoprolol | 50-100 | 1.6 | 3/0 | II* | II | | I | | II | II | | | | | | | |
| | C07AB03 Atenolol | 50-100 | 1.2 | 5/0 | I | I | I | 0 | | I | I* | | | | | | | |
| | C07AB04 Acebutolol | | | | I* | I | | 0 | | I | I* | | | | | | | |
| | C07AB05 Betaxolol | | | | I* | I | | 0 | | I | I* | | | | | | | |
| | C07AB07 Bisoprolol | 5 | 1 | 1/0 | I* | I | I | 0 | | I | I* | | | | | | | |
| | C07AB08 Celiprolol | | | | I* | I | | 0 | | I | | | | | | | | |
| | C07AB12 Nebivolol | | | | | II | | | | II | | | | | | | | |
| | C07AG Alpha and beta blocking agents | | | | | | | | | | | | | | | | | |
| | C07AG01 Labetalol | | | | I* | I | | 0 | | I | | | | | | | | |
| | C07AG02 Carvedilol | | | | II* | II | II | | | II | II | | | | | | | |
| | C07B Beta blocking agents and thiazides | | | | | | | | | | | | | | | | | |
| | C07BA Beta blocking agents, non-selective and thiazides | | | | | | | | | | | | | | | | | |
| | C07BA02 Oxprenolol and thiazides | | | | | | | | | | | | | | | | | |
| | Oxprenolol - chlortalidone | | | | | | | I | | | | | | | | | | |
| | C07BB Beta blocking agents, selective and thiazides | | | | | | | | | | | | | | | | | |
| | C07BB02 Metoprolol and thiazides | | | | | | | | | | | | | | | | | |
| | Metoprolol - chlortalidone | | | | | | | I | | | | | | | | | | |
| | C07BB03 Atenolol and thiazide | | | | | | | | | | | | | | | | | |
| | Atenolol - chlortalidone | | | | | | | I | | | | | | | | | | |
| | C07BB07 Bisoprolol and thiazide | | | | | | | | | | | | | | | | | |
| | Bisoprolol - hydrochlorothiazide | | | | | | | 0 | | | | | | | | | | |
| | C07C Beta blocking agents and other diuretics | | | | | | | | | | | | | | | | | |
| | C07CA Beta blocking agents, non-selective and other diuretics | | | | | | | | | | | | | | | | | |
| | C07CA03 Pindolol and other diuretics | | | | | | | | | | | | | | | | | |
| | Pindolol - clopamide | | | | | | | I | | | | | | | | | | |

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| C07D Beta blocking agents, thiazides and other diuretics | | | | | | | | | | | | | | | | |
| <i>C07DA Beta blocking agents, non-selective , thiazides and other antidiuretics</i> | | | | | | | | | | | | | | | | |
| C07DA06 | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| C07F Beta blocking agents and other antihypertensives | | | | | | | | | | | | | | | | |
| <i>C07FB Beta blocking agents, selective and other antihypertensives</i> | | | | | | | | | | | | | | | | |
| C07FB02 | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| C07FB03 | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| C08 CALCIUM CHANNEL BLOCKERS | | | | | | | | | | | | | | | | |
| C08C Selective calcium channel blockers with mainly vascular effects | | | | | | | | | | | | | | | | |
| <i>C08CA Dihydropyridine derivatives</i> | | | | | | | | | | | | | | | | |
| C08CA01 | | | | | + | I | I | | | | II* | | | | | |
| C08CA02 | | | | | + | | I | | | | | | | | | |
| C08CA03 | | | | | + | | 0 | | | | II* | | | | | |
| C08CA04 | | | | | + | | 0 | | | | II* | | | | | |
| C08CA05 | | 3 | 1/0 | | + | I | I | | | | II* | | | | | |
| C08CA06 | | | | | + | | | | | | II* | | | | | |
| C08CA07 | | | | | + | | | | | | | | | | | |
| C08CA08 | | | | | + | | I | | | | II* | | | | | |
| C08CA09 | | | | | + | | I | | | | II* | | | | | |
| C08CA10 | | | | | | | | | | | II* | | | | | |
| C08CA13 | | | | | + | | | | | | II* | | | | | |
| C08D Selective calcium channel blockers with direct cardiac effects | | | | | | | | | | | | | | | | |
| <i>C08DA Phenylalkylamine derivatives</i> | | | | | | | | | | | | | | | | |
| C08DA01 | | | | | + | I | I | | | | | | | | | |
| C08DA51 | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| <i>C08DB Benzothiazepine derivatives</i> | | | | | | | | | | | | | | | | |
| C08DB01 | 90 | 1 | 1/0 | | + | I | I,II | | | | II* | | | | | |
| C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM | | | | | | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| C09A ACE inhibitors | | | | | | | | | | | | | | | | |
| C09AA ACE inhibitors, plain | | | | | | | | | | | | | | | | |
| C09AA01 Captopril | 1 | 1/0 | | | + | I | I | | | II* | | | | | | |
| C09AA02 Enalapril | 1 | 1/0 | | | + | I | | | | II* | | | | | | |
| C09AA03 Lisinopril | | | | | + | | | | | II* | | | | | | |
| C09AA04 Perindopril | | | | | + | | I | | | II* | | | | | | |
| C09AA05 Ramipril | | | | | + | | | | | II* | | | | | | |
| C09AA06 Quinapril | | | | | + | | I | | | II* | | | | | | |
| C09AA07 Benazepril | | | | | + | | I | | | | | | | | | |
| C09AA08 Cilazapril | | | | | + | | I | | | II* | | | | | | |
| C09AA09 Fosinopril | | | | | + | | I | | | II* | | | | | | |
| C09AA10 Trandolapril | | | | | + | | I | | | II* | | | | | | |
| C09AA13 Moexipril | | | | | | | I | | | | | | | | | |
| C09AA16 Imidapril | | | | | | | I | | | | | | | | | |
| C09B ACE inhibitors, combinations | | | | | | | | | | | | | | | | |
| C09BA ACE inhibitors and diuretics | | | | | | | | | | | | | | | | |
| C09BA01 Captopril and diuretics | | | | | | | I | | | | | | | | | |
| C09BA02 Enalapril and diuretics | | | | | | | I | | | | | | | | | |
| C09BA03 Lisinopril and diuretics | | | | | | | I | | | | | | | | | |
| C09BA04 Perindopril and diuretics | | | | | | | I | | | | | | | | | |
| C09BA06 Quinapril and diuretics | | | | | | | I | | | | | | | | | |
| C09BA07 Benazepril and diuretics | | | | | | | I | | | | | | | | | |
| C09BA09 Fosinopril and diuretics | | | | | | | I | | | | | | | | | |
| C09C Angiotensin II antagonists, plain | | | | | | | | | | | | | | | | |
| C09CA Angiotensin II antagonists, plain | | | | | | | | | | | | | | | | |
| C09CA01 Losartan | | | | | | I | I | | | II* | | | | | | |
| C09CA02 Eprosartan | | | | | | | | | | II* | | | | | | |
| C09CA03 Valsartan | | | | | | | I | | | II* | | | | | | |
| C09CA04 Irbesartan | | | | | | | I | | | II* | | | | | | |
| C09CA06 Candesartan | | | | | | | I | | | II* | | | | | | |
| C09CA07 Telmisartan | | | | | | | I | | | II* | | | | | | |
| C09D Angiotensin II antagonists, combinations | | | | | | | | | | | | | | | | |

| DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|--|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| ATC + SUBSTANCE NAME | | | | | | | | | | | | | | | |
| <i>C09DA</i> | <i>Angiotensin II receptor antagonists and diuretics</i> | | | | | | | | | | | | | | |
| C09DA03 | Valsartan and diuretics | | | | | | | | | | | | | | |
| C09DA04 | Irbesartan and diuretics | | | | | | | | | | | | | | |
| C10 LIPID MODIFYING AGENTS | | | | | | | | | | | | | | | |
| <i>C10A</i> | <i>Lipid modifying agents, plain</i> | | | | | | | | | | | | | | |
| <i>C10AA</i> | <i>HMG-CoA reductase inhibitors</i> | | | | | | | | | | | | | | |
| C10AA01 | Simvastatin | | | | | | | | | | | | | | |
| C10AA03 | Pravastatin | | | | | | | | | | | | | | |
| C10AA04 | Fluvastatin | | | | | | | | | | | | | | |
| C10AA05 | Atorvastatin | | | | | | | | | | | | | | |
| C10AA06 | Cerivastatin | | | | | | | | | | | | | | |
| <i>C10AB</i> | <i>Fibrates</i> | | | | | | | | | | | | | | |
| C10AB02 | Bezafibrate | | | | | | | | | | | | | | |
| C10AB04 | Gemfibrozil | | | | | | | | | | | | | | |
| C10AB05 | Fenofibrate | | | | | | | | | | | | | | |
| C10AB08 | Ciprofibrate | | | | | | | | | | | | | | |
| <i>C10AC</i> | <i>Bile acid sequestrants</i> | | | | | | | | | | | | | | |
| C10AC01 | Colestyramine | | | | | | | | | | | | | | |
| <i>C10AX</i> | <i>Other lipid modifying agents</i> | | | | | | | | | | | | | | |
| C10AX03 | Tiadenol | | | | | | | | | | | | | | |
| C10AX04 | Benfluorex | | | | | | | | | | | | | | |
| C10AX06 | Omega-3-triglycerides | | | | | | | | | | | | | | |
| D DERMATOLOGICALS | | | | | | | | | | | | | | | |
| D01 ANTIFUNGALS FOR DERMATOLOGICAL USE | | | | | | | | | | | | | | | |
| <i>D01A</i> | <i>Antifungals for topical use</i> | | | | | | | | | | | | | | |
| <i>D01AC</i> | <i>Imidazole and triazole derivatives</i> | | | | | | | | | | | | | | |
| D01AC06 | Tiabendazole | | | | | | | | | | | | | | |
| D01AC08 | Ketoconazole (topical) | | | | | | | | | | | | | | |
| G GENITO URINAY SYSTEM AND SEX HORMONES | | | | | | | | | | | | | | | |
| G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM | | | | | | | | | | | | | | | |
| <i>G03A</i> | <i>Hormonal contraceptives for systemic use</i> | | | | | | | | | | | | | | |
| <i>G03AC</i> | <i>Progestogens</i> | | | | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| G03AC03 Levonorgestrel | | | | | | I | | | | | | | | | | |
| G03D Progestogens | | | | | | | | | | | | | | | | |
| G03DA Pregnen-4-derivatives | | | | | | | | | | | | | | | | |
| G03DA04 Progesterone | | | | | | I | | | | | | | | | | |
| G03G Gonadotropins and other ovulation stimulants | | | | | | | | | | | | | | | | |
| G03GB Ovulation stimulants, synthetic | | | | | | | | | | | | | | | | |
| G03GB02 Clomifene | | | | | + | | | | | | | | | | | |
| G04 UROLOGICALS | | | | | | | | | | | | | | | | |
| G04B Other urologicals, incl. antispasmodics | | | | | | | | | | | | | | | | |
| G04BD Urinary antispasmodics | | | | | | | | | | | | | | | | |
| G04BD02 Flavoxate | | | | | | | 0 | | | | | | | | | |
| G04BD04 Oxybutynin | | | | | + | II | I | | | | + | + | | | | |
| G04BD07 Tolterodine | | | | | | | I | | | | | | | | | |
| G04BD09 Trospium | | | | | | | I | | | | | | | | | |
| G04BE Drugs in erectile dysfunction | | | | | | | | | | | | | | | | |
| G04BE01 Alprostadil | | | | | | | 0 | I | | | | | | | | |
| G04BE02 Papaverine | | | | | | | | I | | | | | | | | |
| G04BE03 Sildenafil | | | | | | | | I | | | | | | | | |
| G04BE04 Yohimbin | | | | | | | | I | | | | | | | | |
| G04BE06 Moxisylyte | | | | | | | | I | | | | | | | | |
| G04C Drugs used in benign prostatic hypertrophy | | | | | | | | | | | | | | | | |
| G04CA Alpha-adrenoreceptor antagonists | | | | | | | | | | | | | | | | |
| G04CA01 Alfuzosin | | | | | | | 0 | I | | | | | | | | |
| G04CA02 Tamsulosin | | | | | | | | I | I | | | | | | | |
| G04CA03 Terazosin | | | | | + | | | I | I | | | | | | | |
| G04CB Testosterone 5-alpha reductase inhibitors | | | | | | | | | | | | | | | | |
| G04CB01 Finasteride | | | | | | | 0 | 0 | | | | | | | | |
| H SYSTEMIC HORMONAL PREPARATIONS, EXCL SEX HORMONES AND INSULINS | | | | | | | | | | | | | | | | |
| H02 CORTICOIDS FOR SYSTEMIC USE | | | | | | | | | | | | | | | | |
| H02A Corticoids for systemic use, plain | | | | | | | | | | | | | | | | |
| H02AB Glucocorticoids | | | | | | | | | | | | | | | | |
| H02AB01 Betamethasone | | | | | | | | I | | | | | | | | |

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|-------------------------------------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| H02AB02 | Dexamethasone | | | | | 0 | I | | | | | | | | | |
| H02AB06 | Prednisolone | | | | | 0 | I | | | | | | | | | |
| H02AB07 | Prednisone | | | | | 0 | I | | | | | | | | | |
| H02AB08 | Triamcinolone | | | | | 0 | I | | | | | | | | | |
| | Betamethasone - dexchlorpheniramine | | | | | | I | | | | | | | | | |
| H04 PANCREATIC HORMONES | | | | | | | | | | | | | | | | |
| H04A Glycogenolytic hormones | | | | | | | | | | | | | | | | |
| H04AA Glycogenolytic hormones | | | | | | | | | | | | | | | | |
| H04AA01 | Glucagon | | | + | + | 0 | | | II | | | | | | | |
| J ANTIINFECTIVES FOR SYSTEMIC USE | | | | | | | | | | | | | | | | |
| J01 ANTIBACTERIALS FOR SYSTEMIC USE | | | | | | | | | | | | | | | | |
| J01A Tetracyclines | | | | | | | | | | | | | | | | |
| J01AA Tetracyclines | | | | | | | | | | | | | | | | |
| J01AA02 | Doxycycline | | | | + | 0 | | | | | | | | | | |
| J01AA03 | Chlortetracycline | | | | + | | | | | | | | | | | |
| J01AA06 | Oxytetracycline | | | | + | | | | | | | | | | | |
| J01AA07 | Tetracycline | | | | + | I | | | | | | | | | | |
| J01AA08 | Minocycline | | | | + | | | | | | | | | | | |
| J01C Beta-lactam antibacterials, penicillins | | | | | | | | | | | | | | | | |
| J01CA Penicillins with extended spectrum | | | | | | | | | | | | | | | | |
| J01CA07 | Pivmecillinam | | | | | | | 0 | | | | | | | | |
| J01D Other beta-lactamantibacterials | | | | | | | | | | | | | | | | |
| J01DH Carbapenems | | | | | | | | | | | | | | | | |
| J01DH51 | Imipenem and enzyme inhibitor | | | | | | I | | | | | | | | | |
| J01E Sulfonamides and trimethoprim | | | | | | | | | | | | | | | | |
| J01EA Trimethoprim and derivatives | | | | | | | | | | | | | | | | |
| J01EA01 | Trimethoprim | | | | | 0 | 0 | | | | | | | | | |
| J01EB Short-acting sulfonamides | | | | | | | | | | | | | | | | |
| J01EB02 | Sulfamethizole | | | | | | 0 | | | | | | | | | |
| J01EE Combinations of sulfonamides and trimethoprim, incl. Derivatives | | | | | | | | | | | | | | | | |
| J01EE02 | Sulfadiazine - trimethoprim | | | | | | 0 | | | | | | | | | |
| J01EE51 | Sulfamethoxazol - trimethoprim | | | | | 0 | 0 | | | | | | | | | |

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| J01F <i>Macrolides, Lincosamides and streptogramins</i> | | | | | | | | | | | | | | | | |
| <i>J01FA Macrolides</i> | | | | | | | | | | | | | | | | |
| J01FA10 Azithromycin | | | | | | | 0 | | | | | | | | | |
| J01M <i>Quinolone antibacterials</i> | | | | | | | | | | | | | | | | |
| <i>J01MA Fluoroquinolones</i> | | | | | | | | | | | | | | | | |
| J01MA01 Ofloxacin | | | | | + | 0 | I | | | | | | | | | |
| J01MA02 Ciprofloxacin | | | | | + | I | I | | | | | | | | | |
| J01MA03 Pefloxacin | | | | | | | I | | | | | | | | | |
| J01MA04 Enoxacin | | | | | | | I | | | | | | | | | |
| J01MA06 Norfloxacin | | | | | + | 0 | I | | | | | | | | | |
| J01MA07 Lomefloxacin | | | | | | | I | | | | | | | | | |
| <i>J01MB Other quinolones</i> | | | | | | | | | | | | | | | | |
| J01MB02 Nalidixic acid | | | | | + | | I | | | | | | | | | |
| J01MB04 Pipemidic acid | | | | | + | I | I | | | | | | | | | |
| J01MB05 Oxolinic acid | | | | | + | | | | | | | | | | | |
| J01MB07 Flumequine | | | | | | | I | | | | | | | | | |
| J01X <i>Other antibacterials</i> | | | | | | | | | | | | | | | | |
| <i>J01XE Nitrofurans derivatives</i> | | | | | | | | | | | | | | | | |
| J01XE01 Nitrofurantoin | | | | | | 0 | I | | | | | | | | | |
| <i>J01XX Other antibacterials</i> | | | | | | | | | | | | | | | | |
| J01XX07 Nitroxoline | | | | | | | 0 | | | | | | | | | |
| J02 ANTIMYCOTIS FOR SYSTEMIC USE | | | | | | | | | | | | | | | | |
| J02 <i>Antimycotics for systemic use</i> | | | | | | | | | | | | | | | | |
| <i>J02AB Imidazole derivatives</i> | | | | | | | | | | | | | | | | |
| J02AB02 Ketoconazole (oral) | | | | | + | I | | | | | | | | | | |
| J04 ANTIMYCOBACTERIALS | | | | | | | | | | | | | | | | |
| J04A <i>Drugs for treatment of tuberculosis</i> | | | | | | | | | | | | | | | | |
| <i>J04AB Antibiotics</i> | | | | | | | | | | | | | | | | |
| J04AB02 Rifampicin | | | | | | | I | | | | | | | | | |
| <i>J04AC Hydrazides</i> | | | | | | | | | | | | | | | | |
| J04AC01 Isoniazid | | | | | + | 0 | | | | | | | | | | |
| <i>J04AK Other drugs for treatment of tuberculosis</i> | | | | | | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| J04AK02 Ethambutol | | | | | + | | | | | | | | | | | |
| J05 ANTIVIRALS FOR SYSTEMIC USE | | | | | | | | | | | | | | | | |
| J05A Direct acting antivirals | | | | | | | | | | | | | | | | |
| J05AE Protease inhibitors | | | | | | | | | | | | | | | | |
| J05AE03 Ritonavir | | | | | | | | | | | | + | | | | |
| J05AF Nucleoside and nucleotide reverse transcriptase inhibitors | | | | | | | | | | | | | | | | |
| J01AF01 Zidovudine | | | | | | | | | | | | + | | | | |
| L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | | | | | | | | | | | | | | | | |
| L01 ANTINEOPLASTIC SUBSTANCES | | | | | | | | | | | | | | | | |
| L01A Alkylating agents | | | | | | | | | | | | | | | | |
| L01AA Nitrogen mustard analogs | | | | | | | | | | | | | | | | |
| L01AA06 Ifosfamide | | | | | | | | II | | | | | | | | |
| L01AB Alkyl sulfonates | | | | | | | | | | | | | | | | |
| L01AB01 Busulfan | | | | | | | | I | | | | | | | | |
| L01AD Nitrosoureas | | | | | | | | | | | | | | | | |
| L01AD01 Carmustine | | | | | | | | III | | | | | | | | |
| L01AD05 Fotemustine | | | | | | | | II | | | | | | | | |
| L01AX Other alkylating agents | | | | | | | | | | | | | | | | |
| L01AX03 Temozolomide | | | | | | | | I | | | | | | | | |
| L01AX04 Dacarbazine | | | | | | | | I | | | | | | | | |
| L01B Antimetabolites | | | | | | | | | | | | | | | | |
| L01BA Folic acid analogues | | | | | | | | | | | | | | | | |
| L01BA01 Methotrexate | | | | | | | | II | | | | | | | | |
| L01BA04 Raltitrexed | | | | | | | | I | | | | | | | | |
| L01BB Purine analogues | | | | | | | | | | | | | | | | |
| L01BB04 Cladribine | | | | | | | | II | | | | | | | | |
| L01BB05 Fludarabine | | | | | | | | II | | | | | | | | |
| L01BC Pyrimidinenalogues | | | | | | | | | | | | | | | | |
| L01BC01 Cytarabine | | | | | | | | II | | | | | | | | |
| L01BC02 Fluorouracil | | | | | | 0 | | II | | | | | | | | |
| L01BC05 Gemcitabine | | | | | | | | II | | | | | | | | |
| L01C Plant alkaloids and other natural products | | | | | | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| L01CA <i>Vinca- alkaloids and analogues</i> | | | | | | | | | | | | | | | | |
| L01CA01 Vinblastine | | | | | | | II | | | | | | | | | |
| L01CA02 Vincristine | | | | | | | II | | | | | | | | | |
| L01CA03 Vindesine | | | | | | | II | | | | | | | | | |
| L01CA04 Vinorelbine | | | | | | | II | | | | | | | | | |
| L01CB <i>Podophyllotoxine derivatives</i> | | | | | | | | | | | | | | | | |
| L01CB01 Etoposide | | | | | | | II | | | | | | | | | |
| L01CD <i>Taxanes</i> | | | | | | | | | | | | | | | | |
| L01CD01 Paclitaxel | | | | | | | II | | | | | | | | | |
| L01CD02 Docetaxel | | | | | | | II | | | | | | | | | |
| L01D <i>Cytotoxic antibiotics and related substances</i> | | | | | | | | | | | | | | | | |
| L01DB <i>Antracyclines and related substances</i> | | | | | | | | | | | | | | | | |
| L01DB01 Doxorubicin | | | | | | | II | | | | | | | | | |
| L01DB02 Daunorubicin | | | | | | | II | | | | | | | | | |
| L01DB03 Epirubicin | | | | | | | II | | | | | | | | | |
| L01DB06 Idarubicin | | | | | | | II | | | | | | | | | |
| L01DB07 Mitoxantrone | | | | | | | II | | | | | | | | | |
| L01X <i>Other antineoplastic agents</i> | | | | | | | | | | | | | | | | |
| L01XA <i>Platinum compounds</i> | | | | | | | | | | | | | | | | |
| L01XA01 Cisplatin | | | | | | | II | | | | | | | | | |
| L01XA02 Carboplatin | | | | | | | II | | | | | | | | | |
| L01XA03 Oxaliplatin | | | | | | | II | | | | | | | | | |
| L01XB <i>Methylhydrazines</i> | | | | | | | | | | | | | | | | |
| L01XB01 Procarbazine | | | | | | | II | | | | | | | | | |
| L01XC <i>Monoclonal antibodies</i> | | | | | | | | | | | | | | | | |
| L01XC02 Rituximab | | | | | | | II | | | | | | | | | |
| L01XX <i>Other antineoplastic agents</i> | | | | | | | | | | | | | | | | |
| L01XX02 Asparaginase | | | | | | | II | | | | | | | | | |
| L01XX05 Hydroxycarbamide | | | | | | | II | | | | | | | | | |
| L01XX08 Pentostatin | | | | | | | II | | | | | | | | | |
| L01XX11 Estramustine | | | | | | | 0 | | | | | | | | | |
| L01XX14 Tretinoïn | | | | | | | 0 | | | | | | | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|-------------------------|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| L01XX17 | Topotecan | | | | | | | II | | | | | | | | | |
| L01XX19 | Irinotecan | | | | | + | | II | | | | | | | | | |
| L01XX23 | Mitotane | | | | | | | | | | | | + | | | | |
| L02 ENDOCRINE THERAPIES | | | | | | | | | | | | | | | | | |
| L02A Hormones and analogs | | | | | | | | | | | | | | | | | |
| L02AA Estrogens | | | | | | | | | | | | | | | | | |
| L02AA01 | Diethylstilbestrol | | | | | | | I | | | | | | | | | |
| L02AA04 | Fosfestrol | | | | | | | 0 | | | | | | | | | |
| not yet determined | Estradiol di-undecylate | | | | | | | I | | | | | | | | | |
| L02AB Progestogens | | | | | | | | | | | | | | | | | |
| L02AB02 | Medroxyprogesterone | | | | | | | 0 | I | | | | | | | | |
| L02AE Gonadotropin-releasing-hormone analogs | | | | | | | | | | | | | | | | | |
| L02AE01 | Buserelin | | | | | | | I | | | | | | | | | |
| L02AE02 | Leuprorelin | | | | | | | I | | | | | | | | | |
| L02AE03 | Goserelin | | | | | | | 0 | | | | | | | | | |
| L02AE04 | Triptorelin | | | | | | | I | | | | | | | | | |
| L02B Hormone antagonists | | | | | | | | | | | | | | | | | |
| L02BB Antiandrogenen | | | | | | | | | | | | | | | | | |
| L02BB01 | Flutamide | | | | | | | 0 | | | | | | | | | |
| L02BB02 | Nilutamide | | | | | | | I | | | | | | | | | |
| L02BBO3 | Bicalutamide | | | | | | | I | | | | | | | | | |
| not yet determined | Cyproterone | | | | | + | I | 0 | | | | | | | | | |
| L02BG Enzyme inhibitors | | | | | | | | | | | | | | | | | |
| L02BG01 | Aminogluthetimide | | | | | | | I | | | | | | | | + | |
| L02BG02 | Formestane | | | | | | | II | | | | | | | | | |
| L02BG03 | Anastrozole | | | | | | | I | | | | | + | | | | |
| L02BG04 | Letrozole | | | | | | | I | | | | | | | | | |
| L02BG06 | Exemestane | | | | | | | | | | | | | | | | + |
| L03 IMMUNOSTIMULATORS | | | | | | | | | | | | | | | | | |
| L03A Cytokines and immunomodulators | | | | | | | | | | | | | | | | | |
| L03AA Colony stimulating factors | | | | | | | | | | | | | | | | | |
| L03AA10 | Lenograstim | | | | | + | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| L03AB Interferons | | | | | | | | | | | | | | | | |
| L03AB01 Interferon alfa natural | | | | | | | I | | | | | + | | | | |
| L03AB02 Interferon beta natural | | | | | | | I | | | | | | | | | |
| L03AB03 Interferon gamma | | | | | | | I | | | | | + | | | | |
| L03AC Interleukins | | | | | | | | | | | | | | | | |
| L03AC01 Aldesleukin | | | | | | | | | | | | | | | | + |
| L04 IMMUNOSUPPRESSIVES | | | | | | | | | | | | | | | | |
| L04A Immunosuppressive agents | | | | | | | | | | | | | | | | |
| L04AA Selective immunosuppressive agents | | | | | | | | | | | | | | | | |
| L04AA05 Tacrolimus | | | | | | | | | | | | | | | | + |
| M MUSCULO-SKELETAL SYSTEM | | | | | | | | | | | | | | | | |
| M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS | | | | | | | | | | | | | | | | |
| M01A Antiinflammatory and antirheumatic products, non-steroids | | | | | | | | | | | | | | | | |
| M01AA Butylpyrazolidines | | | | | | | | | | | | | | | | |
| M01AA01 Phenylbutazon | 200 | 2.5 | 2/0 | | + | | I | | | | | | | | | |
| M01AA03 Oxyphenbutazone (oxipizona) | | | | | + | | | | | | | | | | | |
| M01AB Acetic acid derivatives and related substances | | | | | | | | | | | | | | | | |
| M01AB01 Indometacin | 25 50 | 2.5 3 | 2/1 1/2 | | + | I | II | | | | | + | + | | | + |
| M01AB02 Sulindac | | | | | + | | II | | | | | | | | | |
| M01AB03 Tolmetin | | | | | + | | | | | | | | | | | |
| M01AB05 Diclofenac | | | | | + | I | I | | I | | | | | | | |
| M01AB08 Etodolac | | | | | | | I | | | | | | | | | |
| M01AB10 Fentiazac | | | | | + | | | | | | | | | | | |
| M01AB11 Acemetacin | | | | | + | | | | | | | + | | | | |
| M01AB14 Proglumetacin | | | | | + | | | | | | | | | | | |
| M01AB15 Ketorolac | | | | | + | | | | | | | | | | | |
| M01AB16 Aceclofenac | | | | | + | | | | | | | | | | | |
| M01AC Oxicams | | | | | | | | | | | | | | | | |
| M01AC01 Piroxicam | | | | | + | | I | | | | | | | | | |
| Piroxicam-β cyclodextrine | | | | | | | I | | | | | | | | | |
| M01AC02 Tenoxicam | | | | | | | I | | | | | | | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN | |
|--|--------------------|-----------|-----------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|--|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| M01AC06 | Meloxicam | | | | | + | | I | | | | | | | | | | |
| <i>M01AE Propionic acid derivatives</i> | | | | | | | | | | | | | | | | | | |
| M01AE01 | Ibuprofen | | | | | | 0 | I | I | I | | | | | | | | |
| M01AE02 | Naproxen | | | | | + | I | I | I | I | | | | | | | | |
| M01AE03 | Ketoprofen | | | | | + | | I | I | I | | | | | | | | |
| M01AE04 | Fenoprofen | | | | | | | I | I | I | | | | | | | | |
| M01AE05 | Fenbufen | | | | | + | | | | | | | | | | | | |
| M01AE09 | Flurbiprofen | | | | | + | | I | | | | | | | | | | |
| M01AE11 | Tiaprofenic acid | 400 | 1 | 1/0 | | + | | I | | | | | | | | | | |
| M01AE16 | Alminoprofen | | | | | | | I | | | | | | | | | | |
| M01AE17 | Dexketoprofen | | | | | + | | | | | | | | | | | | |
| not yet determined | Butibufen | | | | | + | | | | | | | | | | | | |
| <i>M01AG Fenamates</i> | | | | | | | | | | | | | | | | | | |
| M01AG01 | Mefenamic acid | | | | | + | I | I | I | I | | | | | | | | |
| M01AG04 | Meclofenamic acid | | | | | + | | | | | | | | | | | | |
| <i>M01AH Coxibs</i> | | | | | | | | | | | | | | | | | | |
| M01AH04 | Parecoxib | | | | | | | | I | I | | | | | | | | |
| <i>M01AX Other antiinflammatory and antirheumatic agents, non-steroids</i> | | | | | | | | | | | | | | | | | | |
| M01AX01 | Nabumetone | | | | | | 0 | I | | | | | | | | | | |
| M01AX02 | Niflumic Acid | | | | | + | | I | | | | | | | | | | |
| M01AX17 | Nimesulide | | | | | | | I | | | | | | | | | | |
| M01AX18 | Feprazone | | | | | + | | | | | | | | | | | | |
| M01AX22 | Morniflumate | | | | | + | | | | | | | | | | | | |
| not yet determined | Isonixin | | | | | + | | | | | | | | | | | | |
| M03 MUSCLE RELAXANTS | | | | | | | | | | | | | | | | | | |
| <i>M03A Muscle relaxants, peripherally acting agents</i> | | | | | | | | | | | | | | | | | | |
| <i>M03AB Choline derivatives</i> | | | | | | | | | | | | | | | | | | |
| M03AB01 | Suxamethonium | | | | | | | | | II,III | | | | | | | | |
| <i>M03AC Other quaternary ammonia compounds</i> | | | | | | | | | | | | | | | | | | |
| M03AC03 | Vecuronium | | | | | | | | | II,III | | | | | | | | |
| M03AC04 | Atracurium | | | | | | | | | II,III | | | | | | | | |
| M03AC09 | Rocuronium bromide | | | | | | | | | II,III | | | | | | | | |

| ATC + SUBSTANCE NAME | | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|---------------------|--|-----------|------------|--|-----|------|-------|--------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| M03AC10 | Mivacurium chloride | | | | | | | | II,III | | | | | | | | | |
| M03AC11 | Cisatracurium | | | | | | | | II,III | | | | | | | | | |
| M03B Muscle relaxants, centrally acting agents | | | | | | | | | | | | | | | | | | |
| M03BA Carbamic acid esters | | | | | | | | | | | | | | | | | | |
| M03BA02 | Carisoprodol | | | | | | | | | | | | + | | + | + | + | |
| M03BA03 | Methocarbamol | | | | | | + | | I | | | | | | + | | + | |
| M03BA05 | Febarbamate | | | | | | + | | | | | | | | | | | |
| not yet determined | Tetrabamate | | | | | | + | | III | | | | | | | | | |
| M03BB Oxazol-, thiazine-, and triazine-derivatives | | | | | | | | | | | | | | | | | | |
| M03BB02 | Chlormezanone | | 100 | 2 | 2/0 | | | | | | | | | | + | | | |
| | | | 200 | 2 | 2/0 | | | | | | | | | | | | | |
| M03BB03 | Chlorzoxazone | | | | | | | | | | | | | | + | | + | |
| M03BC Ethers , chemically close to antihistamines | | | | | | | | | | | | | | | | | | |
| M03BC01 | Orphenadrine | | | | | | | | | | | | + | | | w | | |
| M03BX Other centrally acting agents | | | | | | | | | | | | | | | | | | |
| M03BX01 | Baclofen | | 5 | 1 | 1/1 | | + | III | | | | | + | + | + | + | + | |
| | | | 20 | 2 | 1/0 | | | | | | | | | | | | | |
| M03BX02 | Tizanidine | | | | | | + | | | | | | + | + | + | + | + | |
| M03BX03 | Fenyramidol | | | | | | | | | | | | + | | | | | |
| M03BX05 | Thiocolchicoside | | | | | | | | I | | | | + | | | | | |
| M03BX07 | Tetrazepam | | | | | II* | + | | I,II | | II | | + | | | | | |
| M03BX06 | Mephenesin | | | | | | | | I | | | | | | | | | |
| M03BX08 | Cyclobenzaprine | | | | | | | | I | | | | | | | | | |
| M03C Muscle relaxants, directly acting agents | | | | | | | | | | | | | | | | | | |
| M03CA Dantrolene and derivatives | | | | | | | | | | | | | | | | | | |
| M03CA01 | Dantrolene | | | | | | | | | | | | | | | + | | |
| M04 ANTIGOUT PREPARATIONS | | | | | | | | | | | | | | | | | | |
| M04A Antigout preparations | | | | | | | | | | | | | | | | | | |
| M04AA Preparations inhibiting uric acid production | | | | | | | | | | | | | | | | | | |
| M04AA01 | Allopurinol | | | | | | | | I | | | | | | | | | |
| M04AB Preparations increasing uric acid excretion | | | | | | | | | | | | | | | | | | |
| M04AB03 | Benzbromarone | | | | | | | 0 | 0 | | | | | | | | | |

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|-----------|------------|--|-----|------|-------|--------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| M05 DRUGS FOR THE TREATMENT OF BONE DISEASES | | | | | | | | | | | | | | | | |
| <i>M05B Drugs affecting bone structure and mineralisation</i> | | | | | | | | | | | | | | | | |
| <i>M05BA Bisphosphonates</i> | | | | | | | | | | | | | | | | |
| M05BA03 Pamidronic acid | | | | | | | I | | | | | | | | | |
| N NERVOUS SYSTEM | | | | | | | | | | | | | | | | |
| N01 ANESTHETICS | | | | | | | | | | | | | | | | |
| <i>N01A Anesthetics, general</i> | | | | | | | | | | | | | | | | |
| <i>N01AB Halogenated hydrocarbons</i> | | | | | | | | | | | | | | | | |
| N01AB01 Halothane | | | | | | | II,III | III | III | | | | | | | |
| N01AB04 Enflurane | | | | | | | | III | III | | | | | | | |
| N01AB06 Isoflurane | | | | | | | | III | III | | | | | | | |
| N01AB07 Desflurane | | | | | | | | III | III | | | | | | | |
| N01AB08 Sevoflurane | | | | | | | II,III | III | III | | | | | | | |
| <i>N01AH Opioid anesthetics</i> | | | | | | | | | | | | | | | | |
| N01AH01 Fentanyl | | | | III | III | III | II,III | III | III | III | + | | + | + | + | + |
| N01AH02 Alfentanil | | | | | | | II,III | III | III | | + | | + | w | | + |
| N01AH03 Sufentanil | | | | | | | II,III | III | III | | + | | + | + | | + |
| N01AH06 Remifentanil | | | | | | | II,III | III | III | | | | | | + | |
| <i>N01AX Other general anesthetics</i> | | | | | | | | | | | | | | | | |
| N01AX03 Ketamine | | | | | | | II,III | III | III | | | | | | | |
| N01AX07 Etomidate | | | | | | | II,III | III | III | | | | | | | |
| N01AX10 Propofol | | | | | | | II,III | III | III | | | | | | | |
| N01AX13 Nitrous oxide | | | | | | | | II | II | | | | | | | |
| not yet determined Flunitrazepam (Narcozep) | | | | | | | II,III | III | | | | | | | | |
| <i>N01B Anesthetics, local</i> | | | | | | | | | | | | | | | | |
| <i>N01BA Esters of aminobenzoic acid</i> | | | | | | | | | | | | | | | | |
| N01BA02 Procaine | | | | | | | I | II | II | | | | | | | |
| <i>N01BB Amides</i> | | | | | | | | | | | | | | | | |
| N01BB01 Bupivacaine | | | | | | | I | III | III | | | | | | | |
| N01BB02 Lidocaine | | | | | | I | I | II | II | | | | | | | |
| N01BB03 Mepivacaine (carbocaine) | | | | | | 0 | I | II | II | | | | | | | |
| N01BB07 Etidocaine | | | | | | | I | | | | | | | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN | |
|--------------------------------------|---|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|---|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| N01BB08 | Articaine | | | | | | | | II | II | | | | | | | | |
| N01BB09 | Ropivacaine | | | | | | | I | II | II | | | | | | | | |
| N01BB51 | Bupivacaine, combinations | | | | | | | | II | II | | | | | | | | |
| N01BB52 | Lidocaine, combinations | | | | | | | | II | II | | | | | | | | |
| N01BB53 | Mepivacaine, combinations | | | | | | | | II | II | | | | | | | | |
| N01BB57 | Etidocaine, combinations | | | | | | | I | | | | | | | | | | |
| N01BB58 | Articaine, combinations | | | | | | | | II | II | | | | | | | | |
| N02 ANALGESICS | | | | | | | | | | | | | | | | | | |
| N02A Opioids | | | | | | | | | | | | | | | | | | |
| N02AA Natural opium alkaloids | | | | | | | | | | | | | | | | | | |
| N02AA01 | Morphine | 10 | U | 0/1 | III | III | | | II | III | III | | | | + | + | + | + |
| | | 20 | 4 | 1/1 | | | | | | | | | | | | | | |
| | Morphine (chlorhydrate) | | | | | | I | II | | | | | | | | | | |
| | Morphine (sulphate) | | | | | | | II | | | | | | | | | | |
| N02AA02 | Opium | | | | | | | I | | | | + | | | | | + | |
| N02AA03 | Hydromorphone | | | | | | | | II | II | | + | | + | | | + | + |
| N02AA04 | Nicomorphine | | | | | | | | | | | + | | + | | | + | |
| N02AA05 | Oxycodone | | | | | | | II | II | II | | + | | + | + | | + | + |
| N02AA08 | Dihydrocodeine | | | | II* | II | II | I | | II | II* | + | + | + | | | | |
| N02AA59 | Codeine, combinations excl .psycholeptics | | | | | | | | I, II | I, II | | | | | | | | |
| | Codeine - noramydopyrine - paracetamol | | | | | | | I | | | | | | | | | | |
| | Codeine - noramydopyrine - tiemonium | | | | | | | I | | | | | | | | | | |
| | Codeine - belladonna - caffeine - paracetamol | | | | | | | I | | | | | | | | | | |
| | Codeine - cineole | | | | | | | I | | | | | | | | | | |
| | Codeine - chlrorpheniramine | | | | | | | II | | | | | | | | | | |
| | Codeine - erysinum | | | | | | | I | | | | | | | | | | |
| | Codeine - ethylmorphine | | | | | | | II | | | | | | | | | | |
| | Codeine - gaiacol | | | | | | | I | | | | | | | | | | |
| | Codeine - paracetamol | | | | | | | I | | | | | + | | | | + | |
| | Codeine - paracetamol - caffeine | | | | | | | | | | | | + | | | | | |
| | Codeine - phenyltoloxamine | | | | | | | II | | | | | | | | | | |
| | Codeine - sodium benzoate | | | | | | | I | | | | | | | | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|----------------------|---|----------------|------------|--|------|------|-------|--------|--------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| | Codeine - sodium benzoate - alcohol | | | | | | | I | | | | | | | | | |
| | Codeine - sodium benzoate - cineole | | | | | | | II | | | | | | | | | |
| | Codeine - sulfogaiacol | | | | | | | I | | | | | | | | | |
| | not yet determined Oxymorphone | | | | | | | | | | | + | | | | | |
| N02AB | Phenylpiperidine derivatives | | | | | | | | | | | | | | | | |
| | N02AB01 Ketobemidone | | | | | | | | | | | + | | | | + | |
| | N02AB02 Pethidine | 50-150 | U | 0/2 | III* | III | III | II | II | III | | + | | + | + | + | + |
| | N02AB03 Fentanyl | | | | III | III | III | II,III | II,III | III | III | + | | + | + | + | + |
| N02AC | Diphenylpropylamine derivatives | | | | | | | | | | | | | | | | |
| | N02AC01 Dextromoramide | | | | III* | | | | II | III | | + | | + | | | |
| | N02AC03 Piritramide | | | | III* | | | | | III | | + | | | | | |
| | N02AC04 Dextropropoxyphene | 65 150 | 2.5 3.3 | 2/1 2/1 | II.2 | II | | I | II | II | II | + | | + | + | + | + |
| | N02AC05 Bezitramide | | | | III* | | | | | III | | + | | | | | |
| | N02AC54 Dextropropoxyphene comb.inations excl . psycholeptics | | | | | | | | II | II | | | | | | | |
| | Dextropropoxyphene – paracetamol | | | | | | | I | | | | | | | | | |
| | Dextropropoxyphene – paracetamol - caffeine | | | | | | | I | | | | | | | | | |
| N02AD | Benzomorphan derivatives | | | | | | | | | | | | | | | | |
| | N02AD01 Pentazocine | 50-100 | 3 | 3/0 | III | + | | III | II | III | | + | | + | + | | |
| N02AE | Oripavine derivatives | | | | | | | | | | | | | | | | |
| | N02AE01 Buprenorphine | 0.2-0.4 | 3.5 | 2/1 | III | III | | II | II | III | | + | | + | + | + | + |
| N02AF | Morphinan derivatives | | | | | | | | | | | | | | | | |
| | N02AF01 Butorphanol | | | | | | | | | | | | | + | | | |
| | N02AF02 Nalbuphine | | 3 | 1/0 | | | | III | II | II | | + | | + | | | |
| | not yet determined Levorphanol | | | | | | | | | | | + | | | | | |
| N02AX | Other opioids | | | | | | | | | | | | | | | | |
| | N02AX01 Tilidine | | | | III* | III | | | | III | | + | | | | | |
| | N02AX02 Tramadol | | | | II.2 | III | III | I | II | III | II | | | + | + | + | + |
| | N02AX52 Tramadol, combinations | | | | | | | | II | III | | | | | | | |
| | not yet determined Meptazinol | 100-200 400 | 1.5 1 | 4/0 1/0 | | | | | | | | | | | | | |
| N02B | Other analgesics and antipyretics | | | | | | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| N02BA Salicylic acid and derivatives | | | | | | | | | | | | | | | | |
| N02BA10 Benorilate | | | | | | | 0 | | | | | | | | | |
| N02BA11 Diflunisal | | | | | | | 0 | | | | | | | | | |
| N02BA20 Acetylsalicylic acid, combinations | | | | | | | | | | | | | | | | |
| Lysine acetylsalicylate - metoclopramide | | | | | | | I | II | | | | | | | | |
| Calcium carbasalate - metoclopramide | | | | | | | I | | | | | | | | | |
| N02BA51 Acetylsalicylic acid, combinations excl. psycholeptics | | | | | | | | | I,II | | | | | | | |
| Acetylsalicylic acid | | | | | | | 0 | | | | | | | | | |
| Acetylsalicylic acid - codeine | | | | | | | I | I | | | | | | | | |
| Acetylsalicylic acid - codeine - caffeine | | | | | | | I | I | | | | | | | | |
| Acetylsalicylic acid - codeine - paracetamol | | | | | | | I | I | | | | | | | | |
| N02BB Pyrazolones | | | | | | | | | | | | | | | | |
| N02BB02 Metamizole sodium (noramipopyrine) | | | | | | | 0 | 0 | | | | | | | | |
| N02BB52 Metamizole sodium, combinations excl. psycholeptics | | | | | | | | | | | | | | | | |
| Noramipopyrine - caffeine | | | | | | | | I | | | | | | | | |
| N02BE Anilides | | | | | | | | | | | | | | | | |
| N02BE01 Paracetamol | | | | | | | 0 | 0 | | | | | | | | |
| N02BE05 Propacetamol | | | | | | | I | | | | | | | | | |
| N02BE51 Paracetamol, combinations excl psycholeptics | | | | | | | | I | I,II | | | | | | | |
| Belladonna - opium - paracetamol - caffeine | | | | | | | I | | | | | | | | | |
| N02BG Other analgesics and antipyretics | | | | | | | | | | | | | | | | |
| N02BG03 Glafenine | 200-400 | 1 | 1/0 | | | | | | | | | | | | | |
| N02BG04 Floctafenine | | | | | + | | I | I | I | | | | + | | | |
| N02BG06 Nefopam | | | | | | | I | | | | | | | | | |
| N02BG07 Flupirtine | 100 | 3 | 1/0 | | | | | | | II | | | | | | |
| not yet determined Clonixin | | | | | | | | | | II | | | | | | |
| N02C Antimigraine preparations | | | | | | | | | | | | | | | | |
| N02CA Ergot alkaloids | | | | | | | | | | | | | | | | |
| N02CA01 Dihydroergotamine | | | | | | | | 0 | | II* | | | | | | |
| N02CA02 Ergotamine | | | | | | | | | | | | | | + | | + |
| N02CA04 Methysergide | | | | | | | I | | | | | | | | | |
| N02CA52 Ergotamine, combinations excl. psycholeptics | | | | | | | | I | I | | | | | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|-----------------------------|-----------|-----------|--|------|------|-------|--------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Ergotamine – caffeine – cyclizine | | | | | | | | I | | | | | | | | | |
| Ergotamine - caffeine - belladonna - paracetamol | | | | | | | | | | | II* | | | | | | |
| Ergotamine – propifenazone | | | | | | | | | | | II* | | | | | | |
| <i>N02CC Selective serotonin (5HT1) agonists</i> | | | | | | | | | | | | | | | | | |
| N02CC01 | Sumatriptan | | | | | + | I | I | II | II | II | | + | | + | | + |
| N02CC02 | Naratriptan | | | | | + | | I | II | II | II | | | | | | + |
| N02CC03 | Zolmitriptan | | | | | + | I | I | II | II | II | | + | | | | |
| N02CC04 | Rizatriptan | | | | | | | I | II | II | II | | | | | | + |
| N02CC05 | Almotriptan | | | | | | | | II | II | | | | | | | + |
| N02CC06 | Eletriptan | | | | | | | | II | II | | | | | | | + |
| N02CC07 | Frovatriptan | | | | | | | | II | II | | | | | | | + |
| <i>N02CX Other antimigraine preparations</i> | | | | | | | | | | | | | | | | | |
| N02CX01 | Pizotifen | | | | | + | | I | II | II | | | | + | | | |
| N02CX02 | Clonidine | | | | | + | | | | | II* | | | + | | | |
| N02CX05 | Dimetotiazine | | | | | + | | | | | | | | | | | |
| N02CX06 | Oxetorone | | | | | | | I | II | II | | | | | | | |
| N03 ANTIEPILEPTICS | | | | | | | | | | | | | | | | | |
| <i>N03A Antiepileptics</i> | | | | | | | | | | | | | | | | | |
| <i>N03AA Barbiturates and derivatives</i> | | | | | | | | | | | | | | | | | |
| N03AA01 | Methylphenobarbital | 30 | U | 0/2 | | | | II | | | II | | + | | + | | |
| | | 100 | U | 0/2 | | | | | | | | | | | | | |
| | | 200 | 4 | 1/0 | | | | | | | | | | | | | |
| N03AA02 | Phenobarbital | 15 | 3.7 | 3/0 | III | III | | III | II | III | III | + | + | + | + | + | + |
| | | 30 | 3.7 | 3/1 | | | | | | | | | | | | | |
| | | 100-150 | 4 | 3/0 | | | | | | | | | | | | | |
| | Phenobarbital, combinations | | | | | | | | II | | | | | | | | |
| N03AA03 | Primidone | 125 | U | 0/1 | III* | III | III | III | II | III | III | | + | | + | + | + |
| <i>N03AB Hydantoin derivatives</i> | | | | | | | | | | | | | | | | | |
| N03AB02 | Phenytoin | 200 | 2 | 2/0 | III | III | III | I, III | II | III | III | | | | + | + | + |
| N03AB05 | Fosphenytoin | | | | | II | | III | II | III | | | | | | + | + |
| <i>N03AD Succinimide derivatives</i> | | | | | | | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|--------------------------|-----------|-----------|------------|--|-----|------|----------|--------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| N03AD01 | Ethosuximide | 250 | 3 | 1/0 | II* | II | | III | II | III | | | | | | + | + | + |
| N03AD03 | Mesuximide | | U | 0/1 | | | | | | | | | | | | | | |
| <i>N03AE Benzodiazepine derivatives</i> | | | | | | | | | | | | | | | | | | |
| N03AE01 | Clonazepam | 0.5 | 4 | 1/0 | II.2 | II | II | I,III | II,III | II | II | + | + | | | + | + | + |
| <i>N03AF Carboxamide derivatives</i> | | | | | | | | | | | | | | | | | | |
| N03AF01 | Carbamazepine | 200 | 3 | 2/1 | II.2 | II | II | I,II,III | II | II | II | | | | | + | + | + |
| | | 600 | 3.2 | 4/0 | | | | | | | | | | | | | | |
| N03AF02 | Oxcarbazepine | | | | | II | | | II | II | | | | | | | + | + |
| <i>N03AG Fatty acid derivatives</i> | | | | | | | | | | | | | | | | | | |
| N03AG01 | Valproic acid | 5mg/kg BW | 2 | 2/0 | II.1 | II | II | III | II | II | II* | | | | | + | + | + |
| N03AG02 | Valpromide | | | | | II | | II, III | II | II | | | | | | | | |
| N03AG03 | Aminobutyric acid | 1000-2000 | 1 | 1/0 | | | | | | | | | | | | | | |
| N03AG04 | Vigabatrin | | 1 | 1/0 | II* | II | | III | II | II | II | | | | | + | + | + |
| N03AG05 | Progabide | | | | | | | | II | II | | | | | | | | |
| N03AG06 | Tiagabine | | | | | II | | III | II | II | III | | + | | | | + | + |
| <i>N03AX Other antiepileptics</i> | | | | | | | | | | | | | | | | | | |
| N03AX09 | Lamotrigine | 120 | 1 | 2/0 | II* | II | II | III | II | II | II* | | | | | w | | + |
| | | 300 | 1 | 1/0 | | | | | | | | | | | | | | |
| N03AX10 | Felbamate | | | | II* | II | | III | II | II | II | | | | | | | |
| N03AX11 | Topiramate | | | | | II | | | II | II | III | | | | | | + | + |
| N03AX12 | Gabapentin (carbapentin) | | | | | II | II | III | II | II | II | | + | | + | + | + | + |
| N03AX13 | Pheneturide | | | | II* | | | | | II | | | | | | | | |
| N03AX14 | Levetiracetam | | | | | II | | | II | II | I | | | | | | | |
| N03AX16 | Pregabalin | | | | | | | | | | | | | | | | | + |
| N03AX30 | Beclamide | | | | | + | | | | | | | | | | | | |
| N04 ANTI-PARKINSON DRUGS | | | | | | | | | | | | | | | | | | |
| <i>N04A Anticholinergic agents</i> | | | | | | | | | | | | | | | | | | |
| <i>N04AA Tertiary amines</i> | | | | | | | | | | | | | | | | | | |
| N04AA01 | Trihexyphenidyl | | | | | | + | III | II | II | II | | | | | | | |
| N04AA02 | Biperiden | | | | | | + | III | II | II | II | III | | | w | | | + |
| N04AA03 | Metixene | | | | | | + | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | | | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|--|-------|-----------|-----------|--|-----|------|--------|--------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| N04AA04 | Procyclidine | 2.5 | U | 0/1 | | + | | | | | | | | | | | | |
| N04AA11 | Bornaprine | | | | | + | | | | | | | | | | | | |
| N04AA12 | Tropatepine | | | | | | | | II | II | II | | | | | | | |
| <i>N04AC Ethers of tropine or tropine derivatives</i> | | | | | | | | | | | | | | | | | | |
| N04AC01 | Benzatropine | 0.5 | U | 0/1 | | | | | | | | | | | | | | |
| <i>N04B Dopaminergic agents</i> | | | | | | | | | | | | | | | | | | |
| <i>N04BA Dopa and dopa derivatives</i> | | | | | | | | | | | | | | | | | | |
| N04BA02 | Levodopa and decarboxylase inhibitor | | | | | | | I | II | II | II | III | | | | | | |
| N04BA03 | Levodopa, decarboxylase inhibitor and COMT inhibitor | | | | | | | | | II | | | | | | | | |
| <i>N04BB Adamantane derivatives</i> | | | | | | | | | | | | | | | | | | |
| N04BB01 | Amantadine | | | | | + | | | II | I | I | II | | | | | | |
| <i>N04BC Dopamine agonists</i> | | | | | | | | | | | | | | | | | | |
| N04BC01 | Bromocriptine | | | | | | | I | II | II | II | II | | | | | | |
| N04BC02 | Pergolide | | | | | + | | | | II | II | II | + | | | | | |
| N04BC04 | Ropinirole | | | | | | | | III | II | II | II | | | | | + | + |
| N04BC05 | Pramipexole | | | | | | | | | II | II | | | | | | + | |
| N04BC06 | Cabergoline | | | | | | | 0 | | II | II | | | | | | + | |
| N04BC07 | Apomorphine | | | | | | | | III | II | II | | | | | | + | |
| N04BC08 | Piribedil | | | | | | | | I | | | II | | | | | + | |
| N04BC09 | Rotigotin | | | | | | | | | | | | | | | | + | |
| not yet determined | Lisuride | | | | | | | II | II | II | II | | | | | | | |
| <i>N04BD Monoamine oxidase B inhibitors</i> | | | | | | | | | | | | | | | | | | |
| N04BD01 | Selegiline | | | | | + | | | II | I | I | II | | | | | | |
| <i>N04BX Other dopaminergic agents</i> | | | | | | | | | | | | | | | | | | |
| N04BX02 | Entacapone | | | | | + | | | II | II | II | I* | | | | | | |
| N05 PSYCHOLEPTICS | | | | | | | | | | | | | | | | | | |
| <i>N05A Antipsychotics</i> | | | | | | | | | | | | | | | | | | |
| <i>N05AA Phenothiazines with aliphatic side-chain</i> | | | | | | | | | | | | | | | | | | |
| N05AA01 | Chlorpromazine | 10-20 | 3 | 1/0 | III | III | III | II,III | II,III | III | III | | + | + | | | | |
| | | 25-50 | 4 | 2/2 | | | | | | | | | | | | | | |
| N05AA02 | Levomepromazine | 10 | 4 | 1/1 | III* | III | III | II,III | II,III | III | III | | + | + | w | | | |
| | | 25 | 4 | 1/0 | | | | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | | | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|---------------------------------|--------|-----------|-----------|--|-----|------|--------|--------|--------|--------|-----|-------|--------|----|-----|----|-----|
| | | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| N05AA03 | Promazine | 25-50 | 4 | 1/1 | III* | | | | | | III | | + | + | | | | + |
| N05AA05 | Triflupromazine (fluopromazine) | 5 | 3 | | | | | | | | | | | + | | | | |
| N05AA06 | Cyamemazine | | | | | | | | II,III | II,III | III | II | | | | | | |
| <i>N05AB Phenothiazines with piperazine structure</i> | | | | | | | | | | | | | | | | | | |
| N05AB01 | Dixyrazine | | | | II* | | | | | | II | | | | | w | | |
| N05AB02 | Fluphenazine | 1-2 | U | 0/2 | II* | II | II | III | II | II | II | II | | + | | | | |
| | | 5-15 | 3 | | | | | | | | | | | | | | | |
| N05AB03 | Perphenazine | 4-8 | U | 0/2 | II* | II | | | III | II | II | | | + | w | | | |
| | Perphenazine enantate | | | | | | | III | | | | | | | | | | |
| N05AB04 | Prochlorperazine | 5 | 3 | 2/1 | | | | | | | | | | + | | | | |
| | | 10 | 3.5 | 2/1 | | | | | | | | | | | | | | |
| N05AB06 | Trifluoperazine | 5 | 3 | 1/1 | | III | | III | II,III | III | | | + | + | | | | |
| N05AB08 | Thiopropazine | | | | II* | III | | III | II | III | | | + | | | | | |
| N05AB10 | Perazine | | | | | | | | | | | | | + | | | | |
| <i>N05AC Phenothiazines with piperidine structure</i> | | | | | | | | | | | | | | | | | | |
| N05AC01 | Periciazine | | | | III* | III | | | II | III | | | | | | | | |
| N05AC02 | Thioridazine | 25-100 | 3.6 | 3/1 | III | III | III | II | II | III | III | | + | + | w | | | |
| N05AC04 | Pipotiazine | | | | III* | III | | III | II,III | III | | | | | + | | | |
| | Pipotiazine palmitate | | | | | | | III | | | | | | | | | | |
| <i>N05AD Butyrophenone derivatives</i> | | | | | | | | | | | | | | | | | | |
| N05AD01 | Haloperidol | 1 | 2.3 | 3/0 | II.2 | II | II | II,III | II,III | II | II | | + | + | w | | | |
| | | 10 | 3 | 1/1 | | | | | | | | | | | | | | |
| | Haloperidol decanoate | | | | | | | III | | | | | + | | | | | |
| N05AD02 | Trifluoperidol | | | | | | | | II | II | | | | | | | | |
| N05AD03 | Melperone | | | | II* | | | | | II | II | | | | | w | | |
| N05AD05 | Pipamperone | | | | II* | | | II,III | II | II | | | + | + | | | | |
| N05AD06 | Bromperidol | 1 | 3 | 0/1 | II* | | | | | II | | | | + | | | | |
| N05AD07 | Benperidol | 0.25 | 1 | 0/1 | II* | | | | | II | | | + | + | | | | |
| N05AD08 | Droperidol | 5 | U | 0/1 | II.2 | | | III | III | II | | | | + | w | | | |
| N05AD09 | Fluanisone | | | | | | | | II,III | III | | | | | | | | |
| <i>N05AE Indole derivatives</i> | | | | | | | | | | | | | | | | | | |
| N05AE03 | Sertindole | | | | | | | | II | II | | | | | | | | |

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|-------------------------------|-----------|--|------|------|-------|----------|--------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| <i>N05AF Thioxanthen derivatives</i> | | | | | | | | | | | | | | | | |
| N05AF01 | Flupentixol | 1 | 2/0 | II.2 | II | | III | II,III | II | II | | | + | | | |
| | | 5-15 | 1/1 | | | | | | | | | | | | | |
| | Flupentixol decanoate | | | | | | III | | | | | | | | | |
| N05AF03 | Chlorprothixene | 20 | 1/0 | | | | | | | | | | | + | | |
| N05AF04 | Tiotixene | | | | | | | | | | | | | + | | |
| N05AF05 | Zuclopenthixol | 10 | 0/1 | II.2 | II | | III | II,III | II | II | | + | + | w | | |
| | Zuclopenthixol dichlorhydrate | | | | | | III | | | | | | | | | |
| | Zuclopenthixol decanoate | | | | | | III | | | | | + | | | | |
| | Zuclopenthixol acetate | | | | | | III | | | | | | | | | |
| <i>N05AG Diphenylbutylpiperidine derivatives</i> | | | | | | | | | | | | | | | | |
| N05AG01 | Fluspirilene | | | II* | | | | | II | | | | | | | + |
| N05AG02 | Pimozide | 1-2 | 0/2 | II* | II | | III | II | II | II | | + | + | | | |
| N05AG03 | Penfluridol | 10-20 | 0/1 | II* | III | | III | II | II | | | | | | | + |
| <i>N05AH Diazepines, oxazepines and thiazepines</i> | | | | | | | | | | | | | | | | |
| N05AH01 | Loxapine | | | III* | II | | III | II,III | III | | | + | + | | | |
| N05AH02 | Clozapine | 100 | 1/1 | | II | | III | II | II | II | | + | + | | | |
| N05AH03 | Olanzapine | | | | II | II | III | II,III | II | II | | + | | | | |
| N05AH04 | Quetiapine | | | | II | | | | II | II | | | | | | |
| not yet determined | Fluperlapine | 100 | 1/0 | | | | | | | | | | | | | |
| <i>N05AL Benzamides</i> | | | | | | | | | | | | | | | | |
| N05AL01 | Sulpiride | 50 | 2/2 | II.2 | II | | II,III | II,III | II | II | | + | + | | | |
| | | 100 | 3/1 | | | | | | | | | | | | | |
| N05AL02 | Sultopride | | | II.2 | | | III | II,III | II | | | | | | | |
| N05AL03 | Tiapride | 100 | 1/0 | II.1 | II | | I,II,III | II,III | II | II* | | | | + | | |
| N05AL04 | Remoxipride | 100 | 1/0 | | | | | | | | | | | | | |
| N05AL05 | Amisulpride | 100 | 1/0 | | | | III | II,III | II | II | | | | | | |
| N05AL06 | Veralipride | | | II* | | | | II | II | II | | | | | | |
| <i>N05AN Lithium</i> | | | | | | | | | | | | | | | | |
| N05AN01 | Lithium | 600 | 3/0 | II.1 | II | II | II | II | II | I | | | | + | | |
| <i>N05AX Other antipsychotics</i> | | | | | | | | | | | | | | | | |
| N05AX07 | Prothipendyl | | | III* | | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | | | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|----------------------|-----------------------------------|-------|-----------|-----------|--|-----|------|----------|--------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| N05AX08 | Risperidone | | | | | II* | II | II | III | II | II | II | | + | + | w | | |
| N05AX09 | Clotiapine | | | | | II* | II | | | | II | | | | | | | |
| N05AX11 | Zotepine | | | | | | | | | | | II* | | | | | | |
| N05B | Anxiolytics | | | | | | | | | | | | | | | | | |
| N05BA | Benzodiazepine derivatives | | | | | | | | | | | | | | | | | |
| N05BA01 | Diazepam | 2 | 2.8 | 15/2 | III | III | III | II,III | II,III | III | III | + | + | + | + | + | + | |
| | | 5 | 3.2 | 19/0 | | | | | | | | | | | | | | |
| | | 10 | 3.9 | 17/0 | | | | | | | | | | | | | | |
| | | 15 | 3.9 | 15/0 | | | | | | | | | | | | | | |
| | | 20 | 4 | 14/1 | | | | | | | | | | | | | | |
| N05BA02 | Chlordiazepoxide | 5 | 2.9 | 7/0 | III | III | | I,II | II | III | III | + | + | + | + | + | + | |
| | | 10 | 3 | 7/0 | | | | | | | | | | | | | | |
| | | 20-25 | 3.5 | 2/4 | | | | | | | | | | | | | | |
| N05BA03 | Medazepam | 5 | 2.3 | 3/3 | | | | | II | II | | + | | + | | | | |
| | | 10 | 3 | 2/4 | | | | | | | | | | | | | | |
| | | 15 | 4 | 1/4 | | | | | | | | | | | | | | |
| N05BA04 | Oxazepam | 10 | 3 | 11/1 | II.2 | III | | I,II,III | II | III | II | + | | + | + | + | + | |
| | | 20 | 3 | 11/1 | | | | | | | | | | | | | | |
| | | 30 | 4 | 4/5 | | | | | | | | | | | | | | |
| | | 50 | 4 | 6/3 | | | | | III | | | | | | | | | |
| N05BA05 | Potassium clorazepate | 5 | 3 | 6/1 | II* | II | II | I,II,III | II,III | II | II | + | + | + | + | | + | |
| | | 15 | 3 | 1/0 | | | | | | | | | | | | | | |
| | Clorazepate, combinations | | | | | | | | III | | | | | | | | | |
| N05BA06 | Lorazepam | 0.5 | 3.6 | 11/3 | III | III | III | I,II,III | II,III | III | III | + | + | + | + | + | + | |
| | | 1 | 3.9 | 10/1 | | | | | | | | | | | | | | |
| | | 2.5 | 4 | 10/0 | | | | | | | | | | | | | | |
| | | 5 | 4 | 7/3 | | | | | | | | | | | | | | |
| N05BA07 | Adinazolam | 30 | 3 | 1/2 | | | | | | | | | | | | | | |
| N05BA08 | Bromazepam | 1.5 | 2.6 | 7/1 | III | III | | I,II,III | II | III | III | + | + | + | | + | | |
| | | 3 | 3.1 | 6/2 | | | | | | | | | | | | | | |
| | | 6 | 3.8 | 6/1 | | | | | | | | | | | | | | |
| | | 12 | 4 | 6/1 | | | | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|----------------------|------------------------------------|-----------|------------|--|------|------|-------|----------|--------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| N05BA09 | Clobazam | 10 | 1.9 | 7/0 | II.1 | II | | I,II,III | II | II | II* | + | + | + | + | + | + |
| | | 20 | 2.3 | 6/1 | | | | | | | | | | | | | |
| N05BA10 | Ketazolam | 30 | 3 | 2/1 | III | III | | | | III | II | + | | + | | | |
| N05BA11 | Prazepam | 10 | 3 | 1/2 | II* | + | | I,II | II | II | II | + | + | + | | | |
| | | 40 | | | | | | III | III | | | | | | | | |
| N05BA12 | Alprazolam | 0.25 | 2.5 | 6/2 | II.2 | III | III | I,II,III | II | III | II | + | + | + | + | + | + |
| | | 0.5 | 2.8 | 6/2 | | | | | | | | | | | | | |
| | | 1 | 3.5 | 2/4 | | | | | | | | | | | | | |
| N05BA13 | Halazepam | | | | | III | | | | III | II | + | | | | | |
| N05BA14 | Pinazepam | | | | | III | | | | III | | + | | | | | |
| N05BA15 | Camazepam | 10 | 2 | 1/1 | | II | | | | II | | + | | | | | |
| | | 20 | 3 | 1/0 | | | | | | | | | | | | | |
| N05BA16 | Nordazepam | 5 | 3 | 1/2 | II* | | | I,II,III | II,III | II | II | + | | + | | | |
| | | 10 | 3 | 1/2 | | | | | | | | | | | | | |
| N05BA17 | Fludiazepam | | | | | | | | | | | + | | | | | |
| N05BA18 | Ethyl loflazepate | | | | II* | | | I,II,III | II | II | II | + | | | | | |
| N05BA21 | Clotiazepam | | | | III* | III | | I,II,III | II | III | | + | | | | | |
| N05BA22 | Cloxazolam | | | | II.2 | | | | | II | II | + | | | | | |
| N05BA23 | Tofisopam | 100 | 1 | 1/0 | | | | | II | II | | | | | | | |
| not yet determined | Bentazepam | | | | | III | | | | III | | | | | | | |
| not yet determined | Metaclazepam | 7.5 | 3 | 0/1 | | | | | | | | | | | | | |
| not yet determined | Mexazolam | | | | | | | | | | II | | | | | | |
| not yet determined | Oxazolam | | | | | | | | | | | + | | | | | |
| not yet determined | Nimetazepam | | | | | | | | | | | + | | | | | |
| not yet determined | Haloxazolam | | | | | | | | | | | + | | | | | |
| not yet determined | Delorazepam | | | | | | | | | | | + | | | | | |
| not yet determined | N-desmethyl-adinazolam | | | | | | | | | | | | | | | | |
| <i>N05BB</i> | <i>Diphenylmethane derivatives</i> | | | | | | | | | | | | | | | | |
| N05BB02 | Captodiame | | | | | | | | I | | | | | | | | |
| <i>N05BC</i> | <i>Carbamates</i> | | | | | | | | | | | | | | | | |
| N05BC01 | Meprobamate | 400 | 3 | 4/2 | III | III | | II | II,III | III | | + | | + | + | + | |
| | | 800 | 3.5 | 2/3 | | | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | | | DOSE (mg) | WOLSCHRIJN | | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|----------------------|---|---------------|-----------|------------|--|------|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| N05BC51 | Meprobamate, combinations | | | | | | | | | | III | III | | | | | | | |
| | Not yet determined | Ethinamate | | | | | | | | | | | | + | | | | | |
| <i>N05BD</i> | <i>Dibenzo-bicyclo-octadien derivatives</i> | | | | | | | | | | | | | | | | | | |
| | N05BD01 | Benzoctamine | 10 | U | 0/1 | | | | | | | | | | | | | | |
| | | | 20 | U | 0/1 | | | | | | | | | | | | | | |
| <i>N05BE</i> | <i>Azaspirodecandione derivatives</i> | | | | | | | | | | | | | | | | | | |
| | N05BE01 | Buspirone | 5 | 1.2 | 13/0 | II.1 | II | | | I | I | II* | | + | + | | | | |
| | | | 10 | 1.4 | 12/0 | | | | | | | | | | | | | | |
| | | | 20 | 2.2 | 9/2 | | | | | | | | | | | | | | |
| | | | 30 | 3 | 1/0 | | | | | | | | | | | | | | |
| <i>N05BX</i> | <i>Other anxiolytics</i> | | | | | | | | | | | | | | | | | | |
| | N05BX01 | Mephenoxalone | | | | | | | | | | | | | | | | + | |
| | N05BX03 | Etifoxine | | | | | | | | I | I | | | | | | | | |
| | N06BX06 | Citicoline | | | | | | | | | | | II* | | | | | | |
| | not yet determined | Pipequaline | | 3 | 1/0 | | | | | | | | | | | | | | |
| <i>N05C</i> | <i>Hypnotics and sedatives</i> | | | | | | | | | | | | | | | | | | |
| <i>N05CA</i> | <i>Barbiturates, plain</i> | | | | | | | | | | | | | | | | | | |
| | N05CA01 | Pentobarbital | 100 | 4 | 1/2 | | | | | | | | | + | | + | + | | |
| | | | 200 | U | 0/2 | | | | | | | | | | | | | | |
| | N05CA02 | Amobarbital | 15 | 4 | 2/2 | III | | | | | | III | | + | | + | | | |
| | | | 50 | 4 | 3/1 | | | | | | | | | | | | | | |
| | | | 100 | 4 | 1/1 | | | | | | | | | | | | | | |
| | | | 200 | 4 | 1/1 | | | | | | | | | | | | | | |
| | N05CA03 | Butobarbital | 50 | 4 | 1/2 | | | | | III | III | | | | | + | | | |
| | | | 100 | 4 | 1/1 | | | | | | | | | | | | | | |
| | | | 200 | 4 | 1/1 | | | | | | | | | | | | | | |
| | N05CA04 | Barbital | 250-500 | U | 0/1 | | III | | | | | | | + | | + | | | |
| | N05CA05 | Aprobarbital | | | | | | | | | | | | | | + | | | |
| | N05CA06 | Secobarbital | 50 | 4 | 5/1 | III | | | | | | III | | + | | + | | | |
| | | | 100 | 4 | 2/3 | | | | | | | | | | | | | | |
| | | | 200 | 4 | 3/1 | | | | | | | | | | | | | | |
| | N05CA10 | Cyclobarbital | 100 | 4 | 1/0 | | | | | | | | | + | | + | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN | |
|----------------------|-----------------------------------|-----------|------------|--|------|------|-------|----------|-------|--------|-----|-------|--------|----|-----|----|-----|--|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| N05CA11 | Heptabarbital | 400 | 4 | 1/0 | | | | | | | | | | | | | | |
| | | 100 | U | 0/1 | | | | | | | | | | | | | | |
| | | 200 | U | 0/1 | | | | | | | | | | | | | | |
| N05CA16 | Hexobarbital | 250 | U | 0/2 | | | | | | | | | | + | | | | |
| | | 500 | U | 0/1 | | | | | | | | | | | | | | |
| N05CA19 | Thiopental | | | | | | | III | III | | | | | | + | | + | |
| N05CA21 | Allobarbital | 30 | 4 | 1/1 | | | | | | | | | | + | | | | |
| | | 100 | 4 | 1/0 | | | | | | | | | | | | | | |
| | | 200 | 4 | 1/0 | | | | | | | | | | | | | | |
| not yet determined | Brallobarbital | | | | III* | | | | III | | | | | + | | | | |
| not yet determined | Butalbital | 50 | 4 | 1/1 | | | | | | | | | | + | + | | + | |
| | | 100 | 4 | 1/1 | | | | | | | | | | | | | | |
| <i>N05CC</i> | <i>Aldehydes and derivatives</i> | | | | | | | | | | | | | | | | | |
| N05CC01 | Chloral hydrate | 500-1000 | 4 | 1/1 | | | | | | | | | | + | | | + | |
| <i>N05CD</i> | <i>Benzodiazepine derivatives</i> | | | | | | | | | | | | | | | | | |
| N05CD01 | Flurazepam | 15 | 4 | 4/4 | III | III | | | III | III | III | + | | + | + | | | |
| | | 30 | 4 | 5/3 | | | | | | | | | | | | | | |
| N05CD02 | Nitrazepam | 2.5 | 3.6 | 3/4 | II.2 | III | | I,II,III | III | III | | + | + | + | + | + | + | |
| | | 5 | 3.6 | 5/3 | | | | | | | | | | | | | | |
| | | 10 | 4 | 5/2 | | | | | | | | | | | | | | |
| N05CD03 | Flunitrazepam | 0.5 | 4 | 3/4 | III | III | | II | III | III | III | + | + | + | + | + | | |
| | | 1 | 4 | 4/3 | | | | | | | | | | | | | | |
| | | 2 | 4 | 4/3 | | | | | | | | | | | | | | |
| N05CD04 | Estazolam | | | | | | | | III | III | | + | | | | | | |
| N05CD05 | Triazolam | 0.125 | 3 | 4/3 | II.2 | III | | I,II,III | III | III | II | + | + | + | + | + | + | |
| | | 0.25 | 3.7 | 6/3 | | | | | | | | | | | | | | |
| | | 0.5 | 4 | 6/3 | | | | | | | | | | | | | | |
| N05CD06 | Lormetazepam | 0.5 | 3 | 1/5 | II.2 | III | III | I,II,III | III | III | II | + | + | + | | + | | |
| | | 1 | 3 | 2/3 | | | | | | | | | | | | | | |
| | | 2 | 4 | 2/3 | | | | | | | | | | | | | | |
| N05CD07 | Temazepam | 5 | 2.7 | 6/2 | II.1 | III | | I,II,III | III | III | II* | + | + | + | + | | + | |
| | | 10 | 3.4 | 2/5 | | | | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|---------------|-----------|------------|--|------|------|-------|----------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| N05CD08 | Midazolam | 20 | 4 | 2/5 | | | | | | | | | | | | | |
| | | 30 | 4 | 1/6 | | | | | | | | | | | | | |
| | | 7.5 | 4 | 2/2 | III | III | | I,II,III | III | III | | + | | + | + | + | + |
| N05CD09 | Brotizolam | 15 | 4 | 1/3 | | | | | | | | | | | | | |
| | | 0.125 | 3 | 0/6 | II.2 | III | | | III | III | II | | | + | | | |
| | | 0.25 | 3.7 | 2/3 | | | | | | | | | | | | | |
| N05CD10 | Quazepam | 0.5 | U | 0/1 | | | | | | | | | | | | | |
| | | 15 | U | 0/3 | | III | | | | III | II | | + | | | | |
| N05CD11 | Loprazolam | 0.5 | U | 0/2 | II.2 | III | | I,II,III | III | III | II | + | | + | | | |
| | | 1 | 3.5 | 1/2 | | | | | | | | | | | | | |
| | | 2 | 4 | 1/1 | | | | | | | | | | | | | |
| <i>N05CE Piperidinedione derivatives</i> | | | | | | | | | | | | | | | | | |
| N05CE01 | Glutethimide | 125 | 4 | 1/2 | | | | | | | | + | | | | | |
| | | 250 | 4 | 1/2 | | | | | | | | | | | | | |
| | | 500 | U | 0/2 | | | | | | | | | + | | | | |
| N05CE02 | Methyprylon | | | | | | | | | | | + | | | | | |
| <i>N05CF Benzodiazepine related drugs</i> | | | | | | | | | | | | | | | | | |
| N05CF01 | Zopiclone | 7.5 | 3.8 | 3/4 | II.2 | II | | | III | III | | | + | + | + | + | + |
| N05CF02 | Zolpidem | 10 | 3.5 | 1/2 | II.2 | II | II | | III | II | II | + | + | + | + | + | + |
| | | 20 | 3.5 | 1/2 | | | | | | | | | | | | | |
| N05CF03 | Zaleplon | | | | | | | | | | | | | | | + | + |
| <i>N05CM Other hypnotics and sedatives</i> | | | | | | | | | | | | | | | | | |
| N05CM01 | Methaqualone | | | | | + | | | | | | + | | | | | |
| N05CM02 | Clomethiazol | 300 | 3.5 | 1/3 | | | I | | | | | | + | + | + | | + |
| | | 600-1200 | 4 | 1/2 | | | | | | | | | | | | | |
| N05CM03 | Bromisoval | | | | | | | | | | | | | + | | | |
| N05CM04 | Carbromal | | | | | | | | | | | | | + | | | |
| N05CM05 | Atropine | 0.4-0.6 | 3.1 | 5/1 | | | | | | | | | | | | | |
| | | 0.85-1.7 | 3 | 2/1 | | | | | | | | | | | | | |
| | | 2 | 4 | 1/0 | | | | | | | | | | | | | |
| N05CM08 | Ethchlorvynol | | | | | | | | | | + | | | | | | |
| N05CM09 | Valerian | | | | | + | | | | | I* | | | | | | + |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|-------------------|-----------|------------|--|------|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| N05CM11 | Bromides | | | | | | | | I | | | | | | | | |
| N05CM16 | Niaprazine | | | | | | | | III | III | | | | | | | |
| not yet determined | Doxylamine | | | | | | | | III | | | | | | | | |
| not yet determined | Bromolactobionate | | | | | | | | I | | | | | | | | |
| not yet determined | Kava-kava | 100 | 1.3 | | | | | | | | | | | | | | |
| N06 PSYCHOANALEPTICS | | | | | | | | | | | | | | | | | |
| N06A Antidepressants | | | | | | | | | | | | | | | | | |
| <i>N06AA Non-selective monoamine reuptake inhibitors</i> | | | | | | | | | | | | | | | | | |
| N06AA01 | Desipramine | 25 | 2.5 | 2/3 | II* | | | I | II | II | | | | | | | + |
| | | 50 | 3 | 0/2 | | | | | | | | | | | | | |
| | | 75 | 4 | 1/1 | | | | | | | | | | | | | |
| N06AA02 | Imipramine | 25 | 2.7 | 3/3 | II.2 | II | II | I | II | II | II | | | | | | + |
| | | 50 | 3.3 | 3/1 | | | | | | | | | | | | | w |
| | | 75 | 4 | 2/1 | | | | | | | | | | | | | |
| N06AA03 | Imipramine oxide | | | | | + | | | | | | | | | | | |
| N06AA04 | Clomipramine | 25 | 2.7 | 5/2 | II.2 | II | | I | II | II | II | | | | | | + |
| N06AA05 | Opipramol | 50 | 3 | 1/0 | II* | | | | II | II | | | | | | | + |
| N06AA06 | Trimipramine | 12.5 | 3 | 1/1 | II* | + | | I | II | III | II* | | | | | | + |
| | | 25 | 3 | 1/1 | | | | | | | | | | | | | |
| N06AA07 | Lofepramine | 70 | 3 | 0/1 | II* | II | | | | II | II | | | | | | |
| N06AA08 | Dibenzepin | 80 | 1 | 1/0 | | | | | | | | | | | | | |
| N06AA09 | Amitriptyline | 12.5 | 3.5 | 2/0 | III | III | III | II | II | III | III | | | | | | + |
| | | 25 | 3.9 | 12/0 | | | | | | | | | | | | | |
| | | 50 | 3.9 | 13/0 | | | | | | | | | | | | | |
| | | 75 | 3.9 | 13/0 | | | | | | | | | | | | | |
| N06AA10 | Nortriptyline | 10 | 2.3 | 4/3 | II.2 | II | II | | | II | II | | | | | | + |
| | | 50 | 2 | 3/3 | | | | | | | | | | | | | w |
| | | 75 | 3.5 | 2/2 | | | | | | | | | | | | | |
| N06AA12 | Doxepin | 25 | 3 | 7/1 | II.2 | III | | I | II | III | | | | | | | + |
| | | 50 | 3.6 | 5/0 | | | | | | | | | | | | | w |
| N06AA14 | Melitracen | | | | II* | | | | | II | | | | | | | |
| N06AA15 | Butriptyline | 25 | 2 | 1/0 | | | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|--------------------|-----|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| N06AA16 | Dosulepin | 75 | 2 | 1/0 | II.2 | III | | I | II | III | II* | | | | + | | | |
| N06AA17 | Amoxapine | | | | | III | | I | II | III | | | | | | | | |
| N06AA19 | Amineptine | | | | | II | | | | II | | + | | | | | | |
| N06AA21 | Maprotiline | 25 | 2.2 | 3/3 | II.2 | II | | I | II | II | II | | | | + | | | |
| | | 75 | 3 | 2/2 | | | | | | | | | | | | | | |
| | not yet determined | 25 | 1.3 | 3/0 | | | | | | | | | | | | | | |
| | not yet determined | 75 | 1 | 1/0 | | | | | | | | | | | | | | |
| <i>N06AB Selective serotonin reuptake inhibitors</i> | | | | | | | | | | | | | | | | | | |
| N06AB03 | Fluoxetine | 20 | 1.8 | 4/1 | II.1 | I | I | I | II | I | II* | | | | + | | | |
| | | 40 | 2 | 2/2 | | | | | | | | | | | | | | |
| | | 60 | 2.5 | 2/1 | | | | | | | | | | | | | | |
| N06AB04 | Citalopram | 40 | 2 | 1/1 | II.1 | I | | I | II | II | | | | | + | | | |
| N06AB05 | Paroxetine | 20 | 1 | | II.1 | I | I | I | II | I | II* | | | | + | | | |
| | | 30 | 1.4 | 5/0 | | | | | | | | | | | | | | |
| N06AB06 | Sertraline | 100 | 2 | 1/0 | II.1 | I | I | I | II | II | II* | | | | + | w | | |
| N06AB08 | Fluvoxamine | 50 | 2.2 | 4/2 | II.1 | I | I | I | II | II | II* | | + | | + | | | |
| N06AB09 | Etoperidone | | | | | | + | | | | | | | | | | | |
| N06AB10 | Escitalopram | | | | | | | | II | II | | | | | | | | |
| | not yet determined | 200 | 2 | 1/0 | | | | | | | | | | | | | | |
| | not yet determined | 50 | 1 | 1/0 | | | | | | | | | | | | | | |
| <i>N06AF Monoamine oxidase inhibitors, non-selective</i> | | | | | | | | | | | | | | | | | | |
| N06AF02 | Nialamide | | | | II* | | | | | II | | | | | | | | |
| N06AF03 | Phenelzine | | | | II* | + | | | | II | | | | | + | | | |
| N06AF04 | Tranlycypromine | | | | | II | | | | II | | | | | + | | | |
| N06AF05 | Iproniazide | | | | | | | I | II | II | | | | | | | | |
| N06AF06 | Iproclozide | | | | II* | | | | | II | | | | | | | | |
| | not yet determined | | | | | | + | | | | II | | | | | | | |
| <i>N06AG Monoamine oxidase A inhibitors</i> | | | | | | | | | | | | | | | | | | |
| N06AG02 | Moclobemide | 100 | 1 | | II* | I | | I | II | II | II | | | | | | | |
| | | 200 | 1 | | | | | | | | | | | | | | | |
| N06AG03 | Toloxatone | | | | | | | I | II | II | | | | | | | | |
| <i>N06AX Other antidepressants</i> | | | | | | | | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|----------------------|--|-----------|------------|--|------|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| N06AX01 | Oxtripitan | | | | | | | | | | III | | | | | | |
| N06AX02 | Tryptophan | 100 | 1.5 | 2/2 | | | | | | | | | | | | | + |
| N06AX03 | Mianserin | 10 | 3 | 5/2 | III | III | III | II | II | III | III | | | | | | + |
| | | 20 | 3.4 | 7/0 | | | | | | | | | | | | | |
| N06AX05 | Trazodone | 50 | 3.5 | 2/0 | III | III | | | | III | III | | | | | | + |
| | | 75 | 3 | 8/0 | | | | | | | | | | | | | |
| N06AX06 | Nefazodone | | | | | II | | | | II | | | + | | | | |
| N06AX07 | Minaprine | 50 | 1 | 2/0 | | | | | | | | | | | | | |
| | | 100 | 1 | 1/0 | | | | | | | | | | | | | |
| N06AX09 | Viloxazine | 100 | 1 | 2/0 | II.1 | II | | I | II | II | II* | | | | | | |
| N06AX11 | Mirtazapine | | | | | III | | I | II | III | | | + | | | | |
| N06AX14 | Tianeptine | | | | | | | I | II | II | II | | | | | | |
| N06AX16 | Venlafaxine | | | | | II | II | I | II | I | II | | | | + | w | |
| N06AX17 | Milnacipran | | | | | | | I | II | II | III | | | | | | |
| N06AX18 | Reboxetine | | | | | | | | | I | II | | | | | | |
| not yet determined | Ritanserin | 5 | 1 | 1/0 | | | | | | | | | | | | | |
| N06B | Psychostimulants, agents used for ADHD and nootropics | | | | | | | | | | | | | | | | |
| N06BA | Centrally acting sympathomimetics | | | | | | | | | | | | | | | | |
| N06BA01 | Amphetamine | 5 | 3.5 | 2/1 | II.1 | II | | | | II | | + | | | | + | |
| | | 10 | 3 | 1/1 | | | | | | | | | | | | | |
| N06BA02 | Dexamphetamine | 5 | 3.5 | 2/1 | II.1 | | | | | II | | + | | | | | |
| | | 10 | 3 | 1/1 | | | | | | | | | | | | | |
| N06BA03 | Metamphetamine | | | | | | | | | | | + | | | | | |
| N06BA04 | Methylphenidate | 10 | 3 | 0/3 | I | I | I | II | II | I | | + | | | + | | + |
| N06BA05 | Pemoline | 37.5 | 2 | 2/1 | I* | I | | | | I | | | | | | | |
| NO6BA07 | Modafinil | | | | | + | | III | | | II* | | | | | | |
| N06BA10 | Fenetylline | | | | I* | | | | | I | | | | | | | |
| not yet determined | Fenproporex | | | | | | | I | | I | | | | | | | |
| N06BC | Xanthine derivatives | | | | | | | | | | | | | | | | |
| N06BC01 | Caffeine | 50 | 1 | 1/0 | | | | | | | | | + | | | | |
| N06BX | Other psychostimulants and nootropics | | | | | | | | | | | | | | | | |
| N06BX03 | Piracetam | 800 | 1 | 1/0 | | | | | II | II | II | | | | | | |

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|-----------|------------|--|------|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| N06BX13 Idebenone | | | | I | I | | | | I | II | | | | | | |
| N06BX14 Prolintane | | | | | | | | | | | + | | | | | |
| N06BX15 Pipradrol | | | | | | | | | | | | | | | | |
| N06BX17 Adrafinil | | | | | | | I | | | | | | | | | |
| N06BX18 Vinpocetine | | | | | + | | | | | | | | | | | |
| N06D Anti-dementia drugs | | | | | | | | | | | | | | | | |
| N06DA Anticholinesterases | | | | | | | | | | | | | | | | |
| N06DA01 Tacrine | | | | | + | | | | | | | | | | | |
| N06DA02 Donepezil | | | | | | 0 | | II | II | I* | | | | | | |
| N06DA03 Rivastigmine | | | | | | | | II | II | III | | | | | | |
| N06DA04 Galantamine | | | | | | | | II | II | | | | | | | |
| N06DX Other anti-dementia drugs | | | | | | | | | | | | | | | | |
| N06DX01 Memantine | | | | | | | | II | II | | | | | | | |
| N06DX02 Ginkgo Biloba | | | | | + | | | | | II* | | | | | | |
| N07 OTHER NERVOUS SYSTEM DRUGS | | | | | | | | | | | | | | | | |
| N07A Parasympathomimetics | | | | | | | | | | | | | | | | |
| N07AA Anticholinesterases | | | | | | | | | | | | | | | | |
| N07AA02 Pyridostigmine | 30 | 1 | 1/0 | | | | | | | | | | | | | |
| N07B Drugs used in addictive disorders | | | | | | | | | | | | | | | | |
| N07BA Drugs used in nicotine dependence | | | | | | | | | | | | | | | | |
| N07BA01 Nicotine | | | | | | 0 | I | | | I | | | | | | |
| N07BA02 Bupropion (amfebutamone) | 100 | 2 | 3/1 | | I | I | | II | II | II* | | | | | | |
| not yet determined Nicotinamide | | | | | | | 0 | | | | | | | | | |
| N07BB Drugs used in alcohol dependence | | | | | | | | | | | | | | | | |
| N07BB01 Disulfiram | | | | | | I | III | II | II | II* | | | | | | |
| Disulfiram, combinations | | | | | | | | II | | | | | | | | |
| Disulfiram – nicotinamide - adenine | | | | | | | III | | | | | | | | | |
| N07BB03 Acamprosate | | | | | | 0 | | | | I* | | | | | | |
| N07BB04 Naltrexone | | | | | | | III | II | II | | | | | | | |
| N07BC Drugs used in opioid dependence | | | | | | | | | | | | | | | | |
| N07BC01 Buprenorphine | | | | III | III | | III | II | II | | + | | + | + | + | + |
| N07BC02 Methadone | 2.5-10 | 3 | 2/1 | II.2 | III | | III | II | II | II | | | + | | + | + |

| ATC + SUBSTANCE NAME | | | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|-------------------------|-------|-----------|-----------|--|-----|------|-------|--------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| N07BC03 | Levacetylmethadol | | | | | | + | | | | | | | | | | | |
| N07C Antivertigo preparations | | | | | | | | | | | | | | | | | | |
| <i>N07CA Antivertigo preparations</i> | | | | | | | | | | | | | | | | | | |
| N07CA01 | Betahistine | 42583 | 1 | 1/0 | I | | | | 0 | | I | I | | | | | | |
| N07CA02 | Cinnarizine | 25 | 1 | 1/1 | II.2 | II | | | | | II | II | | + | + | + | + | + |
| | | 50 | 3 | 1/1 | | | | | | | | | | | | | | |
| N07CA03 | Flunarizine | | | | | | II | II | I | II | II | | | | + | | + | |
| N07CA04 | Acetylleucine | | | | | | | | 0 | | | | | | | | | |
| N07X Other nervous system drugs | | | | | | | | | | | | | | | | | | |
| <i>N07XX Other nervous system drugs</i> | | | | | | | | | | | | | | | | | | |
| N07XX02 | Riluzole | | | | | | | | | I | I | | | | | | | + |
| N07XX04 | Hydroxybutyric acid | | | | | | | | II,III | | | | | | | | | + |
| P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS | | | | | | | | | | | | | | | | | | |
| P01 ANTIPROTOZOAL PRODUCTS | | | | | | | | | | | | | | | | | | |
| P01B Antimalarials | | | | | | | | | | | | | | | | | | |
| <i>P01BA Aminoquinolines</i> | | | | | | | | | | | | | | | | | | |
| P01BA01 | Chloroquine | | | | | | | I | | | | | | | | | | |
| <i>P01BC Methanolquinolines</i> | | | | | | | | | | | | | | | | | | |
| P01BC01 | Quinine | | | | | | | I | | | | | | | | | | |
| | Quinine – ascorbic acid | | | | | | | | | I | | | | | | | | |
| | Quinine aubepine | | | | | | | | | I | | | | | | | | |
| | Quinine thiamine | | | | | | | | | I | | | | | | | | |
| P02 ANTITREMATODALS | | | | | | | | | | | | | | | | | | |
| P02B Anthelmintics | | | | | | | | | | | | | | | | | | |
| <i>P02BA Quinoline derivatives and related substances</i> | | | | | | | | | | | | | | | | | | |
| P02BA02 | Oxamniquine | | | | | | | | | | | | | | | | | + |
| <i>P02BX Other antitremitodal agents</i> | | | | | | | | | | | | | | | | | | |
| P02BX02 | Niridazole | | | | | | | | | | | | | | | | | + |
| R RESPIRATORY SYSTEM | | | | | | | | | | | | | | | | | | |
| R01 NASAL PREPARATIONS | | | | | | | | | | | | | | | | | | |
| R01B Nasal decongestants for systemic use | | | | | | | | | | | | | | | | | | |
| <i>R01BA Sympathomimetics</i> | | | | | | | | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|--------------------------------|-----------|-----------|--|------|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| R01BA01 | Phenylpropanolamine | 25-50 | U | 0/2 | I* | I | | | | I | | | | | + | | + |
| R01BA02 | Pseudoephedrine | 60 | 2 | 1/2 | | | | | | | | | | | | | |
| R01BA52 | Pseudoephedrine, combinations | | | | | | | | | | | | | | | | |
| | Pseudoephedrine - loratadine | | | | | | | | | | I | | | | | | |
| | Pseudoephedrine - triprolidine | | | | | | | | | | II* | | | | | | |
| R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES | | | | | | | | | | | | | | | | | |
| <i>R03B Other drugs for obstructive airway diseases, inhalants</i> | | | | | | | | | | | | | | | | | |
| <i>R03BB Anticholinergics</i> | | | | | | | | | | | | | | | | | |
| R03BB01 | Ipratropium bromide | | | | | | | | | | | | | + | | | |
| | not yet determined | | | | | | | | | | | | | + | | | |
| <i>R03BX Other drugs for obstructive airway diseases, inhalants</i> | | | | | | | | | | | | | | | | | |
| R03BX01 | Fenspiride | | | | | | | | I | | | | | | | | |
| <i>R03C Adrenergics for systemic use</i> | | | | | | | | | | | | | | | | | |
| <i>R03CA Alpha- and beta-adrenoreceptor agonists</i> | | | | | | | | | | | | | | | | | |
| R03CA02 | Ephedrine | | | | | | | | | | | | | | + | | + |
| <i>R03D Other systemic drugs for obstructive airway diseases</i> | | | | | | | | | | | | | | | | | |
| <i>R03DA Xanthines</i> | | | | | | | | | | | | | | | | | |
| R03DA04 | Theophylline | | | | | | | | I | | | | | | | | + |
| R03DA04 | Bamifylline | | | | | | | 0 | | | | | | | | | |
| <i>R03DC Leukotriene receptor antagonists</i> | | | | | | | | | | | | | | | | | |
| R03DC01 | Zafirlukast | | | | | | | | | | | II* | | | | | |
| R03DC03 | Montelukast | | | | | | | | | | | II* | | | | | |
| R05 COUGH AND COLD PREPARATIONS | | | | | | | | | | | | | | | | | |
| <i>R05C Expectorants, excl. combinations with cough suppressants</i> | | | | | | | | | | | | | | | | | |
| <i>R05CB Mucolytics</i> | | | | | | | | | | | | | | | | | |
| R05CB02 | Bromhexine | | | | | | | | | | | | | | | | + |
| <i>R05D Cough suppressants, excl. combinations with expectorants</i> | | | | | | | | | | | | | | | | | |
| <i>R05DA Opium alkaloids and derivatives</i> | | | | | | | | | | | | | | | | | |
| R05DA01 | Ethylmorphine | | | | II* | III | | I | I | III | | + | | | + | | + |
| R05DA03 | Hydrocodone | | | | II* | | | | | II | | + | | | | | |
| R05DA04 | Codeine | <20 | | | | | | | I | I | | + | | + | + | + | + |
| | | 50 | 2 | 1/3 | II.1 | II | II | I | II | II | | | | | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|----------------------|--|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| R05DA07 | Noscapine | 100 | 3.3 | 3/0 | | | | | | | | | | | | | |
| | not yet determined | 15-30 | 1 | 1/0 | | | | II | I | I | | | | | | | |
| R05DA08 | Pholcodine | | | | | II | | I | I | II | | + | | | | | + |
| R05DA09 | Dextromethorphan | 10-20 | 1 | 1/0 | | | I | I | I | I | | + | | | + | | + |
| R05DA10 | Thebacon | | | | II* | | III | | | II | | + | | | | | |
| R05DA12 | Acetyldihydrocodeine | | | | II* | | | | | II | | + | | | | | |
| R05DA20 | Opium alkaloids and derivatives, combinations | | | | | | | | I | | | | | | | | |
| | Opium alkaloids + antihistamine | | | | | | | | II | | | | | | | | |
| | Pholcodine – brompheramine | | | | | | | II | | | | | | | | | |
| | Pholcodine - chlorpheniramine | | | | | | | II | | | | | | | | | |
| | Pholcodine – chlorpheniramine - biccotymol | | | | | | | II | | | | | | | | | |
| | Pholcodine - clocizine | | | | | | | II | | | | | | | | | |
| | Dextromethorphan - mepyramine | | | | | | | II | | | | | | | | | |
| | Triprolidine - dextromethorphan | | | | | | | II | | | | | | | | | |
| <i>R05DB</i> | <i>Other cough suppressants</i> | | | | | | | | | | | | | | | | |
| R05DB03 | Clobutinol | | | | | | | | I | I | | | | | | | |
| R05DB05 | Pentoxyverine | | | | | | | I | I | I | | | | | | | |
| R05DB21 | Cloperastine | | | | | + | | | | | | | | | | | |
| <i>R05F</i> | <i>Cough suppressants and expectorants, combinations</i> | | | | | | | | | | | | | | | | |
| <i>R05FA</i> | <i>Opium derivatives and expectorants</i> | | | | | | | | | | | | | | | | |
| R05FA02 | Opium derivatives and expectorants | | | | | | | | I | II | | | | | | | |
| | Ethylmorphine – sodium benzoate | | | | | | | I | | | | | | | | | |
| | Ethylmorphine – aconite – guaifanesine | | | | | | | II | | | | | | | | | |
| | Pholcodine – biccotymol - cineole | | | | | | | I | | | | | | | | | |
| | Pholcodine - gaiacol | | | | | | | II | | | | | | | | | |
| | Pholcodine - isomyrtol | | | | | | | I | | | | | | | | | |
| | Pholcodine – sodium benzoate | | | | | | | I | | | | | | | | | |
| | Pholcodine – sodium tenoate | | | | | | | I | | | | | | | | | |
| | Pholcodine - erysimum | | | | | | | I | | | | | | | | | |
| <i>R05FB</i> | <i>Other cough suppressants and expectorants</i> | | | | | | | | | | | | | | | | |
| R05FB01 | Cough suppressants and mucolytics | | | | | | | | II | II | | | | | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|--|-----------------|-------------------|--|------|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| R05FB02 | Carbocysteine – promethazine Cough suppressants and expectorants Oxomemazine - guaiafenesine | | | | | | | II | II | II | | | | | | | |
| R06 ANTIHISTAMINES FOR SYSTEMIC USE | | | | | | | | | | | | | | | | | |
| <i>R06A Antihistamines for systemic use</i> | | | | | | | | | | | | | | | | | |
| <i>R06AA Aminoalkyl ethers</i> | | | | | | | | | | | | | | | | | |
| R06AA02 | Diphenhydramine | 25 50 100 | 2.8 3.3 3.8 | 6/1 8/1 6/1 | III | III | III | II | II | III | III | | + | + | + | + | + |
| R06AA04 | Clemastine | 1 | 3.2 | 9/1 | | III | | | | III | II* | | + | + | + | | |
| R06AA06 | Chlorphenoxamine | | | | | | | | II | II | | | | | | | |
| R06AA07 | Diphenylpyraline | 9 | U | 0/1 | | | | | | | | | | | | | |
| R06AA08 | Carbinoxamine | 4 8 12 | U U U | 0/1 0/1 0/3 | II.1 | | | I | II | II | | | | | | | |
| R06AA09 | Doxylamine | | | | | II | III | I | II | III | | | | | | | |
| <i>R06AB Substituted alkylamines</i> | | | | | | | | | | | | | | | | | |
| R06AB01 | Brompheniramine | 4 8 12 | U U 3 | 0/2 0/2 1/2 | II.2 | | | I | II | II | | | | | + | | + |
| R06AB03 | Dimetindene | 2 4 | 2 2 | 1/0 1/0 | | + | | | | | II | | + | + | | | |
| R06AB02 | Dexchlorpheniramine | 2 | 3 | 1/1 | II.2 | II | II | I | II | II | II | | + | | | + | |
| R06AB04 | Chlorphenamine | 1 4 12 | 3 3.5 3.6 | 1/0 4/1 3/0 | II.2 | | II | | II | II | II | | | | | | |
| R06AB05 | Pheniramine | 40 | U | 0/2 | | | | | | II | | | | | | | |
| R06AB06 | Dexbrompheniramine | | | | | | | | | | II* | | | | | | |
| R06AB52 | Dexchlorpheniramine, combinations Dexchlorpheniramine - guaiafenesine | | | | | | | | II | II | II | | | | | | |
| R06AB54 | Chlorpheniramine, combinations Chlorpheniramine - dextromorphone | | | | | | | II | II | II | | | | | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|----------------------|---|-----------|------------|--|------|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| | Pheniramine, combinations | | | | | | | | II | | | | | | | | |
| | Pheniramine - paracetamol - ascorbic acid | | | | | | | I | | | | | | | | | |
| <i>R06AC</i> | <i>Substituted ethylene diamines</i> | | | | | | | | | | | | | | | | |
| | R06AC02 Histapyrrodine | | | | | | | | II | II | | | | | | | |
| | R06AC04 Tripeleennamine | | | | | | | | | | | | | + | | | |
| <i>R06AD</i> | <i>Phenothiazine derivatives</i> | | | | | | | | | | | | | | | | |
| | R06AD01 Alimemazine | | | | | III | | I | II | III | | | | + | + | | |
| | R06AD02 Promethazine | 25 | 4 | 7/1 | III | III | | II | II | III | III | | + | + | + | + | + |
| | | 50 | 4 | 6/0 | | | | | | | | | | | | | |
| | R06AD03 Thiethylperazine | | | | | + | I | | | | | | | | | | |
| | R06AD07 Mequitazine | 5 | 1.4 | 5/0 | II.1 | II | | I | II | II | II* | | | | | | |
| | | 10 | 3 | 3/1 | | | | | | | | | | | | | |
| | R06AD08 Oxomemazine | | | | | | | II | | | | | | + | | | |
| | R06AD09 Isothipendyl | | | | | | | | II | II | | | | | | | |
| | R06AD52 Promethazine, combinations | | | | | | | | II | III | | | | | | | |
| | not yet determined Oxeladine - promethazine | | | | | | | II | | | | | | | | | |
| | not yet determined Trimeprazine | | | | | | | | | | | | | + | | | |
| | not yet determined Meglumine-polysorbate 20 benzoate - promethazine | | | | | | | II | | | | | | | | | |
| <i>R06AE</i> | <i>Piperazine derivatives</i> | | | | | | | | | | | | | | | | |
| | R06AE01 Buclizine | 25 | U | 0/1 | | | | I | II | II | II* | | | | | | |
| | | 50 | U | 0/1 | | | | | | | | | | | | | |
| | R06AE03 Cyclizine | 50 | U | 0/2 | | | | | | | | | | + | + | + | + |
| | R06AE04 Chlorcyclizine | | | | | | | | | | | | | | + | | + |
| | R06AE05 Meclozine | 25 | 4 | 1/0 | II.2 | II | | I | II | II | II | | + | + | + | + | + |
| | R06AE06 Oxatomide | 30 | U | 0/1 | | II | | I | II | II | II | | + | + | | | |
| | R06AE07 Cetirizine | 10 | 1.2 | 5/0 | I | II | II | I | I | II | I | | + | | | | |
| | | 20 | 2.3 | 6/0 | | | | | | | | | | | | | |
| | R06AE09 Levocetirizine | | | | | | | | I | I | I | | | | | | |
| | not yet determined Hydroxyzine | 25 | 3.5 | 4/0 | III | III | III | I,II | II | II | III | | + | + | + | + | + |
| | | 50 | 4 | 3/0 | | | | | | | | | | | | | |
| | | 100 | 4 | 3/0 | | | | | | | | | | | | | |
| <i>R06AX</i> | <i>Other antihistamines for systemic use</i> | | | | | | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN | |
|----------------------|----------------|-----------|------------|--|------|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|--|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| R06AX02 | Cyproheptadine | 4 | U | 0/2 | II.2 | II | II | I | II | II | | | | + | | | | |
| R06AX04 | Phenindamine | 25 | U | 0/1 | | | | | | | | | | | | | | |
| | | 50 | U | 0/1 | | | | | | | | | | | | | | |
| R06AX05 | Antazoline | | | | | | | | | | | | | + | | | | |
| R06AX07 | Triprolidine | 2.5 | 3.8 | 7/0 | III | III | | | II | III | III | | | | | | | |
| | | 5 | 3.8 | 7/0 | | | | | | | | | | | | | | |
| R06AX09 | Azatadine | 1 | 3 | 3/2 | II.1 | II | II | | | II | II* | | | | | | | |
| | | 2 | 3 | 3/1 | | | | | | | | | | | | | | |
| | | 4 | 3 | 1/1 | | | | | | | | | | | | | | |
| R06AX11 | Astemizol | 10 | 1 | 7/0 | I | I | | | | I | | | | | | | | |
| | | 30 | 1.2 | 5/0 | | | | | | | | | | | | | | |
| R06AX12 | Terfenadine | 60 | 1 | 11/0 | I | I | | | | I | | | | | | | | |
| | | 120 | 1.7 | 9/0 | | | | | | | | | | | | | | |
| | | 240 | 2.2 | 6/2 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| R06AX13 | Loratadine | 10 | 1 | 8/0 | I | I | I | 0 | I | I | I | | + | | | | | |
| | | 20 | 1.6 | 5/0 | | | | | | | | | | | | | | |
| R06AX15 | Mebhydrolin | 50 | 3 | 3/0 | | | | | | | | | | | + | | | |
| | | 100 | U | 0/3 | | | | | | | | | | | | | | |
| R06AX16 | Deptropine | | | | | | | | | | | | | | | | + | |
| R06AX18 | Acrivastine | 4 | 1.6 | 3/0 | | | | | | | | | | | | | | |
| | | 8 | 1.6 | 3/0 | | | | | | | | | | | | | | |
| R06AX17 | Ketotifen | 1 | 3.5 | 2/0 | II.2 | II | | I | II | II | II | | + | + | | | | |
| | | 2 | 3.3 | 3/0 | | | | | | | | | | | | | | |
| R06AX19 | Azelastine | | | | | I | I | | I | I | II* | | | | | | | |
| R06AX21 | Tritoqualine | | | | | | | 0 | | | | | | | | | | |
| R06AX22 | Ebastine | | 1 | 1/0 | | I | | | | I | II* | | | | | | | |
| R06AX23 | Pimethixene | | | | | | | | II | II | | | | | | | | |
| R06AX25 | Mizolastine | | | | | II | | I | II | II | II* | | + | | | | | |
| R06AX26 | Fexofenadine | | | | | I | | 0 | | I | I | | | | | | | |
| R06AX27 | Desloratadine | | | | | I | | | I | I | I | | | | | | | |
| not yet determined | Temelastine | 100 | 1 | 1/0 | | | | | | | | | | | | | | |
| not yet determined | Metopina | | | | | | | | | | III | | | | | | | |

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|-------------------------------------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| R07 OTHER RESPIRATORY SYSTEM PRODUCTS | | | | | | | | | | | | | | | | |
| <i>R07A Other respiratory system products</i> | | | | | | | | | | | | | | | | |
| <i>R07AB Respiratory stimulants</i> | | | | | | | | | | | | | | | | |
| R07AB07 | Almitrine | | | | | | I | | | I* | | | | | | |
| S SENSORY ORGANS | | | | | | | | | | | | | | | | |
| S01 OPHTHALMOLOGICALS | | | | | | | | | | | | | | | | |
| <i>S01A Antiinfectives</i> | | | | | | | | | | | | | | | | |
| <i>S01AA Antibiotics</i> | | | | | | | | | | | | | | | | |
| S01AA02 | Chlortetracycline | | | | | 0 | | I | I | | | | | | | |
| S01AA04 | Oxytetracycline | | | | | | | I | I | | | | | | | |
| S01AA11 | Gentamicin | | | | | 0 | | I | I | | | | | | | |
| S01AA12 | Tobramycin | | | | | 0 | | I | I | | | | | | | |
| S01AA16 | Rifamycin | | | | | | | I | I | | | | | | | |
| <i>S01AX Other antiinfectives</i> | | | | | | | | | | | | | | | | |
| S01AX13 | Ciprofloxacin | | | | | | | I | I | | | | | | | |
| | Thiomersal, combinations | | | | | | | II | II | | | | | | | |
| <i>S01B Antiinflammatory agents</i> | | | | | | | | | | | | | | | | |
| <i>S01BA Corticosteroids, plain</i> | | | | | | | | | | | | | | | | |
| S01BA01 | Dexamethasone | | | | | I | I | I | I | | | | | | | |
| S01BA04 | Prednisolone | | | | | | I | | | | | | | | | |
| S01BA05 | Triamcinolone | | | | | | I | | | | | | | | | |
| S01BA06 | Betamethasone | | | | | | I | | | | | | | | | |
| S01BA13 | Rimexolone | | | | | | | I | I | | | | | | | |
| not yet determined | Prednisone | | | | | | I | | | | | | | | | |
| | Betamethasone - dexchlorpheniramine | | | | | | I | | | | | | | | | |
| <i>S01BC Antiinflammatory agents, non steroids</i> | | | | | | | | | | | | | | | | |
| S01BC01 | Indometacin | | | | | I | | I | I | | | | | | | |
| S01BC03 | Diclofenac | | | | | 0 | | I | I | | | | | | | |
| <i>S01C Antiinflammatory agents and antiinfectives in combination</i> | | | | | | | | | | | | | | | | |
| <i>S01CA Corticosteroids and antiinfectives in combination</i> | | | | | | | | | | | | | | | | |
| S01CA01 | Dexamethasone and antiinfectives | | | | | | | I | I | | | | | | | |
| S01CA03 | Hydrocortisone and antiinfectives | | | | | 0 | | I | I | | | | | | | |

| ATC + SUBSTANCE NAME | | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|----------------------|--|-----------|-----------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| S01CA05 | Betamethasone and antiinfectives | | | | | | | | I | I | | | | | | | |
| <i>S01CC</i> | <i>Antiinflammatory agents, non steroids and antiinfectives in combination</i> | | | | | | | | | | | | | | | | |
| S01CC01 | Diclofenac and antiinfectives | | | | | | | | I | | | | | | | | |
| | not yet determined | | | | | | | | I | | | | | | | | |
| <i>S01E</i> | <i>Antiglaucoma preparations and miotics</i> | | | | | | | | | | | | | | | | |
| <i>S01EA</i> | <i>Sympathomimetics in glaucoma therapy</i> | | | | | | | | | | | | | | | | |
| S01EA02 | Dipivefrine | | | | | | I | | I | I | II* | | | | | | |
| S01EA03 | Apraclonidine | | | | | | | | I | I | II* | | | | | | |
| S01EA04 | Clonidine | | | | | + | | | | | II* | | | + | | | |
| S01EA05 | Brimonidine | | | | | | I | | I | I | II* | | | | | | |
| <i>S01EB</i> | <i>Parasympathomimetics</i> | | | | | | | | | | | | | | | | |
| S01EB01 | Pilocarpine | | | | | | II | | II | II | II* | | | | | | |
| S01EB02 | Carbachol | | | | | | | | II | II | | | | | | | |
| S01EB08 | Aceclidine | | | | | | | | II | II | II* | | | | | | |
| S01EB05 | Physostigmine | 3 | 0/1 | | | | | | | | | | | | | | |
| S01EB09 | Acetylcholine | | | | | | | | II | II | | | | | | | |
| S01EB51 | Pilocarpine, combinations | | | | | | | | II | II | II | | | | | | |
| S01EB58 | Aceclidine, combinations | | | | | | | | II | II | | | | | | | |
| <i>S01EC</i> | <i>Carbonic anhydrase inhibitors</i> | | | | | | | | | | | | | | | | |
| S01EC01 | Acetazolamide | | | | | | | + | I | | I | | | | | | |
| S01EC03 | Dorzolamide | | | | | | | | 0 | I | I | II* | | | | | |
| S01EC04 | Brinzolamide | | | | | | | | | I | I | I | | | | | |
| <i>S01ED</i> | <i>Beta blocking agents</i> | | | | | | | | | | | | | | | | |
| S01ED01 | Timolol | | | | | | II* | | II | I | II | | | | | | |
| S01ED02 | Betaxolol | | | | | | I* | | | | I | II* | | | | | |
| S01ED03 | Levobunolol | | | | | | I* | | | I | I | II* | | | | | |
| S01ED04 | Metipranolol | | | | | | I* | | | I | I | II* | | | | | |
| S01ED05 | Carteolol | | | | | | I* | | | I | I | II* | | | | | |
| S01ED06 | Befunolol | | | | | | I* | | | | I | | | | | | |
| S01ED51 | Timolol, combinations | | | | | | | | | I | II | | | | | | |
| | Timolol - latanoprost | | | | | | | | | | | II* | | | | | |
| S01ED54 | Metipranolol, combinations | | | | | | | | | | | II | | | | | |

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCHRIJN | | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|--------------------------|---------------|--|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| S01EE Prostaglandin analogues | | | | | | | | | | | | | | | | | |
| S01EE01 Latanoprost | | | | | + | I | | I | I | I* | | | | | | | |
| S01EE03 Bimatoprost | | | | | | | | I | I | | | | | | | | |
| S01EE04 Travoprost | | | | | | | | I | I | II* | | | | | | | |
| S01F Mydriatics and cycloplegics | | | | | | | | | | | | | | | | | |
| S01FA Anticholinergics | | | | | | | | | | | | | | | | | |
| S01FA01 Atropine | 0.4-0.6 0.85-1.7 2 | 3.1 3 4 | 5/1 2/1 1/0 | | | III | | III | III | II* | | | | | | | |
| not yet determined Hyoscymine | | | | | | | | III | III | | | | | | | | |
| S01FA04 Cyclopentolate | | | | | | | | I | III | III | II* | | | | | | |
| S01FA05 Homatropine | | | | | | | | | III | III | | + | | | | | |
| S01FA06 Tropicamide | | | | | + | | | | III | III | II* | | | | | | |
| S01FA56 Tropicamide, combinations | | | | | | | | | III | III | | | | | | | |
| S01FB Sympathomimetics excl .antiglaucoma preparations | | | | | | | | | | | | | | | | | |
| S01FB01 Phenylephrine | | | | | | | | | III | III | II* | | | | | | |
| S01G Decongestants and antiallergics | | | | | | | | | | | | | | | | | |
| S01GA Sympathomimetics used as decongestants | | | | | | | | | | | | | | | | | |
| S01GA02 Tetryzoline | | | | | | | | | II | II | | | | | | | |
| S01GA05 Phenylephrine | | | | | | | | | II | II | II* | | | | | | |
| S01GA06 Oxedrine | | | | | | | | | II | II | | | | | | | |
| S01GA51 Naphazoline, combinations | | | | | | | | | II | II | | | | | | | |
| S01GA55 Phenylephrine, combinations | | | | | | | | | II | II | | | | | | | |
| S01GA56 Oxedrine, combinations | | | | | | | | | II | II | | | | | | | |
| S01GX Other antiallergics | | | | | | | | | | | | | | | | | |
| S01GX01 Cromoglicic acid | | | | | | 0 | | I | I | II* | | | | | | | |
| S01GX02 Levocabastine | | | | | | I | I | | I | | | | | | | | |
| S01GX07 Azelastine | | | | | | | | | I | I | II* | | | | | | |
| S01GX08 Ketotifen | | | | | | | | | I | I | II | | + | | | | |
| S01GX09 Olopatadine | | | | | | | | | I | I | | | | | | | |
| S01J Diagnostic agents | | | | | | | | | | | | | | | | | |
| S01JA Colouring agents | | | | | | | | | | | | | | | | | |

| ATC + SUBSTANCE NAME | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|-----------|------------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| S01JA01 Fluorescein | | | | | | | | I | I | | | | | | | |
| S01XA Other ophthalmologicals | | | | | | | | | | | | | | | | |
| <i>S01XA Other ophthalmologicals</i> | | | | | | | | | | | | | | | | |
| not yet determined Boric acid | | | | | | | | I | I | | | | | | | |
| not yet determined Polyvinylalcohol | | | | | + | I | | | | | | | | | | |
| not yet determined Carbomer | | | | | | I | | | | | | | | | | |
| V VARIOUS | | | | | | | | | | | | | | | | |
| V03 ALL OTHER THERAPEUTIC PRODUCTS | | | | | | | | | | | | | | | | |
| V03A All other therapeutic products | | | | | | | | | | | | | | | | |
| <i>V03AB Antidotes</i> | | | | | | | | | | | | | | | | |
| V03AB25 Flumazenil | | | | I | + | II | | | I | II* | | | | | | |

Annex II – Overview Table, alphabetical

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|----------|-----------|------------|--|-----|------|-------|--------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Acamprosate | N07BB03 | | | | | | 0 | | | | I* | | | | | | |
| Acarbose | A10BF01 | | | | + | + | I | I | | II | + | | | | | | |
| Acebutolol | C07AB04 | | | | I* | I | | 0 | | I | I* | | | | | | |
| Aceclidine | S01EB08 | | | | | | | | II | II | II* | | | | | | |
| Aceclidine, combinations | S01EB58 | | | | | | | | II | II | | | | | | | |
| Aceclofenac | M01AB16 | | | | | + | | | | | | | | | | | |
| Acemetacin | M01AB11 | | | | | + | | | | | | | + | | | | |
| Acetazolamide | S01EC01 | | | | | + | I | | | | I | | | | | | |
| Acetylcholine | S01EB09 | | | | | | | | II | II | | | | | | | |
| Acetyldihydrocodeine | R05DA12 | | | | II* | | | | | II | | + | | | | | |
| Acetylleucine | N07CA04 | | | | | | | 0 | | | | | | | | | |
| Acetylsalicylic acid | N02BA51 | | | | | | | 0 | | | | | | | | | |
| Acetylsalicylic acid - codeine | N02BA51 | | | | | | | I | I | | | | | | | | |
| Acetylsalicylic acid - codeine - caffeine | N02BA51 | | | | | | | I | I | | | | | | | | |
| Acetylsalicylic acid - codeine - paracetamol | N02BA51 | | | | | | | I | I | | | | | | | | |
| Acetylsalicylic acid, combinations excl psycholeptics | N02BA51 | | | | | | | | | I,II | | | | | | | |
| Acrivastine | R06AX18 | 4 | 1.6 | 3/0 | | | | | | | | | | | | | |
| | | 8 | 1.6 | 3/0 | | | | | | | | | | | | | |
| Adenosine | C01EB10 | | | | | | I | II | | | | | | | | | |
| Adinazolam | N05BA07 | 30 | 3 | 1/2 | | | | | | | | | | | | | |
| Adrafinil | N06BX17 | | | | | | | | I | | | | | | | | |
| Aldesleukin | L03AC01 | | | | | | | | | | | | | | | + | |
| Alfentanil | N01AH02 | | | | | | | II,III | III | III | | + | | + | w | | + |
| Alfuzosin | G04CA01 | | | | | | | 0 | I | | | | | | | | |
| Alimemazine | R06AD01 | | | | | | III | | I | II | III | | | + | + | | |
| Alizapride | A03FA05 | | | | | | + | | I | | | | | | | | |
| Allobarbitol | N05CA21 | 30 | 4 | 1/1 | | | | | | | | | | | | + | |
| | | 100 | 4 | 1/0 | | | | | | | | | | | | | |
| | | 200 | 4 | 1/0 | | | | | | | | | | | | | |
| Allopurinol | M04AA01 | | | | | | | | I | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCRIJN | | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|-------------------------------|----------|-----------|-----------|--|------|-----|------|------------|---------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| Alminoprofen | M01AE16 | | | | | | | I | | | | | | | | | | |
| Almitrine | R07AB07 | | | | | | | I | | | I* | | | | | | | |
| Almotriptan | N02CC05 | | | | | | | | II | II | | | | | | | | + |
| Alprazolam | N05BA12 | 0.25 | 2.5 | 6/2 | II.2 | III | III | I, II, III | II | III | II | + | + | + | + | + | + | + |
| | | 0.5 | 2.8 | 6/2 | | | | | | | | | | | | | | |
| | | 1 | 3.5 | 2/4 | | | | | | | | | | | | | | |
| Alprenolol | C07AA01 | | | | I* | | | | | I | | | | | | | | |
| Alprostadil | G04BE01 | | | | | | 0 | I | | | | | | | | | | |
| Alverini citras - benzocainum | A03AX58 | | | | | | | 0 | | | | | | | | | | |
| Amantadine | N04BB01 | | | | | + | | II | I | I | II | | | | | | | |
| Amfepramone | A08AA03 | 50 | U | 0/1 | I* | I | | | | I | | + | | | | | | + |
| Amfetamine | N06BA01 | 5 | 3.5 | 2/1 | II.1 | II | | | | II | | + | | + | | | | |
| | | 10 | 3 | 1/1 | | | | | | | | | | | | | | |
| Amineptine | N06AA19 | | | | | II | | | | II | | + | | | | | | |
| Aminobutyric acid | N03AG03 | 1000-2000 | 1 | 1/0 | | | | | | | | | | | | | | |
| Aminogluthetimide | L02BG01 | | | | | | | I | | | | | | | | | | + |
| Amiodarone | C01BD01 | | | | | | | 0 | I | | | | | | | | | |
| Amisulpride | N05AL05 | 100 | 1 | 1/0 | | | | III | II, III | II | II | | | | | | | |
| Amitriptyline | N06AA09 | 12.5 | 3.5 | 2/0 | III | III | III | II | II | III | III | | | | + | + | | + |
| | | 25 | 3.9 | 12/0 | | | | | | | | | | | | | | |
| | | 50 | 3.9 | 13/0 | | | | | | | | | | | | | | |
| | | 75 | 3.9 | 13/0 | | | | | | | | | | | | | | |
| Amlodipine | C08CA01 | | | | | + | I | I | | | II* | | | | | | | |
| Amobarbital | N05CA02 | 15 | 4 | 2/2 | III | | | | | III | | + | | + | | | | |
| | | 50 | 4 | 3/1 | | | | | | | | | | | | | | |
| | | 100 | 4 | 1/1 | | | | | | | | | | | | | | |
| | | 200 | 4 | 1/1 | | | | | | | | | | | | | | |
| Amoxapine | N06AA17 | | | | | III | | I | II | III | | | | | | | | |
| Anastrozole | L02BG03 | | | | | | | I | | | | | + | | | | | |
| Antazoline | R06AX05 | | | | | | | | | | | | | | + | | | |
| Apomorphine | N04BC07 | | | | | | | III | II | II | | | | | | | + | |
| Apraclonidine | S01EA03 | | | | | | | | I | I | II* | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--------------------------|----------|-----------|------------|--|------|-----|------|--------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| Aprindine | C01BB04 | | | | | | | I | | | | | | | | | | |
| Aprobarbital | N05CA05 | | | | | | | | | | | | | | + | | | |
| Articaine | N01BB08 | | | | | | | | II | II | | | | | | | | |
| Articaine, combinations | N01BB58 | | | | | | | | II | II | | | | | | | | |
| Asparaginase | L01XX02 | | | | | | | II | | | | | | | | | | |
| Astemizol | R06AX11 | 10 | 1 | 7/0 | I | I | | | | I | | | | | | | | |
| | | 30 | 1.2 | 5/0 | | | | | | | | | | | | | | |
| Atenolol | C07AB03 | 50-100 | 1.2 | 5/0 | I | I | I | 0 | | I | I* | | | | | | | |
| Atenolol - chlortalidone | C07BB02 | | | | | | | I | | | | | | | | | | |
| Atenolol - nifedipine | C07FB03 | | | | | | | 0 | | | | | | | | | | |
| Atorvastatin | C10AA05 | | | | | | | 0 | | | | | | | | | | |
| Atracurium | M03AC04 | | | | | | | II,III | | | | | | | | | | |
| Atropine | A03BA01 | | | | | | | II | | | | | | + | | | | |
| | N05CM05 | 0.4-0.6 | 3.1 | 5/1 | | | | | | | | | | | | | | |
| | | 0.85-1.7 | 3 | 2/1 | | | | | | | | | | | | | | |
| | | 2 | 4 | 1/0 | | | | | | | | | | | | | | |
| | S01FA01 | 0.4-0.6 | 3.1 | 5/1 | | | III | | III | III | II* | | | | | | | |
| | | 0.85-1.7 | 3 | 2/1 | | | | | | | | | | | | | | |
| 2 | | 4 | 1/0 | | | | | | | | | | | | | | | |
| Atropine sulfate | A03BA | | | | | | I | | | | | | | | | | | |
| Azatadine | R06AX09 | 1 | 3 | 3/2 | II.1 | II | II | | | II | II* | | | | | | | |
| | | 2 | 3 | 3/1 | | | | | | | | | | | | | | |
| | | 4 | 3 | 1/1 | | | | | | | | | | | | | | |
| Azelastine | R06AX19 | | | | | I | I | | I | I | II* | | | | | | | |
| | S01GX07 | | | | | | | | I | I | II* | | | | | | | |
| Azithromycin | J01FA10 | | | | | | | 0 | | | | | | | | | | |
| Baclofen | M03BX01 | 5 | 1 | 1/1 | | + | III | | | | | | | + | + | + | + | + |
| | | 20 | 2 | 1/0 | | | | | | | | | | | | | | |
| Bamethan | C04AA31 | | | | | + | | | | | | | | | | | | |
| Bamifylline | R03DA04 | | | | | | | 0 | | | | | | | | | | |
| Barbital | N05CA04 | 250-500 | U | 0/1 | | | III | | | | | + | | + | | | | |
| Beclamide | N03AX30 | | | | | + | | | | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|----------|-----------|-----------|--|------|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Befunolol | S01ED06 | | | | I* | | | | | I | | | | | | | |
| Belladonna - opium - paracetamol - caffeine | N02BE51 | | | | | | | I | | | | | | | | | |
| Belladonna, total alkaloids | A03BA04 | | | | | | | | | | | | + | | | | |
| Benazepril | C09AA07 | | | | | + | | I | | | | | | | | | |
| Benazepril and diuretics | C09BA07 | | | | | | | I | | | | | | | | | |
| Benflumethiazide - reserpine | C03AX | | | | | | | I | | | | | | | | | |
| Benfluorex | C10AX04 | | | | | | | I | | | I* | | | | | | |
| Benorilate | N02BA10 | | | | | | | 0 | | | | | | | | | |
| Benperidol | N05AD07 | 0.25 | 1 | 0/1 | II* | | | | | II | | | + | + | | | |
| Bentazepam | N05BA | | | | | | III | | | III | | | | | | | |
| Benzatropine | N04AC01 | 0.5 | U | 0/1 | | | | | | | | | | | | | |
| Benzbromarone | M04AB03 | | | | | | 0 | 0 | | | | | | | | | |
| Benzocetamine | N05BD01 | 10 | U | 0/1 | | | | | | | | | | | | | |
| | | 20 | U | 0/1 | | | | | | | | | | | | | |
| Benzphetamine | A03AA | | | | | | | | | | | + | | | | | |
| Betahistine | N07CA01 | 42583 | 1 | 1/0 | I | | | 0 | | I | I | | | | | | |
| Betamethasone | H02AB01 | | | | | | | I | | | | | | | | | |
| | S01BA06 | | | | | | | I | | | | | | | | | |
| Betamethasone - dexchlorpheniramine | H02AB | | | | | | | I | | | | | | | | | |
| | S01BA | | | | | | | I | | | | | | | | | |
| Betamethasone and antiinfectives | S01CA05 | | | | | | | | I | I | | | | | | | |
| Betaxolol | C07AB05 | | | | I* | I | | 0 | | I | I* | | | | | | |
| | S01ED02 | | | | I* | | | | | I | II* | | | | | | |
| Bezafibrate | C10AB02 | | | | | | | I | | | | | | | | | |
| Bezitramide | N02AC05 | | | | III* | | | | | III | | + | | | | | |
| Bicalutamide | L02BBO3 | | | | | | | I | | | | | | | | | |
| Bimatoprost | S01EE03 | | | | | | | | I | I | | | | | | | |
| Biperiden | N04AA02 | | | | | + | III | II | II | II | III | | | | w | | + |
| Bisoprolol | C07AB07 | 5 | 1 | 1/0 | I* | I | I | 0 | | I | I* | | | | | | |
| Bisoprolol - hydrochlorothiazide | C07BB07 | | | | | | | 0 | | | | | | | | | |
| Boric acid | S01XA | | | | | | | | I | I | | | | | | | |
| Bornaprine | N04AA11 | | | | | + | | | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN | |
|---------------------------|----------|-----------|------------|--|------|-----|------|----------|------|-------|--------|-----|-------|--------|----|-----|----|-----|---|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | | |
| Brallobarbital | N05CA | | | | III* | | | | | III | | | | | + | | | | |
| Brimonidine | S01EA05 | | | | | | I | | I | I | II* | | | | | | | | |
| Brinzolamide | S01EC04 | | | | | | | | I | I | I | | | | | | | | |
| Bromazepam | N05BA08 | 1.5 | 2.6 | 7/1 | III | III | | I,II,III | II | III | III | III | + | + | + | | + | | |
| | | 3 | 3.1 | 6/2 | | | | | | | | | | | | | | | |
| | | 6 | 3.8 | 6/1 | | | | | | | | | | | | | | | |
| | | 12 | 4 | 6/1 | | | | | | | | | | | | | | | |
| Bromhexine | R05CB02 | | | | | | | | | | | | | | | | | + | |
| Bromides | N05CM11 | | | | | | | | I | | | | | | | | | | |
| Bromisoval | N05CM03 | | | | | | | | | | | | | | | | | + | |
| Bromocriptine | N04BC01 | | | | | | I | II | II | II | II | | | | | | | | |
| Bromolactobionate | N05CM | | | | | | | | I | | | | | | | | | | |
| Bromperidol | N05AD06 | 1 | 3 | 0/1 | II* | | | | | II | | | | | | | | + | |
| Brompheniramine | R06AB01 | 4 | U | 0/2 | II.2 | | | I | II | II | | | | | | | | | + |
| | | 8 | U | 0/2 | | | | | | | | | | | | | | | |
| | | 12 | 3 | 1/2 | | | | | | | | | | | | | | | |
| Brotizolam | N05CD09 | 0.125 | 3 | 0/6 | II.2 | III | | | III | III | II | | | | | | | | + |
| | | 0.25 | 3.7 | 2/3 | | | | | | | | | | | | | | | |
| | | 0.5 | U | 0/1 | | | | | | | | | | | | | | | |
| Buclizine | R06AE01 | 25 | U | 0/1 | | | | I | II | II | II* | | | | | | | | |
| Buclizine | R06AE01 | 50 | U | 0/1 | | | | | | | | | | | | | | | |
| Buflomedil | C04AX20 | | | | | | + | | | | II* | | | | | | | | |
| Buformin | A10BA03 | | | | | | + | | | II | | | | | | | | | |
| Bumetanide | C03CA02 | | | | | | + | | | | | | | | | | | | |
| Buphenine | C04AA02 | | | | | | + | | | | | | | | | | | | |
| Bupivacaine | N01BB01 | | | | | | | I | III | III | | | | | | | | | |
| Bupivacaine, combinations | N01BB51 | | | | | | | | II | II | | | | | | | | | |
| Bupranolol | C07AA19 | 50-200 | 1 | 1/0 | | | | | | | | | | | | | | | |
| Buprenorphine | N02AE01 | 0.2-0.4 | 3.5 | 2/1 | III | III | | II | II | III | | + | | + | + | + | + | + | |
| | N07BC01 | 0.2-0.4 | 3.5 | 2/1 | III | III | | III | II | II | | + | | + | + | + | + | + | |
| Bupropion (amfebutamone) | N07BA02 | 100 | 2 | 3/1 | | I | I | | II | II | II* | | | | | | | | |
| Buserelin | L02AE01 | | | | | | | I | | | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN | | | |
|--------------------------------------|----------|-----------|------------|--|------|------|-------|------------|-------|--------|-----|-------|--------|----|-----|----|-----|--|--|--|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | | | |
| Buspirone | N05BE01 | 5 | 1.2 | 13/0 | II.1 | II | | | I | I | II* | | + | + | | | | | | |
| | | 10 | 1.4 | 12/0 | | | | | | | | | | | | | | | | |
| | | 20 | 2.2 | 9/2 | | | | | | | | | | | | | | | | |
| | | 30 | 3 | 1/0 | | | | | | | | | | | | | | | | |
| Busulfan | L01AB01 | | | | | | | I | | | | | | | | | | | | |
| Butalamine | C04AX23 | | | | | + | | | | | | | | | | | | | | |
| Butalbital | N05CA | 50 | 4 | 1/1 | | | | | | | | | | + | + | | + | | | |
| | | 100 | 4 | 1/1 | | | | | | | | | | | | | | | | |
| Butibufen | M01AE | | | | | + | | | | | | | | | | | | | | |
| Butobarbital | N05CA03 | 50 | 4 | 1/2 | | | | | III | III | | | | + | | | | | | |
| | | 100 | 4 | 1/1 | | | | | | | | | | | | | | | | |
| | | 200 | 4 | 1/1 | | | | | | | | | | | | | | | | |
| Butorphanol | N02AF01 | | | | | | | | | | | | | + | | | | | | |
| Butriptyline | N06AA15 | 25 | 2 | 1/0 | | | | | | | | | | | | | | | | |
| Butylscopolamine | A03BB01 | | | | | | | I | | | | | + | | | | | | | |
| Buzepide metiodide - haloperidol | A03CA | | | | | | | II | | | | | | | | | | | | |
| Cabergoline | N04BC06 | | | | | | 0 | | II | II | | | | | | | | | | |
| Caffeine | N06BC01 | 50 | 1 | 1/0 | | | | | | | | | + | | | | | | | |
| Calcium carbasalate - metoclopramide | N02BA20 | | | | | | | I | | | | | | | | | | | | |
| Camazepam | N05BA15 | 10 | 2 | 1/1 | | II | | | | II | | + | | | | | | | | |
| | | 20 | 3 | 1/0 | | | | | | | | | | | | | | | | |
| Camylofine - metamizol sodium | A03DA05 | | | | | | | 0 | | | | | | | | | | | | |
| Candesartan | C09CA06 | | | | | | | I | | | II* | | | | | | | | | |
| Captodiame | N05BB02 | | | | | | | | I | | | | | | | | | | | |
| Captopril | C09AA01 | | 1 | 1/0 | | + | I | I | | | II* | | | | | | | | | |
| Captopril and diuretics | C09BA01 | | | | | | | I | | | | | | | | | | | | |
| Carbachol | S01EB02 | | | | | | | | II | II | | | | | | | | | | |
| Carbamazepine | N03AF01 | 200 | 3 | 2/1 | II.2 | II | II | I, II, III | II | II | II | | | | + | + | + | | | |
| | | 600 | 3.2 | 4/0 | | | | | | | | | | | | | | | | |
| Carbinoxamine | R06AA08 | 4 | U | 0/1 | II.1 | | | I | II | II | | | | | | | | | | |
| | | 8 | U | 0/1 | | | | | | | | | | | | | | | | |
| | | 12 | U | 0/3 | | | | | | | | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN | |
|-----------------------------------|----------|-----------|------------|--|------|------|-------|--------|--------|--------|-----|-------|--------|----|-----|----|-----|--|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| Carbocysteine – promethazine | R05FB01 | | | | | | | II | | | | | | | | | | |
| Carbomer | S01XA | | | | | | I | | | | | | | | | | | |
| Carboplatin | L01XA02 | | | | | | | II | | | | | | | | | | |
| Carbromal | N05CM04 | | | | | | | | | | | | | + | | | | |
| Carbutamide | A10BB06 | | | | | | | I | II | II | | | | | | | | |
| Carisoprodol | M03BA02 | | | | | | | | | | | | + | | + | + | + | |
| Carmustine | L01AD01 | | | | | | | III | | | | | | | | | | |
| Carteolol | C07AA15 | 10 | 1 | 1/0 | I* | I | | 0 | | | II* | | | | | | | |
| | S01ED05 | | | | I* | | | | I | I | II* | | | | | | | |
| Carvedilol | C07AG02 | | | | II* | II | II | | | II | II | | | | | | | |
| Celiprolol | C07AB08 | | | | I* | I | | 0 | | I | | | | | | | | |
| Cerivastatin | C10AA06 | | | | | | | 0 | | | | | | | | | | |
| Cetiedil | C04AX26 | | | | | + | | | | | | | | | | | | |
| Cetirizine | R06AE07 | 10 | 1.2 | 5/0 | I | II | II | I | I | II | I | | + | | | | | |
| | | 20 | 2.3 | 6/0 | | | | | | | | | | | | | | |
| Chloral hydrate | N05CC01 | 500-1000 | 4 | 1/1 | | | | | | | | | | + | | | + | |
| Chlorcyclizine | R06AE04 | | | | | | | | | | | | | | + | | + | |
| Chlordiazepoxide | N05BA02 | 5 | 2.9 | 7/0 | III | III | | I,II | II | III | III | + | + | + | + | + | + | |
| | | 10 | 3 | 7/0 | | | | | | | | | | | | | | |
| | | 20-25 | 3.5 | 2/4 | | | | | | | | | | | | | | |
| Chlormezanone | M03BB02 | 100 | 2 | 2/0 | | | | | | | | | | + | | | | |
| | | 200 | 2 | 2/0 | | | | | | | | | | | | | | |
| Chloroquine | P01BA01 | | | | | | I | | | | | | | | | | | |
| Chlorphenamine | R06AB04 | 1 | 3 | 1/0 | II.2 | | II | | II | II | II | | | | | | | |
| | | 4 | 3.5 | 4/1 | | | | | | | | | | | | | | |
| | | 12 | 3.6 | 3/0 | | | | | | | | | | | | | | |
| Chlorpheniramine - dextromorphone | R06AB54 | | | | | | II | | | | | | | | | | | |
| Chlorpheniramine, combinations | R06AB54 | | | | | | | II | II | | | | | | | | | |
| Chlorphenoxamine | R06AA06 | | | | | | | II | II | | | | | | | | | |
| Chlorpromazine | N05AA01 | 10-20 | 3 | 1/0 | III | III | III | II,III | II,III | III | III | | + | + | | | | |
| | | 25-50 | 4 | 2/2 | | | | | | | | | | | | | | |
| Chlorpropamide | A10BB02 | | | | + | + | | | II | II | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|------------------------------|----------|-----------|-----------|--|------|------|-------|----------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Chlorprothixene | N05AF03 | 20 | 4 | 1/0 | | | | | | | | | | + | | | |
| Chlortalidone | C03BA04 | | | | | + | I | | | | II* | | | | | | |
| Chlortetracycline | J01AA03 | | | | | + | | | | | | | | | | | |
| | S01AA02 | | | | | | 0 | | I | I | | | | | | | |
| Chlorzoxazone | M03BB03 | | | | | | | | | | | | | + | | + | + |
| Cibenzoline | C01BG07 | | | | | | | I | | | | | | | | | |
| Cilazapril | C09AA08 | | | | | + | | I | | | II* | | | | | | |
| Cimetidine | A02BA01 | 200 | 1.4 | 4/1 | I | I | | I | | I | I | | | | | | |
| | | 400 | 1.4 | 4/1 | | | | | | | | | | | | | |
| | | 800 | 1 | 1/0 | | | | | | | | | | | | | |
| Cinitapride | A03FA | | | | | + | | | | | | | | | | | |
| Cinnarizine | N07CA02 | 25 | 1 | 1/1 | II.2 | II | | | | II | II | | + | + | + | + | + |
| | | 50 | 3 | 1/1 | | | | | | | | | | | | | |
| Ciprofibrate | C10AB08 | | | | | | | 0 | | | | | | | | | |
| Ciprofloxacin | J01MA02 | | | | | + | I | I | | | | | | | | | |
| | S01AX13 | | | | | | | | I | I | | | | | | | |
| Cisapride | A03FA02 | | | | | | | I | | | | | | | | | |
| Cisatracurium | M03AC11 | | | | | | | II,III | | | | | | | | | |
| Cisplatin | L01XA01 | | | | | | | II | | | | | | | | | |
| Citalopram | N06AB04 | 40 | 2 | 1/1 | II.1 | I | | I | II | II | | | | + | | | |
| Citicoline | N06BX06 | | | | | | | | | | II* | | | | | | |
| Cladribine | L01BB04 | | | | | | | II | | | | | | | | | |
| Clebopride | A03FA06 | | | | | + | | | | | | | | | | | |
| Clemastine | R06AA04 | 1 | 3.2 | 9/1 | | III | | | | III | II* | | | + | + | + | |
| Clidinium - chlordiazepoxide | A03CA02 | | | | | | | II | | | | | | | | | |
| Clobazam | N05BA09 | 10 | 1.9 | 7/0 | II.1 | II | | I,II,III | II | II | II* | + | + | + | + | + | + |
| | | 20 | 2.3 | 6/1 | | | | | | | | | | | | | |
| Clobenzorex | A08AA08 | | | | | I | | | | I | | | | | | | |
| Clobutinol | R05DB03 | | | | | | | | I | I | | | | | | | |
| Clomethiazol | N05CM02 | 300 | 3.5 | 1/3 | | | | I | | | | | | + | + | + | + |
| | | 600-1200 | 4 | 1/2 | | | | | | | | | | | | | |
| Clomifene | G03GB02 | | | | | + | | | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|----------|-----------|-----------|--|------|------|-------|----------|--------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Clomipramine | N06AA04 | 25 | 2.7 | 5/2 | II.2 | II | | I | II | II | II | | | + | w | | |
| Clonazepam | N03AE01 | 0.5 | 4 | 1/0 | II.2 | II | II | I,III | II,III | II | II | + | + | | + | + | + |
| Clonidine | C02AC01 | 0.025 | 4 | 2/1 | | + | | I | | | II* | | + | + | | | |
| | | 0.075 | 4 | 2/2 | | | | | | | | | | | | | |
| | | 0.1 | 4 | 1/1 | | | | | | | | | | | | | |
| | N02CX02 | | | | | + | | | | | II* | | | + | | | |
| | S01EA04 | | | | | + | | | | | II* | | | + | | | |
| Clonixin | N02BG | | | | | | | | | | II | | | | | | |
| Cloperastine | R05DB21 | | | | | + | | | | | | | | | | | |
| Clorazepate, combinations | N05BA | | | | | | | | III | | | | | | | | |
| Cloridarol | C01DX15 | | | | | + | | | | | | | | | | | |
| Clotiapine | N05AX09 | | | | II* | II | | | | II | | | | | | | |
| Clotiazepam | N05BA21 | | | | III* | III | | I,II,III | II | III | | + | | | | | |
| Clovoxamine | N06AA | 75 | 1 | 1/0 | | | | | | | | | | | | | |
| Cloxazolam | N05BA22 | | | | II.2 | | | | | II | II | + | | | | | |
| Clozapine | N05AH02 | 100 | 3 | 1/1 | | II | | III | II | II | II | | + | + | | | |
| Codeine | R05DA04 | <20 | | | II.1 | II | II | I | I | I | | + | | + | + | + | + |
| | | 50 | 2 | 1/3 | | | | | II | II | | | | | | | |
| | | 100 | 3.3 | 3/0 | | | | | | | | | | | | | |
| Codeine - belladonna - caffeine - paracetamol | N02AA59 | | | | | | | I | | | | | | | | | |
| Codeine - chlorpheniramine | N02AA59 | | | | | | | II | | | | | | | | | |
| Codeine - cineole | N02AA59 | | | | | | | I | | | | | | | | | |
| Codeine - erysimum | N02AA59 | | | | | | | I | | | | | | | | | |
| Codeine - ethylmorphine | N02AA59 | | | | | | | II | | | | | | | | | |
| Codeine - gaiacol | N02AA59 | | | | | | | I | | | | | | | | | |
| Codeine - noramydopyrine - paracetamol | N02AA59 | | | | | | | I | | | | | | | | | |
| Codeine - noramydopyrine - tiemonium | N02AA59 | | | | | | | I | | | | | | | | | |
| Codeine - paracetamol | N02AA59 | | | | | | | I | | | | | + | | | + | |
| Codeine - paracetamol - caffeine | N02AA59 | | | | | | | | | | | | + | | | | |
| Codeine - phenyltoloxamine | N02AA59 | | | | | | | II | | | | | | | | | |
| Codeine - sodium benzoate | N02AA59 | | | | | | | I | | | | | | | | | |
| Codeine - sodium benzoate - alcohol | N02AA59 | | | | | | | I | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN | |
|---|----------|-----------|------------|--|------|------|-------|--------|--------|--------|-----|-------|--------|----|-----|----|-----|---|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| Codeine - sodium benzoate - cineole | N02AA59 | | | | | | | II | | | | | | | | | | |
| Codeine - sulfogaiacol | N02AA59 | | | | | | | I | | | | | | | | | | |
| Codeine, combinations excl .psycholeptics | N02AA59 | | | | | | | | I, II | I, II | | | | | | | | |
| Colestyramine | C10AC01 | | | | | | | 0 | | | | | | | | | | |
| Cough suppressants and expectorants | R05FB02 | | | | | | | | II | II | | | | | | | | |
| Cough suppressants and mucolytics | R05FB01 | | | | | | | | II | II | | | | | | | | |
| Cromoglicic acid | S01GX01 | | | | | | 0 | | I | I | II* | | | | | | | |
| Cyamemazine | N05AA06 | | | | | | | II,III | II,III | III | II | | | | | | | |
| Cyclandelate | C04AX01 | | | | | | | | | | II* | | | | | | | |
| Cyclizine | R06AE03 | 50 | U | 0/2 | | | | | | | | | | | + | + | + | + |
| Cyclobarbital | N05CA10 | 100 | 4 | 1/0 | | | | | | | | + | | + | | | | |
| | | 400 | 4 | 1/0 | | | | | | | | | | | | | | |
| Cyclobenzaprine | M03BX08 | | | | | | | I | | | | | | | | | | |
| Cyclopentolate | S01FA04 | | | | | | | I | | III | III | II* | | | | | | |
| Cyproheptadine | R06AX02 | 4 | U | 0/2 | II.2 | II | II | I | II | II | | | | | + | | | |
| Cyproterone | L02BB | | | | | + | I | 0 | | | | | | | | | | |
| Cytarabine | L01BC01 | | | | | | | II | | | | | | | | | | |
| Dacarbazine | L01AX04 | | | | | | | I | | | | | | | | | | |
| Dantrolene | M03CA01 | | | | | | | II | | | | | | | + | | | |
| Daunorubicin | L01DB02 | | | | | | | II | | | | | | | | | | |
| Delorazepam | N05BA | | | | | | | | | | | + | | | | | | |
| Deptropine | R06AX16 | | | | | | | | | | | | | | + | | | |
| Desflurane | N01AB07 | | | | | | | | III | III | | | | | | | | |
| Desipramine | N06AA01 | 25 | 2.5 | 2/3 | II* | | | I | II | II | | | | | + | | | |
| | | 50 | 3 | 0/2 | | | | | | | | | | | | | | |
| | | 75 | 4 | 1/1 | | | | | | | | | | | | | | |
| Desloratadine | R06AX27 | | | | | I | | | I | I | I | | | | | | | |
| Dexamethasone | H02AB02 | | | | | | 0 | I | | | | | | | | | | |
| | S01BA01 | | | | | | I | I | I | I | | | | | | | | |
| Dexamethasone and antiinfectives | S01CA01 | | | | | | | | I | I | | | | | | | | |
| Dexamfetamine | N06BA02 | 5 | 3.5 | 2/1 | II.1 | | | | | II | | + | | | | | | |
| | | 10 | 3 | 1/1 | | | | | | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN | |
|---|----------|-----------|-----------|--|------|------|-------|--------|--------|--------|-----|-------|--------|----|-----|----|-----|--|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| Dexbrompheniramine | R06AB06 | | | | | | | | | | II* | | | | | | | |
| Dexchlorpheniramine | R06AB02 | 2 | 3 | 1/1 | II.2 | II | II | I | II | II | II | | | + | | + | | |
| Dexchlorpheniramine - guaiafenesine | R06AB52 | | | | | | | II | | | | | | | | | | |
| Dexchlorpheniramine, combinations | R06AB52 | | | | | | | | II | II | | | | | | | | |
| Dexfenfluramine | A08AA04 | | | | | + | | | | | | | | | | | | |
| Dexketoprofen | M01AE17 | | | | | + | | | | | | | | | | | | |
| Dextromethorphan | R05DA09 | 10-20 | 1 | 1/0 | | | I | I | I | I | | + | | | + | | + | |
| Dextromethorphan - mepyramine | R05DA20 | | | | | | | II | | | | | | | | | | |
| Dextromoramide | N02AC01 | | | | III* | | | | II | III | | + | | + | | | | |
| Dextropropoxyphene | N02AC04 | 65 | 2.5 | 2/1 | II.2 | II | | I | II | II | II | + | | + | + | + | + | |
| | | 150 | 3.3 | 2/1 | | | | | | | | | | | | | | |
| Dextropropoxyphene – paracetamol | N02AC54 | | | | | | | I | | | | | | | | | | |
| Dextropropoxyphene – paracetamol - caffeine | N02AC54 | | | | | | | I | | | | | | | | | | |
| Dextropropoxyphene comb.inations excl . psycholeptics | N02AC54 | | | | | | | | II | II | | | | | | | | |
| Diazepam | N05BA01 | 2 | 2.8 | 15/2 | III | III | III | II,III | II,III | III | III | + | + | + | + | + | + | |
| | | 5 | 3.2 | 19/0 | | | | | | | | | | | | | | |
| | | 10 | 3.9 | 17/0 | | | | | | | | | | | | | | |
| | | 15 | 3.9 | 15/0 | | | | | | | | | | | | | | |
| | | 20 | 4 | 14/1 | | | | | | | | | | | | | | |
| Diazoxide | C02DA01 | | | | | + | | | | | | | | | | | | |
| Dibenzepin | N06AA08 | 80 | 1 | 1/0 | | | | | | | | | | | | | | |
| Diclofenac | M01AB05 | | | | | + | I | I | | I | | | | | | | | |
| | S01BC03 | | | | | | 0 | | I | I | | | | | | | | |
| Diclofenac and antiinfectives | S01CC01 | | | | | | | | I | | | | | | | | | |
| Diethylstilbestrol | L02AA01 | | | | | | | I | | | | | | | | | | |
| Difenoxin | A07DA04 | | | | | | | | | | | + | | | | | | |
| Diflunisal | N02BA11 | | | | | | | 0 | | | | | | | | | | |
| Digitoxin | C01AA04 | | | | | | | II | | | | | | | | | | |
| Digoxin | C01AA05 | | | | | | 0 | II | | | II* | | | | | | | |
| Dihexyverine | A03AA08 | | | | | | | I,II | | | | | | | | | | |
| Dihydrocodeine | N02AA08 | | | | II* | II | II | I | | II | II* | + | + | + | | | | |
| Dihydroergocristine | C04AE04 | | | | | + | | | | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN | |
|-----------------------------------|----------|-----------|------------|--|------|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|--|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| | N02CA01 | | | | | | | 0 | | | II* | | | | | | | |
| Diltiazem | C08DB01 | 90 | 1 | 1/0 | | + | I | I,II | | | II* | | | | | | | |
| Dimenhydrinate | A04AD | | 3 | 1/1 | III | III | III | II | II | III | III | | + | + | | | | |
| Dimenhydrinate - caffeine | A04AD | | | | | | | II | | | | | | | | | | |
| Dimetindene | R06AB03 | 2 | 2 | 1/0 | | + | | | | | II | | | + | + | | | |
| | | 4 | 2 | 1/0 | | | | | | | | | | | | | | |
| Dimetotiazine | N02CX05 | | | | | + | | | | | | | | | | | | |
| Diphenhydramine | R06AA02 | 25 | 2.8 | 6/1 | III | III | III | II | II | III | III | | + | + | + | + | + | |
| | | 50 | 3.3 | 8/1 | | | | | | | | | | | | | | |
| | | 100 | 3.8 | 6/1 | | | | | | | | | | | | | | |
| Diphenoxylate | A07DA01 | | | | | | | I | | | | + | | | | | | |
| Diphenylpyraline | R06AA07 | 9 | U | 0/1 | | | | | | | | | | | | | | |
| Dipivefrine | S01EA02 | | | | | | I | | I | I | II* | | | | | | | |
| Dipyridamole | B01AC07 | | | | | + | | | | | | | | | | | | |
| Disopyramide | C01BA03 | | | | | | | I | | | | | | | | | | |
| Disulfiram | N07BB01 | | | | | | | I | III | II | II | II* | | | | | | |
| Disulfiram – nicotamide - adenine | N07BB | | | | | | | | III | | | | | | | | | |
| Disulfiram, combinations | N07BB | | | | | | | | II | | | | | | | | | |
| Dixyrazine | N05AB01 | | | | II* | | | | | II | | | | | w | | | |
| Docetaxel | L01CD02 | | | | | | | II | | | | | | | | | | |
| Dolasetron | A04AA04 | | | | | | | I | I | I | | | | | | | | |
| Domperidone | A03FA03 | 10-20 | U | 0/1 | | | | 0 | 0 | | | | | | | | | |
| Donepezil | N06DA02 | | | | | | | 0 | | II | II | I* | | | | | | |
| Dorzolamide | S01EC03 | | | | | | | 0 | | I | I | II* | | | | | | |
| Dosulepin | N06AA16 | 75 | 2 | 1/0 | II.2 | III | | I | II | III | II* | | | + | | | | |
| Doxazosin | C02CA04 | | | | | + | I | | | | | | | | | | | |
| Doxepin | N06AA12 | 25 | 3 | 7/1 | II.2 | III | | I | II | III | | | | + | w | | | |
| | | 50 | 3.6 | 5/0 | | | | | | | | | | | | | | |
| Doxorubicin | L01DB01 | | | | | | | II | | | | | | | | | | |
| Doxycycline | J01AA02 | | | | | + | 0 | | | | | | | | | | | |
| Doxylamine | R06AA09 | | | | | II | III | I | II | III | | | | | | | | |
| | N05CM | | | | | | | | III | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|----------|-----------|------------|--|------|------|-------|----------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Dronabinol | A04AD10 | | | | | | | | | | | | | + | | | |
| Droperidol | N05AD08 | 5 | U | 0/1 | II.2 | | | III | III | II | | | | + | w | | |
| Ebastine | R06AX22 | | 1 | 1/0 | | I | | | | I | II* | | | | | | |
| Eletriptan | N02CC06 | | | | | | | | II | II | | | | | | | + |
| Enalapril | C09AA02 | | 1 | 1/0 | | + | I | | | | II* | | | | | | |
| Enalapril and diuretics | C09BA02 | | | | | | | I | | | | | | | | | |
| Enflurane | N01AB04 | | | | | | | | III | III | | | | | | | |
| Enoxacin | J01MA04 | | | | | | | I | | | | | | | | | |
| Entacapone | N04BX02 | | | | | + | | II | II | II | I* | | | | | | |
| Ephedrine | R03CA02 | | | | | | | | | | | | | | + | | + |
| Epirubicin | L01DB03 | | | | | | | II | | | | | | | | | |
| Eprosartan | C09CA02 | | | | | | | | | | II* | | | | | | |
| Ergoloid mesylates (dihydroergotoxine) | C04AE01 | | | | | + | | | | | | | | | | | |
| Ergotamine | N02CA02 | | | | | | | | | | | | | | + | | + |
| Ergotamine - caffeine - belladonna - paracetamol | N02CA52 | | | | | | | | | | II* | | | | | | |
| Ergotamine – caffeine - cyclizine | N02CA52 | | | | | | | I | | | | | | | | | |
| Ergotamine - propifenazone | N02CA52 | | | | | | | | | | II* | | | | | | |
| Ergotamine, combinations excl. psycholeptics | N02CA52 | | | | | | | | I | I | | | | | | | |
| Erythropoietin alpha | B03XA01 | | | | | + | | I | | | | | | | | | |
| Erythropoietin beta | B03XA01 | | | | | + | | I | | | | | | | | | |
| Escitalopram | N06AB10 | | | | | | | | II | II | | | | | | | |
| Estazolam | N05CD04 | | | | | | | | III | III | | + | | | | | |
| Estradiol di-undecylate | L02AA | | | | | | | I | | | | | | | | | |
| Estramustine | L01XX11 | | | | | | | 0 | | | | | | | | | |
| Ethambutol | J04AK02 | | | | | + | | | | | | | | | | | |
| Ethchlorvynol | N05CM08 | | | | | | | | | | | + | | | | | |
| Ethinamate | N05BC | | | | | | | | | | | + | | | | | |
| Ethosuximide | N03AD01 | 250 | 3 | 1/0 | II* | II | | III | II | III | | | | | + | + | + |
| Ethyl loflazepate | N05BA18 | | | | II* | | | I,II,III | II | II | II | + | | | | | |
| Ethylmorphine | R05DA01 | | | | II* | III | | I | I | III | | + | | | + | | + |
| Ethylmorphine – aconite – guiafanesine | R05FA | | | | | | | II | | | | | | | | | |
| Ethylmorphine – sodium benzoate | R05FA | | | | | | | I | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--------------------------|--------------|-----------|------------|--|------|------|-------|--------|--------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Etidocaine | N01BB07 | | | | | | | I | | | | | | | | | |
| Etidocaine, combinations | N01BB57 | | | | | | | I | | | | | | | | | |
| Etifoxine | N05BX03 | | | | | | | | I | I | | | | | | | |
| Etilamfetamine | A08AA06 | | | | I* | | | | | I | | | | | | | |
| Etodolac | M01AB08 | | | | | | | I | | | | | | | | | |
| Etomidate | N01AX07 | | | | | | | II,III | III | III | | | | | | | |
| Etoperidone | N06AB09 | | | | | + | | | | | | | | | | | |
| Etoposide | L01CB01 | | | | | | | II | | | | | | | | | |
| Etozolin | C03CX01 | | | | | + | | | | | | | | | | | |
| Exemestane | L02BG06 | | | | | | | | | | | | | | | | + |
| Famotidine | A02BA03 | 20-40 | 1 | 1/0 | II.1 | I | I | 0 | | II | II* | | | | | | |
| Febarbamate | M03BA05 | | | | | + | | | | | | | | | | | |
| Felbamate | N03AX10 | | | | II* | II | | III | II | II | II | | | | | | |
| Felodipine | C08CA02 | | | | | + | | I | | | | | | | | | |
| Femoxetine | <i>N06AB</i> | 200 | 2 | 1/0 | | | | | | | | | | | | | |
| Fenbufen | M01AE05 | | | | | + | | | | | | | | | | | |
| Fenetylline | N06BA10 | | | | I* | | | | | I | | | | | | | |
| Fenfluramine | A08AA02 | 20 | U | 0/1 | | + | | | | | | | | + | + | | |
| | | 40 | 2 | 1/0 | | | | | | | | | | | | | |
| Fenofibrate | C10AB05 | | | | | | | 0 | | | | | | | | | |
| Fenoprofen | M01AE04 | | | | | | | I | I | I | | | | | | | |
| Fenproporex | <i>N06BA</i> | | | | | I | | I | | I | | | | | | | |
| Fenspiride | R03BX01 | | | | | | | I | | | | | | | | | |
| Fentanyl | N01AH01 | | | | III | III | III | II,III | III | III | III | + | | + | + | + | + |
| | N02AB03 | | | | III | III | III | II,III | II,III | III | III | + | | + | + | + | + |
| Fentiazac | M01AB10 | | | | | + | | | | | | | | | | | |
| Fenylramidol | M03BX03 | | | | | | | | | | | | + | | | | |
| Feprazone | M01AX18 | | | | | + | | | | | | | | | | | |
| Ferrous sulfate | B03AA07 | | | | | | | I | | | | | | | | | |
| Fexofenadine | R06AX26 | | | | | I | | 0 | | I | I | | | | | | |
| Finasteride | G04CB01 | | | | | | | 0 | 0 | | | | | | | | |
| Flavoxate | G04BD02 | | | | | | | 0 | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|-----------------------|----------|-----------|------------|--|------|------|-------|--------|--------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Flecainide | C01BC04 | | | | | + | | I | | | | | | | | | |
| Floctafenine | N02BG04 | | | | | + | | I | I | I | | | | + | | | |
| Fluanisone | N05AD09 | | | | | | | | II,III | III | | | | | | | |
| Fludarabine | L01BB05 | | | | | | | II | | | | | | | | | |
| Fludiazepam | N05BA17 | | | | | | | | | | | + | | | | | |
| Flumazenil | V03AB25 | | | | I | + | II | | | I | II* | | | | | | |
| Flumequine | J01MB07 | | | | | | | I | | | | | | | | | |
| Flunarizine | N07CA03 | | | | | II | II | I | II | II | | | | + | | + | |
| Flunitrazepam | N05CD03 | 0.5 | 4 | 3/4 | III | III | | II | III | III | III | + | + | + | + | + | |
| | | 1 | 4 | 4/3 | | | | | | | | | | | | | |
| | | 2 | 4 | 4/3 | | | | | | | | | | | | | |
| | N01AX | | | | | | | II,III | III | | | | | | | | |
| Fluorescein | S01JA01 | | | | | | | | I | I | | | | | | | |
| Fluorouracil | L01BC02 | | | | | | 0 | II | | | | | | | | | |
| Fluoxetine | N06AB03 | 20 | 1.8 | 4/1 | II.1 | I | I | I | II | I | II* | | | | | | |
| | | 40 | 2 | 2/2 | | | | | | | | | | | | | |
| | | 60 | 2.5 | 2/1 | | | | | | | | | | | | | |
| Flupentixol | N05AF01 | 1 | 1 | 2/0 | II.2 | II | | III | II,III | II | II | | | | | | |
| | | 5-15 | 3 | 1/1 | | | | | | | | | | | | | |
| Flupentixol decanoate | N05AF | | | | | | | III | | | | | | | | | |
| Fluperlapine | N05AH | 100 | 4 | 1/0 | | | | | | | | | | | | | |
| Fluphenazine | N05AB02 | 1-2 | U | 0/2 | II* | II | II | III | II | II | II | | | | | | |
| | | 5-15 | 3 | | | | | | | | | | | | | | |
| Flupirtine | N02BG07 | 100 | 3 | 1/0 | | | | | | | II | | | | | | |
| Flurazepam | N05CD01 | 15 | 4 | 4/4 | III | III | | | III | III | III | + | | + | + | | |
| | | 30 | 4 | 5/3 | | | | | | | | | | | | | |
| Flurbiprofen | M01AE09 | | | | | + | | I | | | | | | | | | |
| Fluspirilene | N05AG01 | | | | II* | | | | | II | | | | + | | | |
| Flutamide | L02BB01 | | | | | | | 0 | | | | | | | | | |
| Fluvastatin | C10AA04 | | | | | | | 0 | | | | | | | | | |
| Fluvoxamine | N06AB08 | 50 | 2.2 | 4/2 | II.1 | I | I | I | II | II | II* | | + | + | | | |
| Formestane | L02BG02 | | | | | | | II | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--------------------------|----------|-----------|-----------|--|-----|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Fosfestrol | L02AA04 | | | | | | | 0 | | | | | | | | | |
| Fosinopril | C09AA09 | | | | | + | | I | | | II* | | | | | | |
| Fosinopril and diuretics | C09BA09 | | | | | | | I | | | | | | | | | |
| Fosphenytoin | N03AB05 | | | | | II | | III | II | III | | | | | | + | + |
| Fotemustine | L01AD05 | | | | | | | II | | | | | | | | | |
| Frovatriptan | N02CC07 | | | | | | | | II | II | | | | | | | + |
| Furosemide | C03CA01 | | | | | + | I | | | | II* | | | | | | |
| Gabapentin (carbapentin) | N03AX12 | | | | | II | II | III | II | II | II | | + | | + | + | + |
| Galantamine | N06DA04 | | | | | | | | II | II | | | | | | | |
| Gemcitabine | L01BC05 | | | | | | | II | | | | | | | | | |
| Gemfibrozil | C10AB04 | | | | | | 0 | 0 | | | | | | | | | |
| Gentamicin | S01AA11 | | | | | | 0 | | I | I | | | | | | | |
| Ginkgo Biloba | N06DX02 | | | | | + | | | | | II* | | | | | | |
| Glafenine | N02BG03 | 200-400 | 1 | 1/0 | | | | | | | | | | | | | |
| Glibenclamide | A10BB01 | | | | + | + | I | I | II | II | + | | | | | | |
| Glibornuride | A10BB04 | | | | | | | I | II | II | | | | | | | |
| Gliclazide | A10BB09 | | | | + | + | I | I | II | II | + | | | | | | |
| Glimepiride | A10BB12 | | | | | | | I | II | II | | | | | | | |
| Glipizide | A10BB07 | | | | + | + | I | I | II | II | + | | | | | | |
| Gliquidone | A10BB08 | | | | + | + | I | | | II | | | | | | | |
| Glisentide | A10BB | | | | | + | | | | II | | | | | | | |
| Glucagon | H04AA01 | | | | + | + | 0 | | | II | | | | | | | |
| Glutethimide | N05CE01 | 125 | 4 | 1/2 | | | | | | | | + | | | | | |
| | | 250 | 4 | 1/2 | | | | | | | | | | | | | |
| | | 500 | U | 0/2 | | | | | | | | | | | | | |
| Glyceryl trinitrate | C01DA02 | | | | | + | I | | | | II* | | | | | | |
| Glycopyrronium | A03AB02 | | | | | | | | | | | | | | | | + |
| Goserelin | L02AE03 | | | | | | | 0 | | | | | | | | | |
| Granisetron | A04AA02 | | | | I | + | | I | I | I | | | | | | | |
| Guanethidine | C02CC02 | 10 | 3 | 2/1 | | | | | | | | | | | | + | |
| Guanfacine | C02AC02 | | | | | + | | I | | | | | | | + | | |
| Halazepam | N05BA13 | | | | | | III | | | III | II | + | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|-----------------------------------|----------|-----------|------------|--|------|------|--------|--------|--------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Haloperidol | N05AD01 | 1 | 2.3 | 3/0 | II.2 | II | II | II,III | II,III | II | II | | + | + | w | | |
| | | 10 | 3 | 1/1 | | | | | | | | | | | | | |
| Haloperidol decanoate | N05AD | | | | | | III | | | | | | + | | | | |
| Halothane | N01AB01 | | | | | | II,III | III | III | | | | | | | | |
| Haloxazolam | N05BA | | | | | | | | | | | + | | | | | |
| Heptabarbital | N05CA11 | 100 | U | 0/1 | | | | | | | | | | | | | |
| | | 200 | U | 0/1 | | | | | | | | | | | | | |
| Hexobarbital | N05CA16 | 250 | U | 0/2 | | | | | | | | | | | + | | |
| | | 500 | U | 0/1 | | | | | | | | | | | | | |
| Hexobendine | C01DX06 | | | | | + | | | | | | | | | | | |
| Histapyrrodine | R06AC02 | | | | | | | | II | II | | | | | | | |
| Homatropine | S01FA05 | | | | | | | | III | III | | | + | | | | |
| Hydralazine | C02DB02 | | | | | + | | | | | | | | | | | |
| Hydrochlorothiazide | C03AA03 | | | | | + | I | | | | II* | | | | | | |
| Hydrocodone | R05DA03 | | | | II* | | | | | II | | + | | | | | |
| Hydrocortisone and antiinfectives | S01CA03 | | | | | | 0 | | I | I | | | | | | | |
| Hydromorphone | N02AA03 | | | | | | | | II | II | | + | | + | | + | + |
| Hydroquinidine | C01BA | | | | | | | I | | | | | | | | | |
| Hydroxybutyric acid | N07XX04 | | | | | | | II,III | | | | | | | | | + |
| Hydroxycarbamide | L01XX05 | | | | | | | II | | | | | | | | | |
| Hydroxyzine | R06AE | 25 | 3.5 | 4/0 | III | III | III | I,II | II | II | III | | + | + | + | + | + |
| | | 50 | 4 | 3/0 | | | | | | | | | | | | | |
| | | 100 | 4 | 3/0 | | | | | | | | | | | | | |
| Hyoscyamine | A03BA03 | | | | | | | | | | | | + | | | | |
| | S01FA | | | | | | | | III | III | | | | | | | |
| Ibuprofen | M01AE01 | | | | | | 0 | I | I | I | | | | | | | |
| Ibutilide | C01BD05 | | | | | | | I | | | | | | | | | |
| Idarubicin | L01DB06 | | | | | | | II | | | | | | | | | |
| Idebenone | N06BX13 | | | | | | | | | | II | | | | | | |
| Ifosfamide | L01AA06 | | | | | | | II | | | | | | | | | |
| Imidapril | C09AA16 | | | | | | | I | | | | | | | | | |
| Imipenem and enzyme inhibitor | J01DH51 | | | | | | | I | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN | |
|--------------------------------|----------|-----------|------------|--|------|------|-------|--------|-------|--------|-----|-------|--------|----|-----|----|-----|--|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| Imipramine | N06AA02 | 25 | 2.7 | 3/3 | II.2 | II | II | I | II | II | II | | | + | w | | | |
| | | 50 | 3.3 | 3/1 | | | | | | | | | | | | | | |
| | | 75 | 4 | 2/1 | | | | | | | | | | | | | | |
| Imipramine oxide | N06AA03 | | | | | + | | | | | | | | | | | | |
| Indalpine | N06AB | 50 | 1 | 1/0 | | | | | | | | | | | | | | |
| Indapamide | C03BA11 | | | | | + | | | | | II* | | | | | | | |
| Indometacin | M01AB01 | 25 | 2.5 | 2/1 | | + | I | II | | | | | + | + | | | + | |
| | | 50 | 3 | 1/2 | | | | | | | | | | | | | | |
| | S01BC01 | | | | | | I | | I | I | | | | | | | | |
| Indometacin and antiinfectives | S01CC | | | | | | | | I | | | | | | | | | |
| Indoramin | C02CA02 | 25 | 3 | 1/0 | | + | | I | | | | | | | | | | |
| Insulin | A10A | | | | + | + | I | II,III | II | II | + | | + | | | | | |
| Interferon alfa natural | L03AB01 | | | | | | | I | | | | | + | | | | | |
| Interferon beta natural | L03AB02 | | | | | | | I | | | | | | | | | | |
| Interferon gamma | L03AB03 | | | | | | | I | | | | | + | | | | | |
| Ipratropium bromide | R03BB01 | | | | | | | | | | | | + | | | | | |
| Iproclozide | N06AF06 | | | | II* | | | | | II | | | | | | | | |
| Iproniazide | N06AF05 | | | | | | | I | II | II | | | | | | | | |
| Irbesartan | C09CA04 | | | | | | | I | | | II* | | | | | | | |
| Irbesartan and diuretics | C09DA04 | | | | | | | I | | | | | | | | | | |
| Irinotecan | L01XX19 | | | | | + | | II | | | | | | | | | | |
| Isoflurane | N01AB06 | | | | | | | | III | III | | | | | | | | |
| Isoniazid | J04AC01 | | | | | + | 0 | | | | | | | | | | | |
| Isonixin | M01AX | | | | | + | | | | | | | | | | | | |
| Isosorbide dinitrate | C01DA08 | 20 | 1 | 1/0 | | + | | | | | II* | | | | | | | |
| Isosorbide mononitrate | C01DA14 | | | | | + | I | | | | | | | | | | | |
| Isothipendyl | R06AD09 | | | | | | | | II | II | | | | | | | | |
| Isoxsuprine | C04AA01 | | | | | + | | | | | II* | | | | | | | |
| Isradipine | C08CA03 | | | | | + | 0 | | | | II* | | | | | | | |
| Kava-kava | N05CM | 100 | 1.3 | | | | | | | | | | | | | | | |
| Ketamine | N01AX03 | | | | | | | II,III | III | III | | | | | | | | |
| Ketazolam | N05BA10 | 30 | 3 | 2/1 | III | III | | | | III | II | + | | + | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|----------|-----------|-----------|--|------|------|-------|--------|--------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Ketobemidone | N02AB01 | | | | | | | | | | | + | | | | + | |
| Ketoconazole | J02AB02 | | | | | + | I | | | | | | | | | | |
| | D01AC08 | | | | | + | 0 | | | | | | | | | | |
| Ketoprofen | M01AE03 | | | | | + | | I | I | I | | | | | | | |
| Ketorolac | M01AB15 | | | | | + | | | | | | | | | | | |
| Ketotifen | R06AX17 | 1 | 3.5 | 2/0 | II.2 | II | | I | II | II | II | | + | + | | | |
| | | 2 | 3.3 | 3/0 | | | | | | | | | | | | | |
| | S01GX08 | | | | | | | | I | I | II | | + | | | | |
| Labetalol | C07AG01 | | | | I* | I | | 0 | | I | | | | | | | |
| Lacidipine | C08CA09 | | | | | + | | I | | | II* | | | | | | |
| Lamotrigine | N03AX09 | 120 | 1 | 2/0 | II* | II | II | III | II | II | II* | | | | w | | + |
| | | 300 | 1 | 1/0 | | | | | | | | | | | | | |
| Lansoprazole | A02BC03 | | | | | | | I | | | | | | | | | |
| Latanoprost | S01EE01 | | | | | + | I | | I | I | I* | | | | | | |
| Lenograstim | L03AA10 | | | | | + | | | | | | | | | | | |
| Lercanidipine | C08CA13 | | | | | + | | | | | II* | | | | | | |
| Letrozole | L02BG04 | | | | | | | I | | | | | | | | | |
| Leuprorelin | L02AE02 | | | | | | | I | | | | | | | | | |
| Levacetylmethadol | N07BC03 | | | | | + | | | | | | | | | | | |
| Levetiracetam | N03AX14 | | | | | | II | | II | II | I | | | | | | |
| Levobunolol | S01ED03 | | | | I* | | | | I | I | II* | | | | | | |
| Levocabastine | S01GX02 | | | | | I | I | | | I | | | | | | | |
| Levocarnitine | A16AA01 | | | | | | | | | | I | | | | | | |
| Levocetirizine | R06AE09 | | | | | | | | I | I | I | | | | | | |
| Levodopa and decarboxylase inhibitor | N04BA02 | | | | | | I | II | II | II | III | | | | | | |
| Levodopa, decarboxylase inhibitor and COMT inhibitor | N04BA03 | | | | | | | | II | | | | | | | | |
| Levomepromazine | N05AA02 | 10 | 4 | 1/1 | III* | III | III | II,III | II,III | III | III | | + | + | w | | |
| | | 25 | 4 | 1/0 | | | | | | | | | | | | | |
| Levonorgestrel | G03AC03 | | | | | | I | | | | | | | | | | |
| Levopenbutolol | C07AA | | | | | | | 0 | | | | | | | | | |
| Levorphanol | N02AF | | | | | | | | | | | + | | | | | |
| Lidocaine | C01BB01 | | | | | | | III | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN | |
|--|----------|-----------|------------|--|------|------|-------|----------|--------|--------|-----|-------|--------|----|-----|----|-----|---|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| | N01BB02 | | | | | | I | I | II | II | | | | | | | | |
| Lidocaine, combinations | N01BB52 | | | | | | | | II | II | | | | | | | | |
| Lisinopril | C09AA03 | | | | | + | | | | | II* | | | | | | | |
| Lisinopril and diuretics | C09BA03 | | | | | | | I | | | | | | | | | | |
| Lisuride | N04BC | | | | | | | II | II | II | | | | | | | | |
| Lithium | N05AN01 | 600 | 2 | 3/0 | II.1 | II | II | II | II | II | I | | | + | | | | |
| Lofepamine | N06AA07 | 70 | 3 | 0/1 | II* | II | | | | II | II | | | | | | | |
| Lomefloxacin | J01MA07 | | | | | | | I | | | | | | | | | | |
| Loperamide | A07DA03 | | | | | | 0 | I | | | | | | | | | | |
| Loperamide oxide | A07DA05 | | | | | | | I | | | | | | | | | | |
| Loprazolam | N05CD11 | 0.5 | U | 0/2 | II.2 | III | | I,II,III | III | III | II | + | | + | | | | |
| | | 1 | 3.5 | 1/2 | | | | | | | | | | | | | | |
| | | 2 | 4 | 1/1 | | | | | | | | | | | | | | |
| Loratadine | R06AX13 | 10 | 1 | 8/0 | I | I | I | 0 | I | I | I | | + | | | | | |
| | | 20 | 1.6 | 5/0 | | | | | | | | | | | | | | |
| Lorazepam | N05BA06 | 0.5 | 3.6 | 11/3 | III | III | III | I,II,III | II | III | III | III | + | + | + | + | + | + |
| | | 1 | 3.9 | 10/1 | | | | | | | | | | | | | | |
| | | 2.5 | 4 | 10/0 | | | | | | | | | | | | | | |
| | | 5 | 4 | 7/3 | | | | | | | | | | | | | | |
| Lormetazepam | N05CD06 | 0.5 | 3 | 1/5 | II.2 | III | III | I,II,III | III | III | II | + | + | + | | + | | |
| | | 1 | 3 | 2/3 | | | | | | | | | | | | | | |
| | | 2 | 4 | 2/3 | | | | | | | | | | | | | | |
| Losartan | C09CA01 | | | | | | | I | I | | II* | | | | | | | |
| Loxapine | N05AH01 | | | | III* | II | | III | II,III | III | | | + | + | | | | |
| Lysine acetylsalicylate - metoclopramide | N02BA20 | | | | | | | I | II | | | | | | | | | |
| Maprotiline | N06AA21 | 25 | 2.2 | 3/3 | II.2 | II | | I | II | II | II | | | | | | + | |
| | | 75 | 3 | 2/2 | | | | | | | | | | | | | | |
| Mazindol | A08AA05 | 1 | 3 | 0/1 | | | | | | | | + | | + | | | | |
| Mebhydrolin | R06AX15 | 50 | 3 | 3/0 | | | | | | | | | | | | | + | |
| | | 100 | U | 0/3 | | | | | | | | | | | | | | |
| Meclofenamic acid | M01AG04 | | | | | + | | | | | | | | | | | | |
| Meclozine | R06AE05 | 25 | 4 | 1/0 | II.2 | II | | I | II | II | II | | + | + | + | + | + | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN | |
|--|----------|-----------|-----------|--|------|------|-------|------|--------|--------|-----|-------|--------|----|-----|----|-----|--|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| Medazepam | N05BA03 | 5 | 2.3 | 3/3 | | | | | II | II | | + | | + | | | | |
| | | 10 | 3 | 2/4 | | | | | | | | | | | | | | |
| | | 15 | 4 | 1/4 | | | | | | | | | | | | | | |
| Medroxyprogesterone | L02AB02 | | | | | | 0 | I | | | | | | | | | | |
| Mefenamic acid | M01AG01 | | | | | + | I | I | I | I | | | | | | | | |
| Meglumine-polysorbate 20 benzoate - promethazine | R06AD52 | | | | | | | II | | | | | | | | | | |
| Melitracen | N06AA14 | | | | II* | | | | | II | | | | | | | | |
| Meloxicam | M01AC06 | | | | | + | | I | | | | | | | | | | |
| Melperone | N05AD03 | | | | II* | | | | | II | II | | | | w | | | |
| Memantine | N06DX01 | | | | | | | | II | II | | | | | | | | |
| Mephenesin | M03BX06 | | | | | | | I | | | | | | | | | | |
| Mephenoqualone | N05BX01 | | | | | | | | | | | | | + | | | | |
| Mepivacaine (carbocaine) | N01BB03 | | | | | | 0 | I | II | II | | | | | | | | |
| Mepivacaine, combinations | N01BB53 | | | | | | | | II | II | | | | | | | | |
| Meprobamate | N05BC01 | 400 | 3 | 4/2 | III | III | | II | II,III | III | | + | | + | + | | + | |
| | | 800 | 3.5 | 2/3 | | | | | | | | | | | | | | |
| | C01EB | | | | | | | I | | | | | | | | | | |
| Meprobamate, combinations | N05BC51 | | | | | | | | III | III | | | | | | | | |
| Meptazinol | N02AX | 100-200 | 1.5 | 4/0 | | | | | | | | | | | | | | |
| | | 400 | 1 | 1/0 | | | | | | | | | | | | | | |
| Mequitazine | R06AD07 | 5 | 1.4 | 5/0 | II.1 | II | | I | II | II | II* | | | | | | | |
| | | 10 | 3 | 3/1 | | | | | | | | | | | | | | |
| Mesalazine | A07EC02 | | | | | | 0 | | | | | | | | | | + | |
| Mesuximide | N03AD03 | | U | 0/1 | | | | | | | | | | | | | | |
| Metaclazepam | N05BA | 7.5 | 3 | 0/1 | | | | | | | | | | | | | | |
| Metamfetamine | N06BA03 | | | | | | | | | | | + | | | | | | |
| Metamizole sodium (noramydopyrine) | N02BB02 | | | | | | 0 | 0 | | | | | | | | | | |
| Metformin | A10BA02 | | | | + | + | 0 | I | | II | + | | | | | | | |
| Metformin - rosiglitazone | A10BD03 | | | | | | | | | II | | | | | | | | |
| Metformin - sulfonamides | A10BD02 | | | | | | | | II | II | | | | | | | | |
| Methadone | N07BC02 | 2.5-10 | 3 | 2/1 | II.2 | III | | III | II | II | II | | | + | | + | + | |
| Methaqualone | N05CM01 | | | | | + | | | | | | + | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|----------------------------|----------|-----------|------------|--|-----|------|-------|----------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Methocarbamol | M03BA03 | | | | | + | | I | | | | | | | + | | + |
| Methotrexate | L01BA01 | | | | | | | II | | | | | | | | | |
| Methyldigoxin | C01AA08 | | | | | | | | | | II* | | | | | | |
| Methyldopa (levorotatory) | C02AB01 | 250 | 3 | 1/0 | | | | | | | | | + | + | | | |
| Methyldopa (racemic) | C02AB02 | 250 | 3.5 | 2/1 | | + | III | I | | | II* | | + | + | | | |
| Methylphenidate | N06BA04 | 10 | 3 | 0/3 | I | I | I | II | II | I | | + | | + | + | + | |
| Methylphenobarbital | N03AA01 | 30 | U | 0/2 | | II | | | | II | | + | | + | | | |
| | | 100 | U | 0/2 | | | | | | | | | | | | | |
| | | 200 | 4 | 1/0 | | | | | | | | | | | | | |
| Methyprylon | N05CE02 | | | | | | | | | | | + | | | | | |
| Methysergide | N02CA04 | | | | | | | I | | | | | | | | | |
| Metipranolol | S01ED04 | | | | I* | | | | I | I | II* | | | | | | |
| Metipranolol, combinations | S01ED54 | | | | | | | | | | II | | | | | | |
| Metixene | N04AA03 | | | | | + | | | | | | | | | | | |
| Metoclopramide | A03FA01 | 5-10 | U | 0/1 | | + | I | I | | II | | | + | + | | | |
| Metolazone | C03BA08 | | | | | | | | | | II* | | | | | | |
| Metopimazine | A04AD05 | | | | | + | | I | II | II | | | | | | | |
| Metopina | R06AX | | | | | | | | | | III | | | | | | |
| Metoprolol | C07AB02 | 50-100 | 1.6 | 3/0 | II* | II | | I | | II | II | | | | | | |
| Metoprolol - chlortalidone | C07BB02 | | | | | | | I | | | | | | | | | |
| Metoprolol - felodipin | C07FB02 | | | | | | | I | | | | | | | | | |
| Mexazolam | N05BA | | | | | | | | | | II | | | | | | |
| Mexiletine | C01BB02 | | | | | | | I | | | | | | | | | |
| Mianserin | N06AX03 | 10 | 3 | 5/2 | III | III | III | II | II | III | III | | | + | | | |
| | | 20 | 3.4 | 7/0 | | | | | | | | | | | | | |
| Midazolam | N05CD08 | 7.5 | 4 | 2/2 | III | III | | I,II,III | III | III | | + | | + | + | + | + |
| | | 15 | 4 | 1/3 | | | | | | | | | | | | | |
| Miglitol | A10BF02 | | | | | | | I | I | | | | | | | | |
| Milnacipran | N06AX17 | | | | | | | I | II | II | III | | | | | | |
| Minaprine | N06AX07 | 50 | 1 | 2/0 | | | | | | | | | | | | | |
| | | 100 | 1 | 1/0 | | | | | | | | | | | | | |
| Minocycline | J01AA08 | | | | | + | | | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---------------------------|----------|-----------|------------|--|-----|------|-------|--------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Minoxidil | C02DC01 | | | | | + | 0 | | | | II* | | | | | | |
| Mirtazapine | N06AX11 | | | | | III | | I | II | III | | | + | | | | |
| Mitotane | L01XX23 | | | | | | | | | | | | + | | | | |
| Mitoxantrone | L01DB07 | | | | | | | II | | | | | | | | | |
| Mivacurium chloride | M03AC10 | | | | | | | II,III | | | | | | | | | |
| Mizolastine | R06AX25 | | | | | II | | I | II | II | II* | | + | | | | |
| Moclobemide | N06AG02 | 100 | 1 | | II* | I | | I | II | II | II | | | | | | |
| | | 200 | 1 | | | | | | | | | | | | | | |
| Modafinil | NO6BA07 | | | | | + | | III | | | II* | | | | | | |
| Moexipril | C09AA13 | | | | | | | I | | | | | | | | | |
| Molsidomine | C01DX12 | | | | | + | | | | | | | | | | | |
| Montelukast | R03DC03 | | | | | | | | | | II* | | | | | | |
| Morniflumate | M01AX22 | | | | | + | | | | | | | | | | | |
| Morphine | N02AA01 | 10 | U | 0/1 | III | III | | | II | III | III | | | + | + | + | + |
| Morphine | N02AA01 | 20 | 4 | 1/1 | | | | | | | | | | | | | |
| Morphine (chlorhydrate) | N02AA | | | | | | | I | II | | | | | | | | |
| Morphine (sulphate) | N02AA | | | | | | | | II | | | | | | | | |
| Moxisylyte | C04AX10 | | | | | + | | | | | | | | | | | |
| | G04BE06 | | | | | | | I | | | | | | | | | |
| Moxonidine | C02AC05 | | | | | | | I | | | | | | | | | |
| Nabumetone | M01AX01 | | | | | | | 0 | I | | | | | | | | |
| Nadolol | C07AA12 | 40-80 | 1 | 1/1 | II* | II | | I | | II | II | | | | | | |
| Nadolol | C07AA12 | 80-320 | 1 | 1/1 | | | | | | | | | | | | | |
| Naftidrofuryl | C04AX21 | | | | | + | | | | | I | | | | | | |
| Nalbuphine | N02AF02 | | 3 | 1/0 | | | | | III | II | II | | + | | + | | |
| Nalidixic acid | J01MB02 | | | | | + | | I | | | | | | | | | |
| Naltrexone | N07BB04 | | | | | | | III | II | II | | | | | | | |
| Naphazoline, combinations | S01GA51 | | | | | | | | II | II | | | | | | | |
| Naproxen | M01AE02 | | | | | + | I | I | I | I | | | | | | | |
| Naratriptan | N02CC02 | | | | | + | | I | II | II | II | | | | | | + |
| Nateglinide | A10BX03 | | | | | | | I | | II | II | | | | | | |
| N-desmethyl-adinazolam | N05BA | | | | | | | | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---------------------------|----------|-----------|------------|--|------|------|-------|----------|--------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Nebivolol | C07AB12 | | | | | II | | | | II | | | | | | | |
| Nefazodone | N06AX06 | | | | | II | | | | II | | | + | | | | |
| Nefopam | N02BG06 | | | | | | | I | | | | | | | | | |
| Nialamide | N06AF02 | | | | II* | | | | | II | | | | | | | |
| Niaprazine | N05CM16 | | | | | | | | III | III | | | | | | | |
| Nicardipine | C08CA04 | | | | | + | | 0 | | | II* | | | | | | |
| Nicergoline | C04AE02 | | | | | + | | | | | II* | | | | | | |
| Nicomorphine | N02AA04 | | | | | | | | | | | + | | + | | + | |
| Nicorandil | C01DX16 | | | | | | | | | | II* | | | | | | |
| Nicotinamide | N07BA | | | | | | | 0 | | | | | | | | | |
| Nicotine | N07BA01 | | | | | | | 0 | I | | I | | | | | | |
| Nifedipine | C08CA05 | | 3 | 1/0 | | + | I | I | | | II* | | | | | | |
| Niflumic Acid | M01AX02 | | | | | + | | I | | | | | | | | | |
| Nilutamide | L02BB02 | | | | | | | I | | | | | | | | | |
| Nilvadipine | C08CA10 | | | | | | | | | | II* | | | | | | |
| Nimesulide | M01AX17 | | | | | | | I | | | | | | | | | |
| Nimetazepam | N05BA | | | | | | | | | | | + | | | | | |
| Nimodipine | C08CA06 | | | | | + | | | | | II* | | | | | | |
| Niridazole | P02BX02 | | | | | | | | | | | | + | | | | |
| Nisoldipine | C08CA07 | | | | | + | | | | | | | | | | | |
| Nitrazepam | N05CD02 | 2.5 | 3.6 | 3/4 | II.2 | III | | I,II,III | III | III | | + | + | + | + | + | + |
| | | 5 | 3.6 | 5/3 | | | | | | | | | | | | | |
| | | 10 | 4 | 5/2 | | | | | | | | | | | | | |
| Nitrendipine | C08CA08 | | | | | + | | I | | II* | | | | | | | |
| Nitrofurantoin | J01XE01 | | | | | | | 0 | I | | | | | | | | |
| Nitrous oxide | N01AX13 | | | | | | | | II | II | | | | | | | |
| Nitroxoline | J01XX07 | | | | | | | 0 | | | | | | | | | |
| Nizatidine | A02BA04 | 150-300 | 1.6 | 2/1 | II.1 | I | | 0 | | II | II* | | | | | | |
| Nizatidine | A02BA04 | 600 | 1 | 1/0 | | | | | | | | | | | | | |
| Noramipopyrine - caffeine | N02BB52 | | | | | | | I | | | | | | | | | |
| Nordazepam | N05BA16 | 5 | 3 | 1/2 | II* | | | I,II,III | II,III | II | II | + | | + | | | |
| | | 10 | 3 | 1/2 | | | | | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|------------------------------------|----------|-----------|-----------|--|------|------|-------|----------|--------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Norfloracin | J01MA06 | | | | | + | 0 | I | | | | | | | | | |
| Nortriptyline | N06AA10 | 10 | 2.3 | 4/3 | II.2 | II | II | | | II | II | | | + | w | | |
| | | 50 | 2 | 3/3 | | | | | | | | | | | | | |
| | | 75 | 3.5 | 2/2 | | | | | | | | | | | | | |
| Noscapine | R05DA07 | 15-30 | 1 | 1/0 | | | | | I | I | | | | | | | |
| Noscapine - promethazine | R05DA | | | | | | | II | | | | | | | | | |
| Octamylamine | R03BB | | | | | | | | | | | | + | | | | |
| Ofloxacin | J01MA01 | | | | | + | 0 | I | | | | | | | | | |
| Olanzapine | N05AH03 | | | | | II | II | III | II,III | II | II | | + | | | | |
| Olopatadine | S01GX09 | | | | | | | | I | I | | | | | | | |
| Omega-3-triglycerides | C10AX06 | | | | | | | 0 | | | | | | | | | |
| Omeprazole | A02BC01 | | | | | | 0 | I | | | | | | | | | |
| Ondansetron | A04AA01 | | | | I | + | | I | | I | I | | | | | | |
| Opipramol | N06AA05 | 50 | 3 | 1/0 | II* | | | | II | II | | | | + | | | |
| Opium | A07DA02 | | | | | | | I | | | | + | | | | + | |
| | N02AA02 | | | | | | | I | | | | + | | | | + | |
| Opium alkaloids + antihistamine | R05DA20 | | | | | | | | II | | | | | | | | |
| Opium derivatives and expectorants | R05FA02 | | | | | | | | I | II | | | | | | | |
| Orphenadrine | M03BC01 | | | | | | | | | | | | + | | w | | + |
| Oxaliplatin | L01XA03 | | | | | | | II | | | | | | | | | |
| Oxamniquine | P02BA02 | | | | | | | | | | | | + | | | | |
| Oxaprotilin | N06AA | 25 | 1.3 | 3/0 | | | | | | | | | | | | | |
| Oxatomide | R06AE06 | 30 | U | 0/1 | | II | | I | II | II | II | | + | + | | | |
| Oxazepam | N05BA04 | 10 | 3 | 11/1 | II.2 | III | | I,II,III | II | III | II | + | | + | + | + | + |
| | | 20 | 3 | 11/1 | | | | | | | | | | | | | |
| | | 30 | 4 | 4/5 | | | | | | | | | | | | | |
| | | 50 | 4 | 6/3 | | | | III | | | | | | | | | |
| Oxazolam | N05BA | | | | | | | | | | | + | | | | | |
| Oxcarbazepine | N03AF02 | | | | | II | | | II | II | | | | | | + | + |
| Oxedrine | S01GA06 | | | | | | | | II | II | | | | | | | |
| Oxedrine, combinations | S01GA56 | | | | | | | | II | II | | | | | | | |
| Oxeladine - promethazine | R06AD52 | | | | | | | II | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN | |
|--|----------|-----------|-----------|--|------|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|---|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| Oxetacaine | C05AD06 | | | | | | | | | | | | | | | | | + |
| Oxetorone | N02CX06 | | | | | | | I | II | II | | | | | | | | |
| Oxitriptan | N06AX01 | | | | | | | | | | III | | | | | | | |
| Oxolinic acid | J01MB05 | | | | | + | | | | | | | | | | | | |
| Oxomemazine | R06AD08 | | | | | | | II | | | | | | | + | | | |
| Oxomemazine - guaiafenesine | R05FB02 | | | | | | | II | | | | | | | | | | |
| Oxovinca | C04AX | | | | | + | | | | | | | | | | | | |
| Oxprenolol | C07AA02 | | | | II* | II | | I | | II | | | | | | | | |
| Oxprenolol - chlortalidone | C07BA02 | | | | | | | I | | | | | | | | | | |
| Oxybutynin | G04BD04 | | | | | + | II | I | | | | | + | + | | | | |
| Oxycodone | N02AA05 | | | | | | | II | II | II | | + | | + | + | + | + | + |
| Oxyfedrine | C01DX03 | | | | | | | | | | I* | | | | | | | |
| Oxymorphone | N02AA | | | | | | | | | | | + | | | | | | |
| Oxyphenbutazone (oxipizona) | M01AA03 | | | | | + | | | | | | | | | | | | |
| Oxytetracycline | J01AA06 | | | | | + | | | | | | | | | | | | |
| | S01AA04 | | | | | | | | I | I | | | | | | | | |
| Paclitaxel | L01CD01 | | | | | | | II | | | | | | | | | | |
| Pamidronic acid | M05BA03 | | | | | | | I | | | | | | | | | | |
| Pantoprazole | A02BC02 | | | | | | | I | | | | | | | | | | |
| Papaverine | G04BE02 | | | | | | | I | | | | | | | | | | |
| Paracetamol | N02BE01 | | | | | | 0 | 0 | | | | | | | | | | |
| Paracetamol, combinations excl psycholeptics | N02BE51 | | | | | | | | I | I,II | | | | | | | | |
| Parecoxib | M01AH04 | | | | | | | | I | I | | | | | | | | |
| Paroxetine | N06AB05 | 20 | 1 | | II.1 | I | I | I | II | I | II* | | | | + | | | |
| | | 30 | 1.4 | 5/0 | | | | | | | | | | | | | | |
| Passiflore aubepine | C01EB | | | | | | | I | | | | | | | | | | |
| Pefloxacin | J01MA03 | | | | | | | I | | | | | | | | | | |
| Pemoline | N06BA05 | 37.5 | 2 | 2/1 | I* | I | | | | I | | | | | | | | |
| Penbutolol | C07AA23 | | | | | | | | | | | | | | | | | |
| Penfluridol | N05AG03 | 10-20 | 3 | 0/1 | II* | III | | III | II | II | | | | | | | | + |
| Pentaerithryl tetranitrate | C01DA05 | | | | | + | | | | | | | | | | | | |
| Pentazocine | N02AD01 | 50-100 | 3 | 3/0 | III | + | | III | II | III | | + | | + | + | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN | |
|---|----------|-----------|------------|--|------|------|-------|------|-------|--------|-----|-------|--------|----|-----|----|-----|--|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| Pentobarbital | N05CA01 | 100 | 4 | 1/2 | | | | | | | | + | | + | + | | | |
| | | 200 | U | 0/2 | | | | | | | | | | | | | | |
| Pentostatin | L01XX08 | | | | | + | | II | | | | | | | | | | |
| Pentoxifylline | C04AD03 | | | | | + | | | | | I | | | | | | | |
| Pentoxyverine | R05DB05 | | | | | | | I | I | I | | | | | | | | |
| Perazine | N05AB10 | | | | | | | | | | | | | | + | | | |
| Pergolide | N04BC02 | | | | | + | | | II | II | II | | + | | | | | |
| Periciazine | N05AC01 | | | | III* | III | | | II | III | | | | | | | | |
| Perindopril | C09AA04 | | | | | + | | I | | | II* | | | | | | | |
| Perindopril and diuretics | C09BA04 | | | | | | | I | | | | | | | | | | |
| Perphenazine | N05AB03 | 4-8 | U | 0/2 | II* | II | | | III | II | | | | + | w | | | |
| Perphenazine enantate | N05AB03 | | | | | | | III | | | | | | | | | | |
| Pethidine | N02AB02 | 50-150 | U | 0/2 | III* | III | III | II | II | III | | + | | + | + | + | + | |
| Phendimetrazine | A03AA | | | | I* | | | | | I | | + | | | | | | |
| Phenelzine | N06AF03 | | | | II* | + | | | | II | | | | + | | | | |
| Pheneturide | N03AX13 | | | | II* | | | | | II | | | | | | | | |
| Phenformin | A10BA01 | | | | | + | | | | II | | | | | | | | |
| Phenformin - sulfonamides | A10BD01 | | | | | | | | | II | | | | | | | | |
| Phenindamine | R06AX04 | 25 | U | 0/1 | | | | | | | | | | | | | | |
| | | 50 | U | 0/1 | | | | | | | | | | | | | | |
| Pheniramine | R06AB05 | 40 | U | 0/2 | | | | | | II | | | | | | | | |
| Pheniramine - paracetamol - ascorbic acid | R06AB | | | | | | | I | | | | | | | | | | |
| Pheniramine, combinations | R06AB | | | | | | | | II | | | | | | | | | |
| Phenmetrazine | A03AA | | | | | | | | | | | + | | | | | | |
| Phenobarbital | N03AA02 | 15 | 3.7 | 3/0 | III | III | | III | II | III | III | + | + | + | + | + | + | |
| | | 30 | 3.7 | 3/1 | | | | | | | | | | | | | | |
| | | 100-150 | 4 | 3/0 | | | | | | | | | | | | | | |
| | C01EB | | | | | | | I | | | | | | | | | | |
| Phenobarbital - calcium gluconate and bromate | C01EB | | | | | | | I | | | | | | | | | | |
| Phenobarbital, combinations | N03AA | | | | | | | | II | | | | | | | | | |
| Phentermine | A08AA01 | | | | I* | | | | | I | | + | | | | | | |
| Phenylbutazon | M01AA01 | 200 | 2.5 | 2/0 | | + | | I | | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--|----------|-----------|-----------|--|------|------|-------|--------|--------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Phenylephrine | S01FB01 | | | | | | | | III | III | II* | | | | | | |
| | S01GA05 | | | | | | | | II | II | II* | | | | | | |
| Phenylephrine, combinations | S01GA55 | | | | | | | | II | II | | | | | | | |
| Phenylpropanolamine | R01BA01 | 25-50 | U | 0/2 | I* | I | | | | I | | | | | + | | + |
| Phenytoin | N03AB02 | 200 | 2 | 2/0 | III | III | III | I, III | II | III | III | | | | + | + | + |
| Phloroglucinol | A03AX12 | | | | | | | 0 | | | | | | | | | |
| Pholcodine | R05DA08 | | | | | II | | I | I | II | | + | | | | | + |
| Pholcodine – biccotymol - cineole | R05FA | | | | | | | I | | | | | | | | | |
| Pholcodine – brompheramine | R05DA20 | | | | | | | II | | | | | | | | | |
| Pholcodine - chlorpheniramine | R05DA20 | | | | | | | II | | | | | | | | | |
| Pholcodine – chlorpheniramine - biccotymol | R05DA20 | | | | | | | II | | | | | | | | | |
| Pholcodine - clocizine | R05DA20 | | | | | | | II | | | | | | | | | |
| Pholcodine - erysimum | R05FA | | | | | | | I | | | | | | | | | |
| Pholcodine - gaiacol | R05FA | | | | | | | II | | | | | | | | | |
| Pholcodine - isomyrtol | R05FA | | | | | | | I | | | | | | | | | |
| Pholcodine – sodium benzoate | R05FA | | | | | | | I | | | | | | | | | |
| Pholcodine – sodium tenoate | R05FA | | | | | | | I | | | | | | | | | |
| Physostigmine | S01EB05 | | 3 | 0/1 | | | | | | | | | | | | | |
| Pilocarpine | S01EB01 | | | | | | II | | II | II | II* | | | | | | |
| Pilocarpine, combinations | S01EB51 | | | | | | | | II | II | II | | | | | | |
| Pimethixene | R06AX23 | | | | | | | | II | II | | | | | | | |
| Pimozide | N05AG02 | 1-2 | 3 | 0/2 | II* | II | | III | II | II | II | | + | + | | | |
| Pinazepam | N05BA14 | | | | | III | | | | III | | + | | | | | |
| Pindolol | C07AA03 | | | | II.2 | | | I | | II | | | | | w | | |
| Pindolol - clopamide | C07CA03 | | | | | | | I | | | | | | | | | |
| Pipamperone | N05AD05 | | | | II* | | | II,III | II | II | | | + | + | | | |
| Pipemidic acid | J01MB04 | | | | | + | I | I | | | | | | | | | |
| Pipequaline | N06BX | | 3 | 1/0 | | | | | | | | | | | | | |
| Pipotiazine | N05AC04 | | | | III* | III | | III | II,III | III | | | | + | | | |
| Pipotiazine palmitate | N05AC | | | | | | | III | | | | | | | | | |
| Pipradrol | N06BX15 | | | | | | | | | | | + | | | | | |
| Piracetam | N06BX03 | 800 | 1 | 1/0 | | | | | II | II | II | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---------------------------|----------|-----------|------------|--|------|------|-------|----------|--------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Pirenzepine | A02BX03 | | | | | + | | | | | | | | | | | |
| Piretanide | C03CA03 | | | | | + | | | | | | | | | | | |
| Piribedil | N04BC08 | | | | | | | I | | | II | | | | | | |
| Piritramide | N02AC03 | | | | III* | | | | | III | | + | | | | | |
| Pirlindole | N06AF | | | | | + | | | | | II | | | | | | |
| Piroxicam | M01AC01 | | | | | + | | I | | | | | | | | | |
| Piroxicam-β cyclodextrine | M01AC | | | | | | | I | | | | | | | | | |
| Pivmecillinam | J01CA07 | | | | | | | 0 | | | | | | | | | |
| Pizotifen | N02CX01 | | | | | + | | I | II | II | | | | | + | | |
| Polyvinylalcohol | S01XA | | | | | + | I | | | | | | | | | | |
| Potassium clorazepate | N05BA05 | 5 | 3 | 6/1 | II* | II | II | I,II,III | II,III | II | II | + | + | + | + | | + |
| | | 15 | 3 | 1/0 | | | | | | | | | | | | | |
| Pramipexole | N04BC05 | | | | | | | | II | II | | | | | | | + |
| Pravastatin | C10AA03 | | | | | | | 0 | | | | | | | | | |
| Prazepam | N05BA11 | 10 | 3 | 1/2 | II* | + | | I,II | II | II | II | + | + | + | | | |
| | | 40 | | | | | | III | III | | | | | | | | |
| Prazosin | C02CA01 | | | | | + | | I | | | | | | | | | |
| Prednisolone | H02AB06 | | | | | | | 0 | I | | | | | | | | |
| | S01BA04 | | | | | | | | I | | | | | | | | |
| Prednisone | H02AB07 | | | | | | | 0 | I | | | | | | | | |
| | S01BA | | | | | | | | I | | | | | | | | |
| Pregabalin | N03AX16 | | | | | | | | | | | | | | | | + |
| Primidone | N03AA03 | 125 | U | 0/1 | III* | III | III | III | II | III | III | | + | | + | + | + |
| Procaine | N01BA02 | | | | | | | I | II | II | | | | | | | |
| Procarbazine | L01XB01 | | | | | | | II | | | | | | | | | |
| Prochlorperazine | N05AB04 | 5 | 3 | 2/1 | | | | | | | | | | | + | | |
| | | 10 | 3.5 | 2/1 | | | | | | | | | | | | | |
| Procyclidine | N04AA04 | 2.5 | U | 0/1 | | + | | | | | | | | | | | |
| Progabide | N03AG05 | | | | | | | | II | II | | | | | | | |
| Progesterone | G03DA04 | | | | | | | I | | | | | | | | | |
| Proglumetacin | M01AB14 | | | | | + | | | | | | | | | | | |
| Prolintane | N06BX14 | | | | I | I | | | | I | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--------------------------------|----------------|-----------|------------|--|------|------|-------|--------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Promazine | N05AA03 | 25-50 | 4 | 1/1 | III* | | | | | III | | | + | + | | | + |
| Promethazine | R06AD02 | 25 | 4 | 7/1 | III | III | | II | II | III | III | | + | + | + | + | + |
| | | 50 | 4 | 6/0 | | | | | | | | | | | | | |
| Promethazine, combinations | R06AD52 | | | | | | | | II | III | | | | | | | |
| Propacetamol | N02BE05 | | | | | | | I | | | | | | | | | |
| Propafenone | C01BC03 | | | | | + | | I | | | | | | | | | |
| Propofol | N01AX10 | | | | | | | II,III | III | III | | | | | | | |
| Propranolol | C07AA05 | 40 | 1.4 | 7/0 | II.2 | II | II | I | | II | II | | | | | | |
| | | 80 | 2.2 | 3/1 | | | | | | | | | | | | | |
| Prothipendyl | N05AX07 | | | | III* | | | | | III | | | | | | | |
| Pseudoephedrine | R01BA02 | 60 | 2 | 1/2 | | | | | | | | | | | | | |
| Pseudoephedrine - loratadine | <i>R01BA52</i> | | | | | | | | | | I | | | | | | |
| Pseudoephedrine - triprolidine | <i>R01BA52</i> | | | | | | | | | | II* | | | | | | |
| Pyridostigmine | N07AA02 | 30 | 1 | 1/0 | | | | | | | | | | | | | |
| Quazepam | N05CD10 | 15 | U | 0/3 | | III | | | | III | II | | + | | | | |
| Quetiapine | N05AH04 | | | | | II | | | | II | II | | | | | | |
| Quinapril | C09AA06 | | | | | + | | I | | | II* | | | | | | |
| Quinapril and diuretics | C09BA06 | | | | | | | I | | | | | | | | | |
| Quinidine | C01BA01 | | | | | | | I | | | | | | | | | |
| Quinine | P01BC01 | | | | | | | I | | | | | | | | | |
| Quinine – ascorbic acid | <i>P01BC</i> | | | | | | | I | | | | | | | | | |
| Quinine aubepine | <i>P01BC</i> | | | | | | | I | | | | | | | | | |
| Quinine thiamine | <i>P01BC</i> | | | | | | | I | | | | | | | | | |
| Raltitrexed | L01BA04 | | | | | | | I | | | | | | | | | |
| Ramipril | C09AA05 | | | | | + | | | | | II* | | | | | | |
| Ranitidine | A02BA02 | 150 | 1.6 | 2/1 | I | I | I | 0 | | I | I | | | | | | |
| | | 300 | 1.6 | 2/1 | | | | | | | | | | | | | |
| Reboxetine | N06AX18 | | | | | I | | | | I | II | | | | | | |
| Remifentanyl | N01AH06 | | | | | | | II,III | III | III | | | | | | | + |
| Remoxipride | N05AL04 | 100 | 3 | 1/0 | | | | | | | | | | | | | |
| Repaglinide | A10BX02 | | | | | | | I | I | II | II | | | | | | |
| Reserpine | C02AA02 | 0.1 | 3.6 | 3/0 | | | | | | | | | | + | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--------------------|----------|-----------|------------|--|------|------|-------|--------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| | | 0.25 | 3.5 | 2/0 | | | | | | | | | | | | | |
| Rifampicin | J04AB02 | | | | | | I | | | | | | | | | | |
| Rifamycin | S01AA16 | | | | | | | | I | I | | | | | | | |
| Rilmenidine | C02AC06 | | | | | | | I | | | | | | | | | |
| Riluzole | N07XX02 | | | | | | | | I | I | | | | | | | + |
| Rimexolone | S01BA13 | | | | | | | | I | I | | | | | | | |
| Risperidone | N05AX08 | | | | II* | II | II | III | II | II | II | | + | + | w | | |
| Ritanserlin | N06AX | 5 | 1 | 1/0 | | | | | | | | | | | | | |
| Ritonavir | J05AE03 | | | | | | | | | | | | + | | | | |
| Rituximab | L01XC02 | | | | | | | II | | | | | | | | | |
| Rivastigmine | N06DA03 | | | | | | | | II | II | III | | | | | | |
| Rizatriptan | N02CC04 | | | | | | I | | II | II | II | | | | | | + |
| Rocuronium bromide | M03AC09 | | | | | | | II,III | | | | | | | | | |
| Ropinirole | N04BC04 | | | | | | | III | II | II | II | | | | | + | + |
| Ropivacaine | N01BB09 | | | | | | | I | II | II | | | | | | | |
| Rotigotin | N04BC09 | | | | | | | | | | | | | | | | + |
| Roxatidine | A02BA06 | | | | | | I | | | I | | | | | | | |
| Scopolamine | A04AD01 | 0.4-0.8 | 4 | 1/2 | | + | | II | II | II | | | | + | + | + | + |
| Secobarbital | N05CA06 | 50 | 4 | 5/1 | III | | | | | III | | + | | + | | | |
| | | 100 | 4 | 2/3 | | | | | | | | | | | | | |
| | | 200 | 4 | 3/1 | | | | | | | | | | | | | |
| Selegiline | N04BD01 | | | | | + | | II | I | I | II | | | | | | |
| Sertindole | N05AE03 | | | | | | | | II | II | | | | | | | |
| Sertraline | N06AB06 | 100 | 2 | 1/0 | II.1 | I | I | I | II | II | II* | | | + | w | | |
| Sevoflurane | N01AB08 | | | | | | | II,III | III | III | | | | | | | |
| Sibutramine | A08AA10 | | | | | | | | | | II | | | | | | |
| Sildenafil | G04BE03 | | | | | | I | I | | | | | | | | | |
| Simvastatin | C10AA01 | | | | | | 0 | 0 | | | | | | | | | |
| Sotalol | C07AA07 | | | | I* | + | | 0 | | I | I* | | | | | | |
| Spirolactone | C03DA01 | | | | | + | I | | | | II | | | | | | |
| Sufentanil | N01AH03 | | | | | | | II,III | III | III | | + | | + | + | | + |
| Sulbutiamine | A11DA02 | | | | | | | | | | II* | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN | |
|--------------------------------|----------|-----------|-----------|--|------|------|-------|----------|--------|--------|-----|-------|--------|----|-----|----|-----|--|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | | |
| Sulfadiazine - trimethoprim | J01EE02 | | | | | | | 0 | | | | | | | | | | |
| Sulfamethizole | J01EB02 | | | | | | | 0 | | | | | | | | | | |
| Sulfamethoxazol - trimethoprim | J01EE51 | | | | | | 0 | 0 | | | | | | | | | | |
| Sulindac | M01AB02 | | | | | + | | II | | | | | | | | | | |
| Sulpiride | N05AL01 | 50 | 2.5 | 2/2 | II.2 | II | | II,III | II,III | II | II | | + | + | | | | |
| | | 100 | 2.3 | 3/1 | | | | | | | | | | | | | | |
| Sultopride | N05AL02 | | | | II.2 | | | III | II,III | II | | | | | | | | |
| Sumatriptan | N02CC01 | | | | | + | I | I | II | II | II | | + | | + | | + | |
| Suxamethonium | M03AB01 | | | | | | | II,III | | | | | | | | | | |
| Tacrine | N06DA01 | | | | | + | | | | | | | | | | | | |
| Tacrolimus | L04AA05 | | | | | | 0 | | | | | | | | | + | | |
| Tamsulosin | G04CA02 | | | | | | I | I | | | | | | | | | | |
| Telmisartan | C09CA07 | | | | | | | I | | | II* | | | | | | | |
| Temazepam | N05CD07 | 5 | 2.7 | 6/2 | II.1 | III | | I,II,III | III | III | II* | + | + | + | + | | + | |
| | | 10 | 3.4 | 2/5 | | | | | | | | | | | | | | |
| | | 20 | 4 | 2/5 | | | | | | | | | | | | | | |
| | | 30 | 4 | 1/6 | | | | | | | | | | | | | | |
| Temelastine | R06AX | 100 | 1 | 1/0 | | | | | | | | | | | | | | |
| Temozolomide | L01AX03 | | | | | | | I | | | | | | | | | | |
| Tenoxicam | M01AC02 | | | | | | | I | | | | | | | | | | |
| Terazosin | G04CA03 | | | | | + | I | I | | | | | | | | | | |
| Terfenadine | R06AX12 | 60 | 1 | 11/0 | I | I | | | | I | | | | | | | | |
| | | 120 | 1.7 | 9/0 | | | | | | | | | | | | | | |
| | | 240 | 2.2 | 6/2 | | | | | | | | | | | | | | |
| Tertatolol | C07AA16 | | | | II* | | | I | | II | II | | | | | | | |
| Tetrabamate | M03BA | | | | | + | | III | | | | | | | | | | |
| Tetracycline | J01AA07 | | | | | + | I | | | | | | | | | | | |
| Tetrazepam | M03BX07 | | | | II* | + | | I,II | | II | | + | | | | | | |
| Tetryzoline | S01GA02 | | | | | | | | II | II | | | | | | | | |
| Thebacon | R05DA10 | | | | II* | | III | | | II | | + | | | | | | |
| Theophylline | R03DA04 | | | | | | | I | | | | | | | | | + | |
| Thiethylperazine | R06AD03 | | | | | + | I | | | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---|----------|-----------|-----------|--|------|------|-------|----------|--------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Thiocolchicoside | M03BX05 | | | | | | | I | | | | | + | | | | |
| Thiomersal, combinations | S01AX | | | | | | | | II | II | | | | | | | |
| Thiopental | N05CA19 | | | | | | | | III | III | | | | | + | | + |
| Thiopropazine | N05AB08 | | | | II* | III | | III | II | III | | | + | | | | |
| Thioridazine | N05AC02 | 25-100 | 3.6 | 3/1 | III | III | III | II | II | III | III | | + | + | w | | |
| Tiabendazole | D01AC06 | | | | | + | | | | | | | + | | | | |
| Tiadenol | C10AX03 | | | | | | | 0 | | | | | | | | | |
| Tiagabine | N03AG06 | | | | | II | | III | II | II | III | | + | | | + | + |
| Tianeptine | N06AX14 | | | | | | | I | II | II | II | | | | | | |
| Tiapride | N05AL03 | 100 | 1 | 1/0 | II.1 | II | | I,II,III | II,III | II | II* | | | + | | | |
| Tiaprofenic acid | M01AE11 | 400 | 1 | 1/0 | | + | | I | | | | | | | | | |
| Tiemonium iodide | A03AB17 | | | | | | | 0 | | | | | | | | | |
| Tilidine | N02AX01 | | | | III* | III | | | | III | | + | | | | | |
| Timolol | C07AA06 | | | | II* | II | II | I | | II | | | | | | | |
| | S01ED01 | | | | II* | | II | | I | II | | | | | | | |
| Timolol - amiloride - hydrochlorothiazide | C07DA06 | | | | | | | I | | | | | | | | | |
| Timolol - latanoprost | S01ED51 | | | | | | | | | | II* | | | | | | |
| Timolol, combinations | S01ED51 | | | | | | | | I | II | | | | | | | |
| Tiotixene | N05AF04 | | | | | | | | | | | | | | + | | |
| Tizanidine | M03BX02 | | | | | + | | | | | | | + | + | + | + | + |
| Tobramycin | S01AA12 | | | | | | 0 | | I | I | | | | | | | |
| Tocopherol (vit E) | A11HA03 | | | | | | | 0 | | | | | | | | | |
| Tofisopam | N05BA23 | 100 | 1 | 1/0 | | | | | II | II | | | | | | | |
| Tolbutamide | A10BB03 | | | | + | + | | | | II | | | | | | | |
| Tolmetin | M01AB03 | | | | | + | | | | | | | | | | | |
| Toloxatone | N06AG03 | | | | | | | I | II | II | | | | | | | |
| Tolterodine | G04BD07 | | | | | | | I | | | | | | | | | |
| Topiramate | N03AX11 | | | | | II | | | II | II | III | | | | | + | + |
| Topotecan | L01XX17 | | | | | | | II | | | | | | | | | |
| Torasemide | C03CA04 | | | | | + | | | | | | | | | | | |
| Tramadol | N02AX02 | | | | II.2 | III | III | I | II | III | II | | | + | + | + | + |
| Tramadol, combinations | N02AX52 | | | | | | | | II | III | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|---------------------------------|----------|-----------|------------|--|------|------|-------|----------|--------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Trandolapril | C09AA10 | | | | | + | | I | | | II* | | | | | | |
| Tranlycypromine | N06AF04 | | | | | II | | | | II | | | | + | | | |
| Travoprost | S01EE04 | | | | | | | | I | I | II* | | | | | | |
| Trazodone | N06AX05 | 50 | 3.5 | 2/0 | III | III | | | | III | III | | | + | | | |
| | | 75 | 3 | 8/0 | | | | | | | | | | | | | |
| Tretinoin | L01XX14 | | | | | | 0 | II | | | | | | | | | |
| Triamcinolone | H02AB08 | | | | | | 0 | I | | | | | | | | | |
| | S01BA05 | | | | | | | I | | | | | | | | | |
| Triamterene | C03DB02 | | | | | + | | | | | | | | | | | |
| Triazolam | N05CD05 | 0.125 | 3 | 4/3 | II.2 | III | | I,II,III | III | III | II | + | + | + | + | + | + |
| | | 0.25 | 3.7 | 6/3 | | | | | | | | | | | | | |
| | | 0.5 | 4 | 6/3 | | | | | | | | | | | | | |
| Trifluoperazine | N05AB06 | 5 | 3 | 1/1 | | III | | III | II,III | III | | + | + | | | | |
| Trifluperidol | N05AD02 | | | | | | | | II | II | | | | | | | |
| Triflupromazine (fluopromazine) | N05AA05 | 5 | 3 | | | | | | | | | | | + | | | |
| Trihexyphenidyl | N04AA01 | | | | | + | III | II | II | II | | | | | | | |
| Trimeprazine | R06AD | | | | | | | | | | | | | + | | | |
| Trimetazidine | C01EB15 | | | | | + | | 0 | | | | | | | | | |
| Trimethoprim | J01EA01 | | | | | | | 0 | 0 | | | | | | | | |
| Trimipramine | N06AA06 | 12.5 | 3 | 1/1 | II* | + | | I | II | III | II* | | | + | | | |
| | | 25 | 3 | 1/1 | | | | | | | | | | | | | |
| Tripelennamine | R06AC04 | | | | | | | | | | | | | + | | | |
| Tripolidine | R06AX07 | 2.5 | 3.8 | 7/0 | III | III | | | II | III | III | | | | | | |
| Tripolidine | R06AX07 | 5 | 3.8 | 7/0 | | | | | | | | | | | | | |
| Tripolidine - dextromethorphan | R05DA20 | | | | | | | II | | | | | | | | | |
| Triptorelin | L02AE04 | | | | | | | I | | | | | | | | | |
| Tritoqualine | R06AX21 | | | | | | | 0 | | | | | | | | | |
| Tropatepine | N04AA12 | | | | | | | II | II | II | | | | | | | |
| Tropicamide | S01FA06 | | | | | + | | | III | III | II* | | | | | | |
| Tropicamide, combinations | S01FA56 | | | | | | | | III | III | | | | | | | |
| Tropisetron | A04AA03 | | | | | + | | I | I | I | | | | | | | |
| Trospium | G04BD09 | | | | | | | I | | | | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|--------------------------|----------|-----------|------------|--|------|------|-------|---------|-------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Tryptophan | N06AX02 | 100 | 1.5 | 2/2 | | | | | | | | | | + | | | |
| Ubidecarenone | C01EB09 | | | | | | | | | | I | | | | | | |
| Urapidil | C02CA06 | | | | | + | | I | | | | | | | | | |
| Valerian | N05CM09 | | | | | + | | | | | I* | | | | | | + |
| Valproic acid | N03AG01 | 5mg/kg BW | 2 | 2/0 | II.1 | II | II | III | II | II | II* | | | | + | + | + |
| Valpromide | N03AG02 | | | | | II | | II, III | II | II | | | | | | | |
| Valsartan | C09CA03 | | | | | | | I | | | II* | | | | | | |
| Valsartan and diuretics | C09DA03 | | | | | | | I | | | | | | | | | |
| Vecuronium | M03AC03 | | | | | | | II,III | | | | | | | | | |
| Venlafaxine | N06AX16 | | | | | II | II | I | II | I | II | | | + | w | | |
| Veralipride | N05AL06 | | | | II* | | | | II | II | II | | | | | | |
| Verapamil | C08DA01 | | | | | + | I | I | | | | | | | | | |
| Verapamil - trandolapril | C08DA51 | | | | | | | I | | | | | | | | | |
| Vigabatrin | N03AG04 | | 1 | 1/0 | II* | II | | III | II | II | II | | | | + | + | + |
| Viloxazine | N06AX09 | 100 | 1 | 2/0 | II.1 | II | | I | II | II | II* | | | | | | |
| Vinblastine | L01CA01 | | | | | | | II | | | | | | | | | |
| Vinburnine | C04AX17 | | | | | + | | | | | | | | | | | |
| Vincamine | C04AX07 | | | | | + | | | | | | | | | | | |
| Vincristine | L01CA02 | | | | | | | II | | | | | | | | | |
| Vindesine | L01CA03 | | | | | | | II | | | | | | | | | |
| Vinorelbine | L01CA04 | | | | | | | II | | | | | | | | | |
| Vinpocetine | N06BX18 | | | | | + | | | | | | | | | | | |
| Xipamide | C03BA10 | | | | | + | | | | | II* | | | | | | |
| Yohimbin | G04BE04 | | | | | | | I | | | | | | | | | |
| Zafirlukast | R03DC01 | | | | | | | | | | II* | | | | | | |
| Zaleplon | N05CF03 | | | | | | | | | | | | | | | + | + |
| Zidovudine | J01AF01 | | | | | | | | | | | | + | | | | |
| Zolmitriptan | N02CC03 | | | | | + | I | I | II | II | II | | + | | | | |
| Zolpidem | N05CF02 | 10 | 3.5 | 1/2 | II.2 | II | II | | III | II | II | + | + | + | + | + | + |
| | | 20 | 3.5 | 1/2 | | | | | | | | | | | | | |
| Zopiclone | N05CF01 | 7.5 | 3.8 | 3/4 | II.2 | II | | | III | III | | | + | + | + | + | + |
| Zotepine | N05AX11 | | | | | | | | | | II* | | | | | | |

| SUBSTANCE NAME | ATC CODE | DOSE (mg) | WOLSCHRIJN | | BEL | SP I | SP II | FR I | FR II | ICADTS | POR | GRE I | GRE II | NL | NOR | DK | FIN |
|-------------------------------|----------|-----------|------------|--|------|------|-------|------|--------|--------|-----|-------|--------|----|-----|----|-----|
| | | | GER | I, II.1, II.2 and III / I*, II* and III* | | | | | | | | | | | | | |
| Zuclopenthixol | N05AF05 | 10 | U | 0/1 | II.2 | II | | III | II,III | II | II | | + | + | w | | |
| Zuclopenthixol acetate | N05AF | | | | | | | III | | | | | | | | | |
| Zuclopenthixol decanoate | N05AF | | | | | | | III | | | | | + | | | | |
| Zuclopenthixol dichlorhydrate | N05AF | | | | | | | III | | | | | | | | | |

Annex III – ATC code choice

| Substance Name | ATC code(s) in overview tables | ATC code(s) not used |
|----------------------------------|--------------------------------|--|
| Aceclofenac | M01AB16 | M02AA25 |
| Alprostadil | G04BE01 | C01EA01 |
| Antazoline | R06AX05 | R01AC04 |
| Apomorphine | N04BC07 | G04BE07 |
| Atropine | A03BA01 N05CM05 S01FA01 | |
| Azelastine | R06AX19 S01GX07 | R01AC03 |
| Betamethasone | S01BA06 | A07EA04 C05AA05 D07AC01 D07CX01 H02AB01 R01AD06 R03BA04 S01CB04 S02BA07 S03BA03 |
| Betamethasone and antiinfectives | S01CA05 | S03CA06 |
| Betaxolol | C07AB05 S01ED02 | |
| Bromocriptine | N04BC01 | G02CB01 |
| Buphenine | C04AA02 | G02CA02 |
| Buprenorphine | N07BC01 N02AE01 | |
| Cabergoline | N04BC06 | G02CB03 |
| Carbachol | S01EB02 | N07AB01 |
| Carteolol | C07AA15 S01ED05 | |
| Chlorphenoxamine | R06AA06 | D04AA34 |
| Chlortetracycline | J01AA03 S01AA02 | |
| Ciprofloxacin | J01MA02 S01AX13 | S02AA15 S03AA07 |
| Clemastine | R06AA04 | D04AA14 |
| Clonidine | C02AC01 N02CX02 S01EA04 | |
| Cromoglicic acid | S01GX01 | A07EB01 D11AX17 R01AC01 R03BC01 |
| Dexamethasone | H02AB02 S01BA01 | A01AC02 C05AA09 |

| Substance Name | ATC code(s) in overview tables | ATC code(s) not used |
|-----------------------------------|--------------------------------|---|
| | | D07AB19 D07XB05 D10AA03 R01AD03 S01CB01 S02BA06 S03BA01 |
| Dexamethasone and antiinfectives | S01CA01 | S02CA06 S03CA01 |
| Diazoxide | C02DA01 | V03AH01 |
| Diclofenac | M01AB05 S01BC03 | D11AX18 M02AA15 |
| Diethylstilbestrol | L02AA01 | G03CB02 G03CC05 |
| Dimetindene | R06AB03 | D04AA13 |
| Diphenhydramine | R06AA02 | D04AA32 |
| Disulfiram | N07BB01 | P03AA04 |
| Droperidol | N05AD08 | N01AX01 |
| Ephedrine | R03CA02 | R01AA03 R01AB05 S01FB02 |
| Ethylmorphine | R05DA01 | S01XA06 |
| Fentanyl | N01AH01 N02AB03 | |
| Fenspiride | R03DX03 | R03BX01 |
| Fentiazac | M01AB10 | M02AA14 |
| Feprazone | M01AX18 | M02AA16 |
| Finasteride | G04CB01 | D11AX10 |
| Flurbiprofen | M01AE09 | M02AA19 S01BC04 |
| Gentamicin | S01AA11 | D06AX07 J01GB03I S02AA14 S03AA06 |
| Guanethidine | C02CC02 | S01EX01 |
| Hexobarbital | N05CA16 | N01AF02 |
| Hydrocortisone and antiinfectives | S01CA03 | S02CA03 S03CA04 |
| Ibuprofen | M01AE01 | C01EB16 G02CC01 M02AA13 |
| Indometacin | M01AB01 S01BC01 | |
| Ipratropium bromide | R03BB01 | R01AX03 |
| Isosorbide dinitrate | C01DA08 | D03AX08 |
| Isothipendyl | R06AD09 | D04AA22 |

| Substance Name | ATC code(s) in overview tables | ATC code(s) not used |
|-----------------------------|---------------------------------------|---|
| Ketoconazole | D01AC08 J02AB02 | G01AF11 J02AB02 |
| Ketoprofen | M01AE03 | M02AA10 |
| Ketorolac | M01AB15 | S01BC05 |
| Ketotifen | R06AX17 S01GX08 | |
| Levocabastine | S01GX02 | R01AC02 |
| Lidocaine | N01BB02 C01BB01 | C05AD01 D04AB01 R02AD02 S01HA07 S02DA01 |
| Lomefloxacin | J01MA07 | S01AX17 |
| Meclofenamic acid | M01AG04 | M02AA18 |
| Medroxyprogesterone | L02AB02 | G03DA02 G03AC06 |
| Meprobamate, combinations | N05BC51 | N05CX01 |
| Methotrexate | L01BA01 | L04AX03 |
| Moxisylyte | C04AX10 G04BE06 | |
| Naproxen | M01AE02 | G02CC02 M02AA12 |
| Nifumic acid | M01AX02 | M02AA17 |
| Norfloxacin | J01MA06 | S01AX12 |
| Ofloxacin | J01MA01 | S01AX11 |
| Olopatadine | S01GX09 | R01AC08 |
| Opium | A07DA02 N02AA02 | |
| Oxedrine | S01GA06 | C01CA08 |
| Oxyphenbutazone (oxipizona) | M01AA03 | M02AA04 S01BC02 |
| Oxytetracycline | J01AA06 S01AA04 | G01AA07 |
| Papaverine | G04BE02 | A03AD01 |
| Phenylbutazon | M01AA01 | M02AA01 |
| Phenylephrine | S01FB01 S01GA05 | C01CA06 R01AA04 R01AB01 R01AB01 |
| Phenylephrine, combinations | S01GA55 | R01BA53 |
| Physostigmine | S01EB05 | V03AB19 |
| Pilocarpine | S01EB01 | N07AX01 |
| Piroxicam | M01AC01 | M02AA07 S01BC06 |

| Substance Name | ATC code(s) in overview tables | ATC code(s) not used |
|-----------------------|---------------------------------------|---|
| Prednisolone | H02AB06 S01BA04 | A07EA01 C05AA04 D07AA03 D07XA02 R01AD02 S02BA03 S03BA02 |
| Procaine | N01BA02 | C05AD05 S01HA05 |
| Promethazine | R06AD02 | D04AA10 |
| Rifamycin | S01AA16 | J04AB03 S02AA12 |
| Rimexolone | S01BA13 | H02AB12 |
| Scopolamine | A04AD01 | S01FA02 N05CM05 |
| Sulfamethizole | J01EB02 | B05CA04 D06AB04 S01AB01 |
| Tacrolimus | L04AA05 | D11AX14 |
| Tetracycline | J01AA07 | A01AB13 D06AA04 S01AA09 S02AA08 S03AA02 |
| Tetryzoline | S01GA02 | R01AA06 R01AB03 |
| Thiopental | N05CA19 | N01AF03 |
| Tiabendazole | D01AC06 | P02CA02 |
| Timolol | C07AA06 S01ED01 | |
| Tobramycin | S01AA12 | J01GB01 |
| Tolbutamide | A10BB03 | V04CA01 |
| Tolmetin | M01AB03 | M02AA21 |
| Tretinoin | L01XX14 | D10AD01 |
| Triamcinolone | H02AB08 S01BA05 | A01AC01 D07AB09 D07XB02 R01AD11 R03BA06 |
| Tripelennamine | R06AC04 | D04AA04 |

Annex IV – Medicines mentioned as ‘ATC not yet determined’ while official ATC code exists

| Substance | Official ATC code | Moved to | Reason |
|-------------------------|-------------------|----------|--|
| Boric acid | S02AA03 | S01XA | Cf. ICADTS |
| Estradiol di-undecylate | G03AC03 | L02AA | Good overlap in L02A, no overlap in G03AC |
| Hydroxyzine | N05BB01 | R06AE | All piperazine derivatives together |
| Hyoscyamine | A03BA03 | S01FA | France II and ICADTS specifically mention hyoscyamine in S01FA (same code as atropine) A03BA03 is still used for Greece II (good overlap) |
| Nicotinamide | A11HA01 | N07BA | France I mentions as ‘used in addictive disorders’ |
| Lisuride | N02CA07 | N04BC | Cf. France II |

Annex V – Multiple ratings for one substance in CERMT list

| Substance | Category | Comment |
|-------------------|----------|---|
| Midazolam | III | Mentioned twice (contradictory) |
| | II | 1) III when < 12 hours, II when 12-24 hours 2) III when 12-24 hours, II when 24-72 hours |
| Loprazolam | III | < 6 hours |
| Lormetazepam | II | 6-12 hours after administration or more than 4 weeks in treatment |
| Temazepam | | |
| Triazolam | I | > 12 hours after administration and less than 4 weeks in treatment |
| Alprazolam | III | Used for prevention of delirium |
| Bromazepam | II | More than 12 weeks in treatment |
| Clobazam | I | Less than 12 weeks in treatment |
| Clotiazepam | | |
| Ethyl loflazepate | | |
| Lorazepam | | |
| Oxazepam | | |
| Nitrazepam | | |
| Nordazepam | | |
| Chlordiazepoxide | | |
| Tetrazepam | I | Less than 12 weeks in treatment |
| Clonazepam | III | In indication of epilepsy |
| | I | When used in low doses for pain relief |
| Diazepam | III | Injectable forms, < 24 hours |
| | III | Oral forms, used for prevention of delirium |
| | II | Oral forms, other indications |
| Flunitrazepam | III | Narcozep, < 48 hours |
| | II | Narcozep, 48-72 hours |
| | II | Rohypnol, all indications |
| Prazepam | III | 40 mg, used for prevention of delirium |
| | II | 10 mg, more than 12 weeks in treatment |
| | I | 10 mg, less than 12 weeks in treatment |
| Chlorpromazine | III | < 48 hours, oral and injectable forms |
| | II | < 48 hours in pre-anaesthetics |
| Levomepromazine | III | Antipsychotic |
| Cyamemazine | II | Anxiolytic in depression |
| Pipamperone | III | Antipsychotic |
| | II | Treatment of aggressive behaviour |
| Droperidol | III | Antipsychotic and anti-emetic |
| | II | All other indications |
| Haloperidol | III | Used as antipsychotic |
| | II | Treatment of anxiety, vomiting, chorea, tics |

| Substance | Category | Comment |
|---|-----------------|---|
| | III | Anti-emetic, < 24 hours |
| | II | Anti-emetic, 24-48 hours |
| Sulpiride | III | Used as antipsychotic |
| | II | Used as anxiolytic |
| Tiapride | III | Treatment of aggressive behaviour and agitation |
| | II | Treatment of chorea, tics |
| | I | Treatment of pain relief |
| Carbamazepine | III | Treatment of epilepsy |
| | II | Treatment of manic depression |
| | I | Treatment of migraine |
| Phenytoin | III | Treatment of epilepsy |
| | III | < 48 hours when used as anti-arrhythmic |
| | I | Treatment of migraine |
| Valpromide | III | Treatment of epilepsy |
| | II | Treatment of manic depression |
| Sumatriptan | I | < 12 hours after migraine crisis |
| Ibutilide | I | < 24 hours |
| Adenosine | II | < 24 hours |
| Diltiazem | II | Used as anti-arrhythmic, < 24 hours |
| | I | For treatment of hypertension |
| Lidocaine | III | Used in cardiac therapy |
| | I | Used as pre-anaesthetic, < 24 hours |
| Atropine | II | < 24 hours |
| Meprobamate | II | Pre-anaesthetic, < 48 hours |
| | I | Used as cardiac sedative |
| Bupivacaine Carbocaine Etidocaine Epinephrine Procaine Ropivacaine | I | < 24 hours |
| Fentanyl | III | Peridural anaesthetics, < 24 hours |
| | II | Peridural anaesthetics, 24-48 hours |
| | III | General anaesthetics, < 24 hours |
| | II | General anaesthetics, 24-72 hours |
| Alfentanil Atracurium Cisatracurium Etomidate Halothane | III | < 24 hours |
| | II | 24-72 hours |

| Substance | Category | Comment |
|--|-----------------|---|
| Hydroxybutyric acid Ketamine Propofol Remifentanil Sevoflurane Sufentanil Vecuronium bromate | | |
| Mivacurium chloride | III | < 48 hours |
| Rocuronium bromide Suxametonium | II | 48-72 hours |
| Erythropoietin alpha Erythropoietin beta | I | < 48 hours |
| Pamidronic acid | I | < 24 hours |
| Propacetamol | I | < 6 hours |
| Potassium Clorazepate | III | Noctran, < 6 hours |
| | II | Noctran, 6-12 hours after administration or more than 4 weeks in treatment |
| | I | Noctran, > 12 hours after administration and less than 4 weeks in treatment |
| | III | Tranxene, oral, 5-10 mg, used for prevention of delirium |
| | II | Tranxene, oral, 5-10 mg, more than 12 weeks in treatment |
| | I | Tranxene, oral, 5-10 mg, less than 12 weeks in treatment |
| | III | Tranxene, oral, 50 mg, used for alcohol desintoxication |
| | II | Tranxene, oral, 50 mg, all other indications |
| | III | Tranxene, injectable, < 24 hours (for single dose) |
| | III | Used as pre-anaesthetic, < 24 hours |
| | II | Used as pre-anaesthetic, 24-48 hours |
| Dihexyverine | II | Injectable form, < 24 hours |
| | I | All other forms |
| Alprostadiil Moxisylite Sildenafil Yohimbine | I | < 12 hours |
| Insulin | III | Insulin-dependent patients |
| | II | Insulin-requiring patients |
| Buprenorphine | III | Use in opioid dependency |
| | II | Analgesic |

| Substance | Category | Comment |
|------------------|-----------------|-----------------------|
| Phenobarbital | III | Treatment of epilepsy |
| | I | Cardiac sedative |
| Hydroxyzine | II | Pre-anaesthetic |
| | I | Antihistamine |

Annex VI – SR, SGC and TTS formulations in Wolschrijn et al.

| SUBSTANCE | DOSE (mg) | Mean impairment score | I, II.1, II.2 and III / I*, II* and III* |
|---|-----------|-----------------------|--|
| BENZODIAZEPINES | | | |
| SLOW RELEASE (SR) | | | |
| Diazepam SR | 10 | 1.0 | 1/0 |
| | 20 | 3.2 | 3/6 |
| Brompheniramine SR | 12 | 3.0 | 0/1 |
| Carbinoxamine SR | 12 | 3.0 | 1/1 |
| | 24 | 3.0 | 0/1 |
| Chlorpheniramine SR | 12 | 3.0 | 1/1 |
| Dexchlorpheniramine SR | 6 | - | 0/1 |
| Triprolidine SR | 10 | 3.5 | 5/1 |
| Clomipramine SR | 75 | 3.5 | 1/2 |
| Carbamazepine SR | 200-400 | 3.0 | 1/1 |
| Valproic acid SR | 5-10 | 3.0 | 1/0 |
| Dextromethorphan SR | 60 | 3.0 | 1/0 |
| Dextropropoxyphene SR | 30-65 | 2.5 | 1/1 |
| Hyoscyamine SR | 0.4-0.6 | - | 0/2 |
| SOFT GEL CAPSULE (SGC) | | | |
| Lormetazepam SGC | 1 | 3.0 | 1/5 |
| | 2 | 4.0 | 1/4 |
| Temazepam SGC | 10 | 3.5 | 2/5 |
| | 20 | 4.0 | 2/5 |
| TRANSDERMAL THERAPEUTIC SYSTEM (TTS) | | | |
| Scopolamine TTS | 1.5 | 4.0 | 1/2 |

Annex VII – Residual effects in Wolschrijn et al.

| SUBSTANCE | DOSE (mg) | Interval since intake | Mean impairment score | I. II.1. II.2 and III / I*. II* and III* |
|------------------------|-----------|-----------------------|-----------------------|--|
| BENZODIAZEPINES | | | | |
| Brotizolam | 0.125 | 8-12h | 1.8 | 5/0 |
| | | 12-16h | 1.4 | 5/0 |
| | | 16-22h | 1.4 | 4/1 |
| | 0.250 | 8-12h | 2.0 | 4/1 |
| | | 12-16h | 1.8 | 4/1 |
| | | 16-22h | 1.4 | 4/1 |
| | 0.500 | 8-12h | 2.0 | 1/0 |
| | | 12-16h | 1.0 | 1/0 |
| | | 16-22h | 1.0 | 1/0 |
| Diazepam | 10 | 8-12h | 3.1 | 12/0 |
| | | 12-16h | 2.4 | 7/5 |
| | | 16-22h | 2.0 | 7/4 |
| | 15 | 8-12h | 3.6 | 8/4 |
| | | 12-16h | 3.1 | 6/6 |
| | | 16-22h | 2.2 | 7/4 |
| | 20 | 8-12h | 3.8 | 7/5 |
| | | 12-16h | 3.1 | 6/6 |
| | | 16-22h | 2.7 | 5/6 |
| Flunitrazepam | 0.5 | 8-12h | 3.1 | 7/1 |
| | | 12-16h | 2.9 | 7/1 |
| | | 16-22h | 2.3 | 5/2 |
| | 1 | 8-12h | 3.8 | 7/1 |
| | | 12-16h | 3.3 | 6/2 |
| | | 16-22h | 2.4 | 3/4 |
| | 2 | 8-12h | 3.6 | 9/0 |
| | | 12-16h | 3.6 | 7/2 |
| | | 16-22h | 2.8 | 5/2 |
| Flurazepam | 15 | 8-12h | 3.7 | 11/0 |
| | | 12-16h | 3.4 | 9/1 |
| | | 16-22h | 2.9 | 4/3 |
| | 30 | 8-12h | 4.0 | 11/0 |
| | | 12-16h | 3.6 | 9/1 |
| | | 16-22h | 3.0 | 4/3 |
| Loprazolam | 0.5 | 8-12h | 3.0 | 2/1 |
| | | 12-16h | 2.3 | 1/2 |
| | | 16-22h | 2.0 | 0/2 |
| | 1 | 8-12h | 3.7 | 3/1 |
| | | 12-16h | 3.0 | 1/2 |
| | | 16-22h | 3.0 | 0/2 |
| | 2 | 8-12h | 4.0 | 3/0 |
| | | 12-16h | 3.7 | 3/0 |
| | | 16-22h | 3.5 | 1/1 |

| SUBSTANCE | DOSE (mg) | Interval since intake | Mean impairment score | I. II.1. II.2 and III / I*. II* and III* |
|--------------|-----------|-----------------------|-----------------------|--|
| Lorazepam | 1 | 8-12h | 3.3 | 6/4 |
| | | 12-16h | 3.0 | 6/4 |
| | | 16-22h | 2.8 | 5/5 |
| | 2.5 | 8-12h | 4.0 | 6/4 |
| | | 12-16h | 3.2 | 3/7 |
| | | 16-22h | 2.9 | 3/6 |
| | 5 | 8-12h | 4.0 | 4/6 |
| | | 12-16h | 3.7 | 3/7 |
| | | 16-22h | 3.3 | 2/7 |
| Lormetazepam | 0.5 | 8-12h | 1.8 | 3/2 |
| | | 12-16h | 1.3 | 4/2 |
| | | 16-22h | 1.8 | 2/3 |
| | 1 | 8-12h | 1.6 | 6/1 |
| | | 12-16h | 1.6 | 6/1 |
| | | 16-22h | 1.7 | 4/2 |
| | 1 (SGC) | 8-12h | 1.7 | 4/3 |
| | | 12-16h | 1.9 | 4/3 |
| | | 16-22h | 2.0 | 3/3 |
| | 2 | 8-12h | 3.0 | 4/2 |
| | | 12-16h | 1.7 | 5/1 |
| | | 16-22h | 1.7 | 4/2 |
| | 2 (SGC) | 8-12h | 3.0 | 2/5 |
| | | 12-16h | 2.4 | 3/4 |
| | | 16-22h | 2.3 | 2/4 |
| Midazolam | 7.5 | 8-12h | 2.5 | 6/1 |
| | | 12-16h | 1.7 | 5/1 |
| | | 16-22h | 1.4 | 4/1 |
| | 30 | 8-12h | 2.4 | 6/1 |
| | | 12-16h | 2.0 | 4/2 |
| | | 16-22h | 1.4 | 4/1 |
| Nitrazepam | 2.5 | 8-12h | 2.7 | 8/1 |
| | | 12-16h | 2.1 | 8/1 |
| | | 16-22h | 1.8 | 6/2 |
| | 5 | 8-12h | 2.9 | 10/0 |
| | | 12-16h | 2.4 | 8/1 |
| | | 16-22h | 2.0 | 6/2 |
| | 10 | 8-12h | 3.8 | 10/0 |
| | | 12-16h | 3.1 | 7/2 |
| | | 16-22h | 2.6 | 6/2 |
| Oxazepam | 10 | 8-12h | 2.6 | 6/3 |
| | | 12-16h | 1.8 | 7/2 |
| | | 16-22h | 1.6 | 6/3 |
| | 20 | 8-12h | 2.7 | 6/3 |
| | | 12-16h | 2.3 | 5/4 |

| SUBSTANCE | DOSE (mg) | Interval since intake | Mean impairment score | I. II.1. II.2 and III / I*. II* and III* | |
|----------------|---------------------|-----------------------|-----------------------|--|-----|
| | 30 | 16-22h | 2.2 | 3/6 | |
| | | 8-12h | 3.2 | 9/2 | |
| | | 12-16h | 2.6 | 10/1 | |
| | 50 | 16-22h | 1.4 | 8/2 | |
| | | 8-12h | 3.5 | 10/2 | |
| | | 12-16h | 2.9 | 10/2 | |
| | Quazepam | 15 | 16-22h | 2.1 | 4/5 |
| | | | 8-12h | 3.0 | 3/1 |
| | | | 12-16h | 3.0 | 3/1 |
| Temazepam | 10 | 16-22h | 2.5 | 2/1 | |
| | | 8-12h | 2.0 | 10/0 | |
| | | 12-16h | 1.8 | 9/1 | |
| | 10 (SGC) | 16-22h | 2.0 | 4/3 | |
| | | 8-12h | 2.0 | 5/2 | |
| | | 12-16h | 1.9 | 6/2 | |
| | 20 | 16-22h | 1.9 | 5/2 | |
| | | 8-12h | 2.3 | 10/2 | |
| | | 12-16h | 2.0 | 10/3 | |
| | 20 (SGC) | 16-22h | 1.9 | 6/1 | |
| | | 8-12h | 2.0 | 5/2 | |
| | | 12-16h | 1.9 | 5/3 | |
| | 30 | 16-22h | 1.7 | 7/0 | |
| | | 8-12h | 2.7 | 10/0 | |
| | | 12-16h | 2.4 | 7/3 | |
| Triazolam | 0.125 | 16-22h | 2.1 | 5/2 | |
| | | 8-12h | 2.4 | 8/1 | |
| | | 12-16h | 1.9 | 9/0 | |
| | 0.250 | 16-22h | 1.3 | 7/1 | |
| | | 8-12h | 2.8 | 9/1 | |
| | | 12-16h | 2.2 | 9/1 | |
| | 0.500 | 16-22h | 1.5 | 7/1 | |
| | | 8-12h | 3.7 | 7/1 | |
| | | 12-16h | 3.0 | 6/2 | |
| 16-22h | 16-22h | 2.1 | 6/2 | | |
| | BARBITURATES | | | | |
| | Allobarbital | 100 | 16-22h | 2.1 | 6/2 |
| 8-12h | | | 4.0 | 1/0 | |
| 12-16h | | | 3.0 | 1/0 | |
| 200 | | 16-22h | 3.0 | 1/0 | |
| | | 8-12h | 4.0 | 1/0 | |
| | | 12-16h | 3.0 | 1/0 | |
| Am(y)obarbital | 100 | 16-22h | 3.0 | 1/0 | |
| | | 8-12h | 4.0 | 3/0 | |
| | | 12-16h | 3.7 | 3/0 | |
| 16-22h | 1.5 | 2/0 | | | |

| SUBSTANCE | DOSE (mg) | Interval since intake | Mean impairment score | I. II.1. II.2 and III / I*. II* and III* |
|---------------|-----------|-----------------------|-----------------------|--|
| | 200 | 8-12h | 4.0 | 2/1 |
| | | 12-16h | 3.3 | 2/1 |
| | | 16-22h | 3.0 | 1/1 |
| Barbital | 250-500 | 8-12h | - | 0/1 |
| | | 12-16h | - | 0/1 |
| | | 16-22h | - | - |
| Butobarbital | 100 | 8-12h | 3.7 | 2/1 |
| | | 12-16h | 3.3 | 2/1 |
| | | 16-22h | 3.0 | 1/1 |
| | 200 | 8-12h | 4.0 | 2/1 |
| | | 12-16h | 3.5 | 2/1 |
| | | 16-22h | 3.0 | 1/1 |
| Cyclobarbital | 100 | 8-12h | 4.0 | 2/0 |
| | | 12-16h | 3.5 | 2/0 |
| | | 16-22h | 3.0 | 1/0 |
| | 400 | 8-12h | 4.0 | 2/0 |
| | | 12-16h | 3.5 | 2/0 |
| | | 16-22h | 3.0 | 1/0 |
| Gluthethimide | 250 | 8-12h | 4.0 | 1/2 |
| | | 12-16h | - | 0/3 |
| | | 16-22h | - | 0/2 |
| | 500 | 8-12h | 4.0 | 1/2 |
| | | 12-16h | - | 0/3 |
| | | 16-22h | - | 0/2 |
| Heptabarbital | 100 | 8-12h | - | 0/1 |
| | | 12-16h | - | 0/1 |
| | | 16-22h | - | 0/1 |
| | 200 | 8-12h | - | 0/1 |
| | | 12-16h | - | 0/1 |
| | | 16-22h | - | 0/1 |
| Hexobarbital | 250 | 8-12h | - | 0/1 |
| | | 12-16h | - | 0/1 |
| | | 16-22h | - | 0/1 |
| | 500 | 8-12h | - | 0/1 |
| | | 12-16h | - | 0/1 |
| | | 16-22h | - | 0/1 |
| Pentobarbital | 100 | 8-12h | 4.0 | 1/3 |
| | | 12-16h | - | 0/3 |
| | | 16-22h | 3.0 | 0/2 |
| | 200 | 8-12h | 4.0 | 2/2 |
| | | 12-16h | 4.0 | 1/3 |
| | | 16-22h | 2.0 | 1/1 |
| Secobarbital | 100 | 8-12h | 4.0 | 5/1 |
| | | 12-16h | 3.5 | 4/3 |

| SUBSTANCE | DOSE (mg) | Interval since intake | Mean impairment score | I. II.1. II.2 and III / I*. II* and III* |
|---------------------------------------|-----------|-----------------------|-----------------------|--|
| | | 16-22h | 2.5 | 2/2 |
| | 200 | 8-12h | 4.0 | 5/0 |
| | | 12-16h | 3.8 | 5/0 |
| | | 16-22h | 3.0 | 2/2 |
| OTHER TRANQUILLIZERS/HYPNOTICS | | | | |
| Chloral hydrate | 500-1000 | 8-12h | - | 0/3 |
| | | 12-16h | 1.0 | 1/2 |
| | | 16-22h | 1.0 | 1/1 |
| Clomethiazole | 300 | | 3.5 | 1/3 |
| | 600-1200 | | 4.0 | 1/2 |
| Methaqualone | 50-300 | 8-12h | 4.0 | 1/0 |
| | | 12-16h | 3.0 | 1/0 |
| | | 16-22h | - | - |
| Paraldehyde | 3000 | 8-12h | - | 0/1 |
| | | 12-16h | - | 0/1 |
| | | 16-22h | - | - |
| | 6000 | 8-12h | - | 0/1 |
| | | 12-16h | - | 0/1 |
| | | 16-22h | - | - |
| Promethazine | 25 | 8-12h | 3.8 | 4/0 |
| | | 12-16h | 3.5 | 2/0 |
| | | 16-22h | 3.0 | 0/1 |
| | 50 | 8-12h | 4.0 | 2/0 |
| | | 12-16h | 3.5 | 2/0 |
| | | 16-22h | - | 0/1 |
| Zolpidem | 10 | 8-12h | 1.0 | 3/0 |
| | | 12-16h | 1.0 | 3/0 |
| | | 16-22h | 1.0 | 3/0 |
| | 20 | 8-12h | 3.0 | 0/2 |
| | | 12-16h | 2.0 | 1/1 |
| | | 16-22h | 1.0 | 2/0 |
| Zopiclone | 7.5 | 8-12h | 2.4 | 8/1 |
| | | 12-16h | 1.3 | 9/0 |
| | | 16-22h | 1.0 | 6/0 |

Annex VIII – Multiple ratings per ATC code in ‘France II’

| ATC | Substance | Category | Comment |
|---------|---|----------|---|
| N02AA59 | Codeine, combinations excl. psycholeptics | I | Codeine < 20 mg |
| | | II | Codeine > 20 mg |
| N02AB03 | Fentanyl | II | Transdermal forms |
| | | III | Transmucosal forms |
| N02BA51 | Acetylsalicylic acid, combinations excl psycholeptics | I | Codeine < 20 mg |
| N02BE51 | Paracetamol, combinations excl psycholeptics | | |
| N03AE01 | Clonazepam | II | Oral forms |
| N05AA01 | Chlorpromazine | | |
| N05AA02 | Levomepromazine | | |
| N05AA06 | Cyamemazine | | |
| N05AB06 | Trifluoperazine | | |
| N05AC04 | Pipotiazine | | |
| N05AD09 | Fluanisone | | |
| N05AH01 | Loxapine | III | Parenteral forms |
| N05AH03 | Olanzapine | | |
| N05AL01 | Sulpiride | | |
| N05AL02 | Sultopride | | |
| N05AL03 | Tiapride | | |
| N05AL05 | Amisulpride | | |
| N05BC01 | Meprobamate | | |
| N05AB03 | Perphenazine | III | Parenteral forms |
| N05AD08 | Droperidol | | |
| N05AD01 | Haloperidol | II | Oral forms |
| N05AF01 | Flupentixol | III | Parenteral forms (except slow release formulations) |
| N05AF05 | Zuclopenthixol | | |
| N05BA01 | Diazepam | II | Oral forms |
| | | III | Oral forms of 10 mg and parenteral forms |
| N05BA04 | Oxazepam | II | Dose < 50 mg |
| | | III | Dose ≥ 50 mg |
| N05BA05 | Clorazepate | II | Oral forms |
| | | III | Oral forms ≥ 20 mg and parenteral forms |
| N05BA06 | Lorazepam | II | Dose < 2,5 mg |
| | | III | Dose ≥ 2,5 mg |
| N05BA11 | Prazepam | II | Dose < 40 mg |
| | | III | Dose ≥ 40 mg |
| N05BA16 | Nordazepam | II | Dose < 15 mg |
| | | III | Dose ≥ 15 mg |